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General Introduction 
Keratinocytes are generated in the basal layer of the epidermis and move to the surface 
through successive stages of differentiation This process of differentiation and 
cornification involves complex metabolic changes, including programmed alterations in 
cell proteins, membrane glycosylation and lipid biosynthesis123 The stratum comeum is 
usually many cell layers thick and provides the main piotective barrier of the skin and 
prevents 98% of the water loss The disorders of keratinization have a defect in 
cornification which leads to a thicker stratum corneum (hyperkeratosis) The underlying 
biochemical mechanisms of these disorders are believed to involve failure of desquamation 
(retention hyperkeratosis) or increased production of stratum comeum cells 
(hyperproliferation hyperkeratosis)4 In general the disorders of keratinization are 
considered to be genetically determined The majority of these diseases are monogenic 
with a mendelian inheritance A few have polygenic inheritance or are acquired 
The monogenic disorders of keratinization comprise a large and heterogeneous group of 
skin diseases Every year new entities are added to the list which already consists of about 
70 diseases5 Williams proposed to abandon terms like ichthyosis, palmoplantar 
keratoderma or erythrokeratoderma and to classify all these types of diseases as disorders 
of cornification by giving each entity a number6 
Classification can be made on clinical grounds, on histological characteristics including 
immunohistochemical and ultrastructural findings, and by molecular biological techniques 
as genetic linkage studies and mutation analyses In the general introduction the different 
approaches will be reviewed In the appendix guidelines for classification will be 
presented 
Clinical manifestations 
In the monogenic disorders of keratinization hyperkeratosis can either occur isolated in the 
skin, or can be associated with abnormalities of other organs In the latter case the skin 
abnormalities mostly are the hallmark of these syndromes and multisystem birth defects 
The skin lesions can be present already at birth (congenital), or they can become manifest 
later in life (vulgar) Hyperkeratosis can occur either generalized, as in ichthyosis, or 
localised as in palmoplantar hyperkeratosis (Table I, appendix) Some disorders of 
keratinization like the epidermolytic type of epidermal naevus are manifestations of 
mosaicism (Table II, appendix) 7 Information about the pedigree of the patients and the 
clinical appearance of the hyperkeratosis can further contribute to establish the diagnosis 
Morphological identification 
Histological examination is often necessary for classification The histopathological and 
ultrastructural finding of epidermolytic hyperkeratosis (also called acanthokeratolysis) is 
typical for bullous congenital ichthyosiform erythroderma, ichthyosis bullosa of Siemens 
and Vomer's disease The absence of the stratum granulosum or at least the presence of 
abortive keratohyalin granules is diagnostic for autosomal dominant ichthyosis vulgaris 
The presence of lipiddroplets in the basal keratmocytes is typical for Refsum's disease β 
Ultrastructural criteria for the classification of the heterogeneous group of lamellar 
ichthyosis have been developed 9 '2 This classification is an important attempt to improve 
the nosology of lamellar ichthyosis However, the question remains to be solved whether 
all these morphological subtypes represent real disease entities in a genetical sense For an 
overview of the histopathological and ultrastructural features see Table III and IV in the 
appendix 
Biochemistry and cell biology 
Two-dimensional electrophoresis of proteins, derived from normal human epidermal 
keratmocytes, yielded 2615 cellular proteins of which 207 were identified n These proteins 
include the keratins, filaggrin, and învolucrin Several attempts were made to elucidate the 
biochemical defect of disorders of keratmization by studying these proteins using two-
dimensional gel electrophoresis, immunoblotting and immunohistochemistry Some of 
these proteins will now be described in detail 
The keratin polypeptides are the largest family of intermediate filaments In corneocytes 
the keratins form 80 % of the dry cell mass More than 20 different keratins can be 
distinguished each coded by a different gene They are classified as Type I and Type II, 
the acidic and neutral-basic keratins Acidic and basic keratins form pairs as 
heterodimers IJ l6 Figure I shows the structure of the two types of keratin The central rod 
domain is homologous for both types and contains alpha-helicoidal segments with 
hydrophobic ammo-acids at regular distances 
Type I 
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Fig 1 Structure of ihe 2 types of keratin The central rod domain is homologous for both types The 
differences between the keratins are present in the terminal domains 
The differences between the keratins are present in the terminal domains The helicoidal 
domains of type I and type II keratins are entwined and are stabilized by hydrophobic 
-> 
interactions Two of such dimers form tetramers assembling filaments The keratinocytes 
of the basal epidermal layer express a dimer of the keratins 5 and 14 Whilst migrating to 
the suprabasal compartment, they express the new differentiation specific keratins 1 and 
10 Genetically inherited structural defects in epidermal keratin filaments have been found 
to cause disruption of cell integrity and cytolysis in an increasing number of skin diseases 
including epidermolysis bullosa simplex and epidermolytic hyperkeratoses1710 In psoriasis 
and other diseases including Daner's disease loss of keratin 1 and extra bands on one-
dimensional electrophoresis have been observed 21 Immunoblotting revealed the expression 
of a specific pair of keratins 16 and 6, 48 and 56 kD respectively, in common skin 
diseases such as psoriasis and epidermal carcinomas characterized by hyperprohferation 2' 
24
 In normal skin keratin 16 and 6 are not expressed at the protein level, but they are 
following injury of normal skin, as the mRNAs for keratin 6 and 16 are found25 
Posttranscriptional regulation of protein expression probably permits repair following 
wounding In Daner's disease the keratotic lesion showed expression of these so-called 
hyperproliferative keratins There was also a delay in "differentiation keratin" expression 
in this disorder These abnormalities might be due to proteolytic damage 26 However, so 
far a detailed study on the profiles of keratins throughout the spectrum of disorders of 
keratinization is not available In view of their role in epidermal proliferation and 
differentiation, it is conceivable that the keratin profile might be diagnostically relevant 
Retinoid treatment can cause changes in the keratin gene regulation In vitro, it inhibits 
keratin 1 expression and induces keratin 13 and 19 expression 2728 So far, no data are 
available on the in vivo modulation of keratin expression during treatment of disorders of 
keratinization with retinoids Insight in the restoration of keratin expression under therapy 
would be relevant for the evaluation of the therapy effects 
Filaggnn is an important structural protein of the comeocyt29 " It is synthesized as 
profilaggnn in the upper stratum granulosum where it is stored in the keratohyalin 
granules Filaggnn causes aggregation of keratin filaments into larger filaments (fil-
aggnne) Abnormalities have been observed in restrictive dermopathy and in harlequin 
ichthyosis Filaggnn and profilaggnn are reduced in ichthyosis vulgaris and the reduction 
correlates with the severity of the disease 52 Filaggnn is increased in bullous congenital 
ichthyosiform erythroderma 33 The comified envelope of the comeocyt is produced by 
cross linking involucnn with other membrane proteins under the influence of 
transglutaminase34 3e Using antibodies against involucnn and transglutaminase, it was 
demonstrated that involucnn expression is altered in diseases characterized by epidermal 
hyperprohferation 35 '8 40 Involucnn and transglutaminase are normally expressed in the 
upper part of the stratum spinosum and stratum granulosum In hyperproliferative states 
like psoriasis the number of filaggnn positive cell layers is markedly reduced and 
involucnn and transglutaminase are expressed prematurely in the epibasal layer3940 
Elias compared the stratum corneum with a brick wall in which the comeocyts are the 
bricks and the intercellular lipids form the mortar Normal desquamation depends on the 
right quality of the mortar4I Recently the biochemical and ultrastructural aspects of 
3 
cohesion in the epidermis have been reviewed42 During differentiation from the basal 
layer to the stratum comeum, lipids become less polar by the action of hydrolytic 
enzymes The lipids become hydrophobic, which gives the stratum comeum its water 
resistant quality Apart from their role to form a permeability barrier, they play a role in 
the dynamics of desquamation Desquamation requires breakdown of particularly 
cholesterol sulphate to cholesterol by steroid sulphatase to loosen cohesion between the 
comeocytes In X-linked recessive ichthyosis, cholesterolsulphate accumulates in the 
homylayer Absence of steroidsulphatase limits intercellular lipid processing and therefore 
squames are retained, resulting in hyperkeratosis 4 3 The relevance of abnormalities in lipid 
metabolism to the pathogenesis of the lamellar ichthyoses is uncertain Increased n-alkanes 
have been reported in the stratum comeum of erythrodermic lamellar ichthyosis 4 4 4 5 These 
alkanes probably have an exogenous source 4 6 Abnormal keratinization, ι с ichthyosis in 
conjunction with abnormal lipid metabolism, is observed in Refsum's disease, Sjogren-
Larsson syndrome, neutral-hpid storage disease (Dorfman-Chanann syndrome), and 
multiple steroid sulphatase deficiency syndrome 4 
Until recently the dermis was regarded as a rather inert support of the epidermis There is 
now more and more evidence that the dermis plays an important role in the homeostasis of 
the epidermis Extracellular matrix proteins, adhesion molecules such as integnns and 
other components, probably have a regulating function in epidermal proliferation and 
differentiation " " 
The biochemical abnormalities in disorders of keratinization are summarized in Table V of 
the appendix 
Treatment 
So far, therapy of disorders of keratinization has been symptomatic only In former days 
only treatment with keratolyses like urea, lactic acid, salicylic acid and propylene glycol 
were available in combination with bland emollients The therapeutic use of vitamin A in 
acne was already documented in 1943 by Straumfjord 53 The development of synthetic 
retinoids has revolutionized the treatment of disorders of keratinization 54 " Topical all-
trans-relinoic acid appeared to be effective, but due to its irritative potential its use 
remained restricted to the treatment of acne vulgaris 64 The availability of etretinate and 
later of acitretin was a major breakthrough However, the risk of systemic side-effects and 
in particular its potential teratogenicity limit there application Important new perspectives 
for the treatment of disorders of keratinization have been provided by the development of 
new, preferably topical, retinoids Although acitretin is a well established treatment of 
psoriasis, the therapeutic experience in disorders of keratinization was only fragmentary 
before the start of the research efforts connected with this thesis Another important 
development is the use of topical retinoids Retinoids belong to the ligands of the so called 
steroid receptor superfamily " The steroid receptor superfamily comprises specific 
receptors which bind retinoids, vitamin D3, estriol, androgens and thyroxin The complex 
of a ligand and its receptor modulates the transcription of various genes, ultimately 
4 
yielding into modulation of epidermal proliferation and keratinization. In this respect it is 
of importance to evaluate ligands for other receptors of the steroid receptor superfamily in 
addition to the well established ligands for the retinole acid receptor. 
The following questions were addressed in this s tudy 
(1) To what extent do clinical descriptions of phenotypes, regarding disorders of 
keratinization, refine and or simplify the existing nosology of monogenic disorders 
of keratinization (Part I ) 9 
(n) To what extent do immunohistochemical and molecular findings refine and or 
simplify the existing nosology of monogenic disorders of keratinization (Part I I ) 9 
(111) To what extent are systemic acitretin, topical 13-cis retinole acid, and topical 
vitamin D 3 (all ligands for members of the steroid receptor superfamily) effective in 
the treatment of monogenic disorders of keratinization (Part III)? 
In the appendix tables are presented for an integrated diagnostic approach. 
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PART I 
Clinical Aspects 

Introduction 
The monogenic disorders of keratinization comprise a large and heterogenous group of 
disorders which are characterized clinically by the formation of visible scales (Table I, 
appendix) 
Classification is difficult, because of inter- and intraindividual variations, differences in 
nomenclature, and the large number of reported cases In recent years a number of new 
'entities" have been described and manifestations which were previously considered to be 
distinct entities have been shown to be variants of the same disorders of keratinization 
The basis of classification are the clinical findings, which provide the first indication for a 
possible diagnosis and the first lead to a new entity Eventually the diagnosis will be made 
by an integrated approach using clinical, histological and biochemical investigations In 
this chapter different clinical presentations of disorders of keratinization are presented 
Ichthyosis is a descriptive term used for a genetic disorder of keratinization showing a 
conspicuous scaling which is generalized and affects the whole integument The process of 
the disease is more or less static but may show some seasonal variation Chapter 1 
describes a form of ichthyosis 
Chapters 2 and 3 describe patients with a localized disorder of keratinization namely a 
palmoplanar hyperkeratosis The palmoplanar hyperkeratosis in itself forms a large and 
heterogenous group too (Table I, appendix) The cases presented here demonstrate that the 
group of palmoplantar hyperkeratosis is still expanding 
Chapters 4, 5 and 6 show a presentation of hyperkeratosis in a naevoid or mosaic pattern 
The observation that CHILD-syndrome is inherited from mother to daughter provides 
further evidence for the concept that a X-lmked dominant mutation is responsible in this 
disease 

Chapter 1 
Ichthyosis Bullosa of Siemens: 
Further Delineation of the Phenotype 
PM Steijlen 
CM Perret 
JH Schuurmans Stekhoven 
DJ Ruiter 
R Happle 
Arch Dermatol Res 1990; 282: 1-5 
SUMMARY 
We report a third family affected with ichthyosis bullosa of Siemens, and we further 
delineate the clinical spectrum of this mild type of epidermolytic hyperkeratosis 
Erythroderma had never been present in any of the affected individuals All of them 
exhibited a brownish, rimpled hyperkeratosis, the main characteristic sites being the joints, 
the shins and the periumbilical region Blistering occurred after slight mechanical trauma 
and even after sweating, resulting in superficially denuded areas Two affected family 
members also suffered from chronic, relapsing pustular eruptions surrounded by a transient 
erythematous flare Light- and electron-microscopic examination revealed epidermolytic 
hyperkeratosis limited to the upper part of the epidermis The pustular lesions were found 
to be subcorneal blisters filled with neutrophils Ichthyosis bullosa of Siemens can be 
clearly distinguished from bullous ichthyosiform erythroderma The observation of 
subcorneal pustular dermatosis occurring in this phenotype provides further evidence for 
the genetic heterogeneity of epidermolytic hyperkeratosis 
In 1937, Hermann Werner Siemens described a Dutch family with non-erythrodermic 
ichthyosis, which was inherited as an autosomal dominant trail6 Six members belonging to 
three consecutive generations exhibited mild ichthyosis and blister formation Owing to 
the different distribution of the skin lesions and the absence of erythroderma, Siemens 
distinguished this entity from bullous congenital ichthyosiform erythroderma as described 
by Brocq in 1902 3 After the original account, ichthyosis bullosa of Siemens fell into 
oblivion until 1986, when Traupe et al reported a second family with the disease ' Their 
observations concerned eight family members over four consecutive generations The two 
family members examined were suffering from a mild ichthyosis with blister formation 
Histopathological granular degeneration (epidermolytic hyperkeratosis) limited to the 
upper part of the epidermis was the most prominent manifestation Taupe et al7 argued 
that ichthyosis bullosa of Siemens shares the histopathological features of epidermolytic 
hyperkeratosis with bullous congenital ichthyosiform erythroderma, but can be 
distinguished from this condition by the lack of erythroderma as well as the granular 
degeneration being confined to the superficial layers of the epidermis 
We now report on a third family with seven affected members over four consecutive 
generations 
CASE REPORTS 
Case I 
The index patient (III,) a 27-year-old woman, had suffered from "dry and scaly skin" since 
early childhood In addition to ichthyotic changes, she exhibited superficial blistering on 
the extensor surfaces of the arms and legs Her father, her son, and two sisters showed the 
same skin changes Moreover, her deceased grandmother was said to have been affected in 
the same manner (Figure 1) The patient also had small superficial blisters (size range, 3-5 
mm) on the extensor surfaces of the arms and legs This blistering was more pronounced 
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during the summer and could be provoked by minor trauma or by intense sweating. 
Erythroderma had never been present. Except from the cosmetic point of view, the lesions 
did not cause complaints. The patient stated that she was the first family member to have 
consulted a physician. Her general health was good, and there were no signs of atopy. On 
physical examination, she displayed a brownish rimpled hyperkeratosis localized 
predominantly on the elbows, the knees and the dorsal aspects of the hands. On the shins, 
there were collarette-like lesions resulting from superficial blister formation (Figure 2). 
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Fig. 1. Pedigree showing ichthyosis bullosa of Siemens occurring in four consecutive generations 
Case 2 
The 20-year-old sister (III9) of the index patient was healthy except for her skin condition. 
Since birth, she had noticed scaling and dryness of the skin. There was no history of 
erythroderma. The scaling and dryness showed no seasonal variations, whereas blistering 
occurred more frequently in the summer. Other than these seasonal variations, her 
condition remained fairly stable. On physical examination, she exhibited similar skin 
changes that were most pronounced on the elbow, the flexural aspects of the knees, 
around the ankles and on the back of the hands and feet. In these regions, circumscribed, 
superficially denuded areas were observable. Occasionally fresh blisters ranging in size 
from 0.5 to 2 cm appeared. 
Case 3 
The 5-year-old son (IV4) of the proposita was born at term after a pregnancy without 
complications. Since birth, he had suffered from a generalized dryness of the skin. There 
were no signs of a congenital erythroderma. Blistering had started at the age of 8 month. 
On examination, dark-brownish, rimpled hyperkeratoses were noted, especially on the 
back of the hands and feet, on the flexural aspect of the knees (Figure 3) and around the 
ankles. Some irregularly shaped, superficially denuded lesions surrounded by a collarette-
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like scaling (Figure 4) were present on the dorsal aspects of the hands and on the flexural 
aspects of the feet, but all of these skin changes were less severe than those of his mother 
and his aunt. 
Case 4 
The 33-year-old sister (III4) of the index patient had suffered from a scaling skin disorder 
since birth. There was no history of congenital erythroderma. Blistering had started 1 
month after birth; it was triggered by warm, humid weather and was most pronounced on 
the flexural side of the knees. On examination, the patient showed the same type of skin 
disorder as her relatives, with rimpled brownish hyperkeratosis around the umbilicus, 
knees and ankles. Superficially denuded areas were observed in these areas. The 
hyperkeratosis was not associated with erythema. 
Fig. 2. Collarette-like lesions on the shins (case 1) Fig. 4. Irregularly shaped, superficially denuded 
lesions surrounded by collarette-like scaling 
(case 3) 
Fig. 3. Dark-brown, rimpled hyperkeratosis on the Fig. 5. Groups of flaccid pustules that are gyrate 
flexural aspect of the right knee (case 3) in shape and surrounded by an erythematous flare 
(case 5) 
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Case 5 
The 51-year-old father (II3) of the proposita had suffered from ichthyosis since birth 
Blistering had started during the 1st year of life, but these episodes had become less 
frequent at the age of 10 years However, since the age of 15 years, he had suffered from 
chronic, relapsing pustular eruptions He presented with marked nmpled hyperkeratosis 
localized on the knees, on the elbows and around the ankles Collarette-like lesions were 
observed on the arms and legs In addition, flaccid, oval pustules were visible on clinically 
uninvolved skin localized beneath the axillary folds The pustules tended to form groups 
that were gyrate in shape and were surrounded, at an early stage of development, by a 
transient erythematous flare (Figure 5) These eruptions could be provoked by heat and 
were most prominent during the summer 
Case 6 
A 40-year-old uncle (II5) of the index patient was suffering from non-erythematous 
congenital ichthyosis Blistering had started at the age of 8 month, resulting in impetigo-
like lesions From the age of 10 years, the patient had been free from blistering However, 
like his brother, he had suffered from chronic, relapsing pustular eruptions since the age of 
18 years On examination, he showed skin changes similar to those described in case 5 
The collarette-like scaling, the pustular eruptions and the surrounding erythematous flare 
were especially marked on the trunk In his case, the pustules were present on the 
ichthyotic skin as well as on uninvolved skin Histopathologwal findings 
Multiple biopsies for light microscopy were taken from cases I, 2, 5 and 6 The findings 
were similar for all samples In ichthyotic lesions, the epidermis was irregularly acanthotic 
and markedly orthohyperkeratotic PAS-positive deposits were seen within intracorneal 
splits, probably reflecting earlier blistering The most prominent feature was granular 
degeneration, or epidermolytic hyperkeratosis ' In the stratum granulosum and the upper 
part of the stratum spinosum, perinuclear halos, keratohyalin clumps and hyperchromalic 
pycnotic nuclei were observed (Figure 6) Histopathological examination of a small, 
freshly induced blister in case 1 showed a more pronounced epidermolytic hyperkeratosis, 
resulting in blistering within the granular layer In the blister, few polymorphonuclear 
leukocytes were visible (Figure 7) Two biopsies of pustules taken from patients 5 and 6 
revealed subcorneal blisters within an acanthotic epidermis Most of these blisters were 
filled with numerous polymorphonuclear leukocytes In addition, the keratinocytes of the 
granular layer displayed mild epidermolytic hyperkeratosis (Figure 8) 
Electron-microscopic findings 
In case 1 and 2, biopsies from ichthyotic skin lesions were taken for ultrastructural 
examination The cells of the granular and upper spinous layers showed marked edema, 
while the keratohyalin granules were fragmented Keratinocytes in the spinocellular layer 
displayed pronounced aggregates of tonofilaments, forming V shapes or shells around the 
nuclei (figure 9) 
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Fig. 6. Mild epidermolytic hyperkeratosis. 
H&E; xlOO 
Fig. 8. Subcorneal blistering with an abundance of 
polymorphonuclear leukocytes. H&E; x40 
Fig. 7. Pronounced epidermolytic hyperkeratosis 
with blistering within the granular layer. Note the 
presence of few polymorphonuclear leukocytes. 
H&E xlOO 
Fig.9. Electron micrograph of keratinocytes in the 
spinocellular layer. Note the pronounced 
perinuclear aggregation of tonofilaments. x2600 
Treatment 
The individuals II3 and II5 were treated with etretinate (35 mg daily), which resulted in 
decreased scaling and the complete disappearance of pustular lesions. After informed 
consent, patient III4 and III, received acitretin (35 mg daily). Within 6 weeks, there was a 
substantial improvement in their cutaneous condition. 
DISCUSSION 
We report a third family affected with ichthyosis bullosa of Siemens. Their ichthyosis was 
rather mild, and the distribution of the scaly lesions in the various affected family 
members was constant. Their signs and symptoms strikingly resembled those described by 
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Siemens and Taupe et al.67 Ichthyosis bullosa of Siemens does indeed appear to be a 
distinct entity. So far, it is not clear whether the clinical differences between ichthyosis 
bullosa of Siemens and bullous ichthyosiform erythroderma reflect allelism or mutations at 
different gene loci. 
Bullous ichthyosiform erythroderma, which was first described by Brocq and was further 
delineated by Lapière has, up to now, been considered by most investigators to be the only 
form of bullous ichthyosis.3,45·8 In this disease, congenital erythroderma is present at birth, 
and the skin is affected by inflammatory erythema and blistering. With increasing age the 
hyperkeratotic skin changes become more prominent, whereas the erythema subsides. In 
spite of light-microscopic and electron-microscopic similarities, we suggest that ichthyosis 
bullosa of Siemens should be distinguished from bullous ichthyosiform erythroderma on 
the basis of its mild clinical appearance, which is constant within a given family, as well 
as the absence of erythroderma. 
A 15-year-old patient with epidermolytic hyperkeratosis was recently presented at the 
annual meeting of the British Association of Dermatologists.2 The child had suffered from 
mild ichthyosis with large flaccid blister formation since the age of 3 years. Congenital 
erythroderma was not mentioned. There was a marked family history of epidermolytic 
hyperkeratosis. This family may represent a further example of ichthyosis bullosa of 
Siemens, suggesting that this disorder is not quite as uncommon as once supposed. 
In addition to ichthyotic skin lesions, two brothers of the present family exhibited chronic, 
relapsing pustular eruptions that were clinically and histopathologically indistinguishable 
from subcorneal pustular dermatosis of the Sneddon-Wilkinson type. Some 
polymorphonuclear granulocytes were also observed in blisters examined in one of the 
patients (case 1), who did not suffer from recurrent pustular eruptions. Up to now, a 
familial occurrence of subcorneal pustular dermatosis has never been reported. It is rather 
unlikely that the occurrence of subcorneal pustular dermatosis in two brothers affected 
with ichthyosis bullosa of Siemens is coincidental. Rather, we would consider ichthyosis 
bullosa of Siemens to be a disease that either predisposes to, or mimics subcorneal 
pustular dermatosis. If this is so, subcorneal pustular dermatosis would be a heterogeneous 
phenomenon. The occurrence of subcorneal pustulosis further delineates the clinical 
spectrum of ichthyosis bullosa of Siemens and may help to distinguish this disease from 
bullous ichthyosiform erythroderma. 
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SUMMARY 
A 33-year-old man suffered from increased vulnerability of the skin with marked plantar 
hyperkeratosis extending to the periungual areas. The nails were thickened because of 
subungual hyperkeratosis. The scalp hair was markedly curly and could easily be plucked 
without pain. Eyebrows and lashes as well as pubic and axillary hair were very sparse. 
Histopathological examination of biopsies obtained from various skin areas consistently 
revealed acantholysis similar toe that observed in Hailey-Hailey disease. Moreover, a scalp 
biopsy showed acantholysis present in the deep parts of hair follicles. Ophthalmological 
examination showed stellate lenticular opacities. To our knowledge this constellation of 
symptoms has so far not been described. We propose the designation "acantholytic 
ectodermal dysplasia". As the patient did not know any of his family members, no 
statement can so far be made regarding the mode of inheritance of this unusual trait. 
INTRODUCTION 
The term "ectodermal dysplasia" is presently defined as a symptom complex of genetically 
determined defects involving two or more of the various ectodermal structures such as 
skin, hair , nails, teeth, and eyes.' Solomon et al.2 proposed three criteria for the definition 
of ectodermal dysplasia: 
(i) the trait should be congenital, 
(ii) the involvement of epidermis and skin appendages should be more or less diffuse, 
and the same is true for mucosal or dental lesions, 
(iii) the lesions are not progressive. 
We here report a case presenting a constellation of ectodermal dysplastic abnormalities 
that to our knowledge, has not previously been described. 
CASE REPORT 
A 33-year-old man suffered since birth from extreme vulnerability of the skin and 
recurrent cutaneous infections. Since childhood he complained of extreme plantar 
hyperkeratoses that hampered him when walking. (He never received oral retinoids ) In 
early childhood he had be placed away from a broken home, and he did not know any of 
this family members. 
On physical examination, sharply demarcated oozing erythematous lesions were noted 
predominantly on the buttocks (Figure 1) and groins (Figure 2). Less severe erosions were 
present in other skin areas. They appeared following mild trauma and often showed 
secondary infection. There was, however, no definite blistering. Marked hyperkeratoses 
was present on the soles (Figure 3). On the toes, hyperkeratosis extended to the periungual 
regions (Figure 4). All of his toe nails and some of his finger nails were thickened and 
showed subungual hyperkeratosis (Figure 4). The palms displayed circumscribed 
hyperkeratotic lesions In addition, follicular hyperkeratoses were found on the thorax. The 
scalp hair was dark an thick and markedly curly and could easily be plucked without pain 
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(Figure 5). His eyebrows and lashes were markedly sparse, and his pubic and axillar hair 
was likewise sparse and rather loose. 
Ophthalmological examination showed stellate opacities of both lenses. These cataracts 
were non-symptomatic. The teeth were normal and sweating was not impaired. 
Histological examination of three biopsies obtained from erosive lesions of the axillar and 
inguinal region consistently displayed suprabasal splitting and acantholysis (Figure 6). No 
dyskeratosis was observed and there was no granular degeneration. Acantholysis was also 
observed within the hair follicles of the scalp (Figure 7). 
Electron microscopical examination of a skin biopsy obtained from the elbow displayed 
clumping of tonofilaments and diminished desmosomal binding sites (Figure 8). 
Fig. 1. Sharply demarcated erosive lesions on the Fig. 2. Erosive lesions in the groins, 
buttocks. 
Fig. 3. Plantar hyperkeratosis. Fig. 4. Periungual and subungual hyperkeratosis 
with thickening of nails. 
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Fig. 5. Curly and sparse hair Fig. 6. Biopsy from an erosive lesion displaying 
suprabasal splitting and acantholysis (xlOO) 
Fig. 7. Scalp biopsy showing acantholysis within Fig. 8. Electron microscopical examination of a 
a hair follicle. (xlOO) biopsy from the elbow displaying clumping of 
tonofilaments and diminished desmosomal binding 
sites. (x2600) 
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DISCUSSION 
This patient has a congenital disorder that diffusely affects the epidermis as well as the 
hair and the nails. In addition, bilateral lenticular opacities were present. Therefore, the 
criteria of an ectodermal dysplasia can be regarded as fulfilled.1,2 
Thus far, no ectodermal dysplasia showing the histopalhological feature of acantholysis 
has been described. On the other hand, this disorder can be clearly distinguished from 
Hailey-Hailey disease because of the associated anomalies.3 Palmoplantar hyperkeratosis 
and lenticular opacities are not observed in patients with Hailey-Hailey disease. Such 
patients may show longitudinal leukonychia but subungual hyperkeratosis with thickening 
of nails is absent. However, acantholysis affecting the hair follicles was previously 
observed in a patient with Hailey-Hailey disease.5 Contrasting with the present case, this 
patient displayed seborrhoeic dermatitis of the scalp and did not show the phenomenon of 
loose hair, nor palmoplantar hyperkeratosis. 
This trait differs from pachyonychia congenita and ectodermal dysplasia of the Clouston 
type because of looseness of hair and the histopathological phenomenon of acantholysis. 
On the other hand, the trait differs from congenital bullous ichthyotic erythroderma of 
Brocq because there were no signs of epidermolytic hyperkeratosis in the various skin 
specimens examined. The findings obtained by electron microscopical examination 
excluded the various types of epidermolysis bullosa. 
In our opinion the present case represents a new genodermatosis for which we propose the 
designation "acantholytic ectodermal dysplasia". Because the patient did not know any of 
his family members, we have no data to determine the mode of inheritance of this trait. 
We are inclined to predict, however, that future reports will show an autosomal recessive 
mode of transmission since otherwise this trait should occur more frequently and would 
therefore have been described earlier. 
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ABSTRACT 
A syndrome of congenital atrichia, palmoplantar hyperkeratosis, mental retardation, and 
early loss of teeth was observed in four siblings (three woman and one man). The 
pedigree is suggestive of either an autosomal recessive mode of inheritance or the 
inheritance of a (small) chromosomal translocation. This combination of findings has not 
been previously reported and is therefore considered to be a new genetic entity. 
INTRODUCTION 
In the classification of the various genetically determined forms of mental retardation, the 
presence of cutaneous features such as defective hair growth or palmoplantar 
hyperkeratosis may be useful diagnostic markers. We describe four siblings who have an 
unusual disorder characterized by congenital atrichia, palmoplantar hyperkeratosis, mental 
retardation, and early loss of teeth. 
CASE REPORTS 
Four siblings had atrichia, mental retardation, and palmoplantar hyperkeratosis. They were 
the oldest of seven children of unrelated, healthy parents. The mother reported five 
spontaneous abortions (Figure 1). Of the remaining live-bom children, one 39 year-old 
woman was alive and unaffected. Two siblings were deceased; a boy affected with trisomy 
21 had died from intestinal atresia at the age of 10 days, and a woman had died at age 37 
years. This woman had progressive optical atrophy, perceptual deafness, and spinocerebel-
lar ataxia in her second decade of life. She had not displayed features such as atrichia, 
palmoplantar keratoderma, mental retardation, or early loss of teeth. Because an autopsy 
was not performed, the cause of death is unknown. Neither the children of this woman nor 
the children of the alive, healthy woman were affected. 
І
1 ¡i |з "t~~ 
III 
Fig. 1. Family pedigree 
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CLINICAL FINDINGS 
A 48-year-old woman (case 1), her 45-year-old brother (case 2), her 43-year-old sister 
(case 3) and her 42-year-old sister (case 4) had mental retardation. The retardation was 
severe in case 4 and moderate in the other three cases. All of the patients had alopecia 
since birth. At the age of approximately 1V4 to 2 years, palmoplantar hyperkeratosis was 
noted. Teeth developed but were lost early or had to be removed because of dysplastic 
defects of an unknown type. 
On clinical examination the scalp of each of the patients was bald (Figure 2). Patient 4, 
however, displayed numerous vellus hairs that were hardly visible. Hair follicle openings 
were preserved, and there was no evidence of scarring (Figure 3). Eyebrows and eyelashes 
were very sparse. Axillary and pubic hair was absent. Moreover, the patients showed an 
adherent hyperkeratosis on their palms and soles with spreading to the dorsal aspects and 
the heels (Figure 4). The hyperkeratotic lesions were surrounded by an erythematous 
border. 
Histological examination of a scalp biopsy from patient 3 showed a normal epidermis but 
follicular plugging. Most follicles revealed a marked atrophy, and many contained 
rudimentary hair shafts. The absolute number of follicles did not appear to be reduced. 
Sebaceous and eccrine sweat glands were normal in size and number (Figure 5). 
Microscopic examination of a biopsy specimen taken from a hyperkeratotic lesion on the 
sole of patient 2 showed a marked orthohyperkeratosis with focal parakeratosis. The 
granular layer was broadened. A marked acanthosis with elongated rete ridges was 
present. Serum tyrosinase measured in patient 1 and 2 was within the normal range. 
Fig. 2. Case 2. Atrichia of scalp and hypotrichosis Fig. 3. Case 3. Presence of hair follicle openings 
of eyebrows. on scalp. 
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Fig. 4. a) Case 1. Adherent hyperkeratosis on the heels, b) Case 2. Plantar hyperkeratosis extending to 
dorsal aspect of foot, c) Case 4. Palmar hyperkeratosis extending to dorsal aspect of hand. 
* 
Fig. 5. Scalp biopsy specimen obtained from case 3 shows follicular plugging and atrophic hair follicles 
containing rudimentary hair shafts. 
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CYTOGENETIC STUDIES 
To exclude any chromosomal abnormality, routine cytogenetic studies were performed on 
G-banded chromosomes from cultured peripheral lymphocytes of patients 2 and 4 These 
studies a revealed a normal male and female karyotype, respectively. Because several 
spontaneous abortions, four identical patients, and three unaffected individuals were 
present in a single generation and both parents were healthy, the pedigree was suspect for 
the inheritance of a (small) chromosomal translocation. Therefore, the chromosomes of the 
mother were studied by means of high-resolution banding technique, but, again, no 
aberrations were found. 
DISCUSSION 
The main features observed in these patients were congenital atrichia, palmoplanar hyper­
keratosis, mental retardation, and early loss of teeth. Some phenotypical variation was 
noted, in patient 4 the scalp showed numerous vellus hairs, whereas the other patients 
were completely bald. Patient 4 was severely retarded, necessitating institutionalization. 
Palmoplantar hyperkeratosis and dental defects were consistent features in all four 
patients. Patient 2 also had epilepsy, but this finding was absent in the other siblings and 
therefore may be unrelated to this hereditary syndrome. 
For differential diagnosis we considered 17 syndromes characterized by at least two of the 
four main symptoms observed in the present family (Table 1). These syndromes included 
four autosomal dominant, one X-linked, and eleven autosomal recessive disorders and one 
sporadic phenotype. None of these phenotypes corresponded to the syndrome described 
here. 
The pedigree is suggestive for an autosomal recessive mode of inheritance. However, the 
presence of a very small unbalanced chromosomal abnormality in the patients as a result 
of a balanced translocation in one of the parents is also a possibility that is not fully 
excluded by our cytogenetic findings. We suggested that this syndrome be considered a 
new entity within the heterogenous group of ectodermal dysplasias. 
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Chapter 4 
Naevus Corniculatus: A New Acantholytic Disorder 
R Happle 
PM Steijlen 
G Kolde 
Br J Dermatol 1990; 122: 107-112 
SUMMARY 
We describe a 33-year-old man with an unusual epidermal naevus that followed the lines 
of Blaschko There were filiform hyperkeratoses, large cutaneous horns and lesions that 
resembled giant comedones and linear hyperkeratotic plaques All of these lesions showed 
acantholysis without dyskeratosis As the disorder is characterized by multiple small or 
large hom-like processes, we propose the term 'naevus comiculatus' 
Various types of epidermal naevi have been described, such as the common verrucous 
type, the epidermolytic t>pe', and the inflammatory linear verrucous epidermal naevus 
(ILVEN) 2 These are not simply variants of each other, but are regarded as being distinct 
entities and all of them have a linear arrangement that follows the lines of Blaschko 3 
We report an epidermal naevus that differs from the types known so far, and for which we 
propose the term 'naevus comiculatus' 
CASE REPORT 
A 33->ear-old patient had a hyperkeratotic skin disorder from birth The family history 
was non-contributory and the patient had a daughter who was normal Physical 
examination revealed an epidermal naevus that was arranged in streaks and involved the 
entire body with the exception of the head (Figure I) The distribution of the skin lesions 
followed the lines of Blaschko Most of the individual lesions consisted of hom-like 
processes (Figure 2) and some areas were covered with filiform hyperkeratoses (Figure 3) 
Other areas showed large cutaneous horns, measuring up to 2 cm The patient was able to 
remove these homs without any pain, to leave a cavity lined by an erythematous keratotic 
wall In other areas, the hyperkeratoses resembled giant comedones Some of the lesions 
coalesced to form large linear verrucous plaques which were especially thick on the soles 
and were the cause of pain whilst walking In 1970 some of the large hyperkeratotic 
lesions of the right sole had been removed surgically, with subsequent grafting of skin 
obtained from the right thigh 
Light and electron microscopical findings 
During the past 20 years, eight biopsies were taken of lesions from various sites Light 
microscopy of these biopsies showed a thickened epidermis with marked 
hyperorthokeratosis (Figure 4) The most prominent feature, however, was acantholysis 
with clefting both suprabasally and in the upper epidermis, resulting in the appearance of a 
'dilapidated brick wall' (Figure 5) Dyskeratotic cells were only rarely noted 
On electron microscopy the keratinoc>tes showed thickened tonofilament bundles as well 
as elongated and branching microvilli (Figure 6 a-c) The wavy tonofilament aggregates 
surrounded the nuclei in a whorling configuration The microvillous projections only 
rarely contained tonofilaments and desmosomal attachments These changes were present 
in the suprabasal layer and were more prominent in the upper epidermis Widening of the 
intercellular spaces, resulting in blister formation, was found throughout the entire 
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epidermis. There was no dyskeratotic degeneration of the acantholytic cells. The granular 
layer showed a regular deposition of keratohyalin granules on the thickened tonofilaments. 
The horny layer was markedly thickened but did not show pathological inclusions. 
JRU 
Fig. 1. Naevus corniculatus, arranged in a systemized pattern following the lines of Blaschko 
Fig. 2 Linear arrangement of horn-like processes on the left hand 
»^жл** 
Fig. 3 Filiform hyperkeratoses on the trunk. 
Fig. 4 Cutaneous horn showing cleavage within the underlying epidermis (original x30) 
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Fig. 5 Intraepidermal cleavage with partial adhesion of the acantholytic prickle cells, giving the 
impression of a dilapidated brick wall (original x80) 
Fig. 6 a. Low-power electron microphotograph of the basal and suprabasal epidermis showing initial 
acantholysis with widened intercellular spaces (x2800) b. Acantholytic cells within the prickle cell layer 
showing characteristic disorganisation of tonofilament bundles (ХІ400) c. High power electron 
microphotograph of the atypical microvillous projections of keratinocytes. There are numerous elongated 
microvilli without tonofilament-desmosome complexes (x6500) 
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DISCUSSION 
This uncommon type of epidermal naevus was characterised by acantholysis and we were 
not able to find a similar case in the available literature. Clearly this naevus is neither 
Hailey-Hailey disease4, Darier's disease5 nor familial dyskeratotic comedones.6 The 
systematized linear distribution is similar to that observed in acantholytic dyskeratotic 
epidermal naevus.78 In this condition, however, the individual lesions resemble those of 
Darier's disease910 and there are neither filiform homs nor comedo-like lesions as 
observed in our patient. The light and electron microscopical findings of our case 
resembled those seen in Hailey-Hailey disease" rather than Darier's disease.' Our case is 
also fundamentally different from the relapsing linear acantholytic dermatosis as described 
by Vakilzadeh and Kolde12, the individual lesions being persistent and inflammation only 
rarely occurring. 
In conclusion, this naevus seems to be a new skin disorder Its clinical, histopathological 
and ultrastructural features separate it from any other genetic acantholytic skin disorders 
and, in particular, from other linear conditions such as relapsing linear acantholytic 
dermatosis and acantholytic dyskeratotic epidermal naevus. 
As hom-like processes are the clinical hallmark of the disorder, we propose the term 
'naevus comiculatus'. The word corniculatus means 'covered with small hom-like 
processes or horns'." The fact that the cutaneous homs can reach such a considerable size 
despite acantholysis at their base, may be explained by the almost complete absence of 
inflammation. This contrasts with that seen in other acantholytic skin disorders though the 
phenomenon of acantholysis may explain why many of these homs can easily be removed 
without pain or bleeding. 
It is likely that this naevus originated from a somatic mutation occurring at an early stage 
of embryogenesis, or from a gametic half chromatid mutation M Whether the distribution is 
bilateral or unilateral, and whether the involvement is widespread or localized, will depend 
on the time during embryonic development when the somatic mutation occurred. 
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Chapter 5 
CHILD-Syndrom bei Mutter und Tochter 
R Happle 
D Karlic 
PM Steijlen 
Hautarzt 1990; 41; 105-108 
ZUSAMMENFASSUNG 
Ein 15jahnges Madchen mit der typischen Symptomatik des CHILD-Syndroms 
(kongenitale Hemidysplasie mit ichthyosiformem Nävus und Ghedmaßendefekten) wird 
beschrieben Als begleitende ipsilaterale Anomalien wurden systematisierte Hypotrichosis, 
Blockwirbel, Halbwirbel, Hypoplasie der Beckenschaufel und Agenesie der Niere 
beobachtet Bei der gezielten Befragung der Mutter ergab sich, daß in ihrer Jugend lineare 
ichthyosiforme Hautveranderungen an 3 verschiedenen Korperstellen bestanden hatten 
Diese hatten sich im frühen Erwachsenenalter spontan zuruckgebildet und dabei 
streifenförmige Kahlstellen sowie eine Onychodystrophie an einem Finger hinterlassen 
Damit ist zum ersten Mal die Vererbung dieser Genodermatose von der Mutter auf die 
Tochter nachgewiesen Das postulierte Konzept der X-chromosomal-dominanten 
Vererbung mit Letalwirkung für männliche Embryonen wird hierdurch untermauert Wir 
ziehen den Schluß, daß die Mutter eines Madchens mit CHILD-Syndrom so lange nicht 
als phänotypisch gesund betrachtet werden kann, als sie nicht sorgfältig auf 
Minimalsymptome der Haut oder des Skelettes untersucht worden ist 
SUMMARY 
A 15-year-old girl with the typical signs and symptoms of the CHILD syndrome 
(congenital hemidysplasia with ichthyosiform nevus and limb defects) is described 
Associated ipsilateral anomalies included systematized hypotrichosis, fused vertebrae, 
hemivertebrae, pelvic hypoplasia and renal agenesis During a careful inquiry, her mother 
reported that during her own adolescence she had linear ichthyosiform skin changes 
localized in 3 different regions of her body These plaques had disappeared spontaneously 
in early adulthood, leaving permanent lesions in the form of hairless streaks and a 
dystrophic fingernail Hence this is the first report of a mother-to-daughter transmission of 
this genodermatosis, lending further support to the proposed concept of X-hnked dominant 
inheritance with lethality for male embryos We conclude that the mother of a girl 
suffering from the CHILD syndrome cannot be considered to be unaffected unless a 
meticulous examination of her skin and bones has ruled out even minimal signs of 
involvement 
Das CHILD-Syndrom gehort zur heterogenen Gruppe der Epidermaln avus-Syndrome 
Ursprunglich galt CHILD als Abkürzung fur "congenital hemidysplasia with ichthyosiform 
erythroderma and limb defects"8 Da die ichthyosiformen Hautveranderungen jedoch von 
sehr geringer Ausdehnung sein können und alle Merkmale eines Nävus aufweisen, 
erscheint folgende Interpretation des Akronymus CHILD sinnvoller "Congenital 
hemidysplasia with ichthyosiform nevus and limb defects" 6 
Wahrend andere Epidermalna vus-Syndrome wie das Schimmelpenning-Feuerstein-Mims-
Syndrom und das Proteus-Syndrom grundsatzlich sporadisch auftreten!, besteht beim 
CHILD-Syndrom die Besonderheit, daß er erblich ist Im jähre 1980 habben wir postuliert, 
daß diesem Phänotyp ein X-chromosomal-dominantes Gen mit Letalwirkung fur mannliche 
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Embryonen zugrundeliegt8 Dieser Erbmodus wurde primar nicht aus 
Familienbeobachtungen abgeleitet, sondern aus dem Überwiegen des weiblichen 
Geschlechts im Verhältnis 19 1 und aus der asymmetrischen, mosaikartigen Verteilung der 
Defekte, die an ein X-Inaktivierungsmuster denken ließ 
Das Konzept ist in der humangenetischen Literatur mit Zustimmung aufgenommen 
worden'32' Es bedarf jedoch noch der Untermauerung durch Familienbeobachtungen Aus 
diesem Grunde halten wir die folgende Kasuistik fur mitteilenswert 
KASUISTIK 
Ein 15 jahnges Madchen aus Jugoslawien wurde in der Hautklinik der Univeisitat 
Nijmegen vorgestellt wegen eines Fehlbildungssyndroms, für das bisher keine 
befriedigende Diagnose gefunden worden war Bei der Untersuchung stellte sich heraus, 
daß die Mutter denselben Phänotyp in schwacher Ausprägung aufwies 
Patientin 1 (Tochter) 
Bei der Geburt des Madchens waren die Mutter und der Vater beide 29 Jahre alt Es 
handelte sich um die erste und einzige Schwangerschaft Ab dem 3 
Schwangerschaftsmonat mußte die Mutter Bettruhe halten wegen eines Abortus imminens, 
Sie bekam Hormone, Vitamine und milde Sedativa Gleich nach der Geburt fiel eine 
Hypoplasie der rechten Korperhalfte mit Asymmetrie des Gesichtes und Verkürzung der 
Extremitäten auf Bei der stationaren Untersuchung in der Kinderklinik der Universität 
Zagreb zeigte das Pneumenzephalogramm eine symmetrische Erweiterung der lateralen 
Ventrikel Im Ausscheidungsurogramm war auf der rechten Seite keine Nierenfunktion 
erkennbar, und sowohl szintigrafisch als auch sonografisch wurde nachgewiesen, daß die 
rechte Niere fehlte Bei der Röntgenuntersuchung des Skelettes wurden außer einer 
asymmetrischen Verkürzung der langen Rohrenknochen auch unregelmäßig verkürzte 
Phalangen an der rechten Hand und am rechten Fuß gefunden Das Os cuboideum fehlte 
auf der rechten Seite Als das Kind 3 Wochen alt war, entstanden scharf umschriebene 
gerötete Areale mit gelblicher Schuppung auf der rechten Korperseite an Vulva, Perineum 
und Oberschenkel und einige Monate spater auch am rechten Fuß Die Diagnose der 
Kinderklinik Zagreb lautete "Russell-Silver-Syndrom, Agenesie der rechten Niere, 
Dermatitis desquamativa Leiner" 
Im 3 Lebensjahr wurde an der rechten Haisseite eine branchiogene Zyste entfernt Im 5 
Lebensjahr entstanden ichtyosiforme entzündliche Plaques in der rechten Achsel und am 
linken Vorfuß Ab dem 12 Lebensjahr entwickelten sich weitere navoide ichthyosiformc 
Hautveranderungen va auf der rechten Korperhalfte (Nacken, Penoralregion, 
submamma re Region, Ellenbeuge, Kniekehle, Hand), aber auch auf der linken Seite 
(Penoralregion, Ellenbeuge, Daumen) 
Im 12 Lebensjahr erfolgte eine weitere stationäre Untersuchung in der Kinderklinik der 
Universität Zagreb Die Röntgenuntersuchung zeigte eine linkskonvexc Skoliose und 
leichte K>phose, Halbwirbel (T8, TU, I 1), Blockwirbel (T10/T11), eine Asymmetrie des 
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Beckens und eine Agenesie der mittleren Phalanx aller Zehen rechts Bei 
Inlelligenzprufungen lagen die Ergebnisse leicht über dem Durchschnitt Aufgrund der 
Untersuchung von Semidunnschnitten lautete die Stellungnahme des Dermatohisto-
pathologen (Dr Dobric) "Es bestehen nicht genügend Hinweise fur Psoriasis, denn die 
Veränderungen sind nahezu ausschließlich auf die Epidermis beschrankt Die 
Hautveranderungen sollten im Zusammenhang mit dem Syndrom gesehen und klinisch 
diagnostiziert werden " Die Entlassungsdiagnose lautete "Russell-Silver-Syndrom und 
Dermatitis psoriasiformis" 
Im 13 Lebensjahr ist an der rechten Hand eine der navoiden Hautveranderungen exzidiert 
worden, ohne daß ein Rezidiv aufgetreten ist 
Jetziger Befund 
Das 15jahnge Madchen macht einen aufgeweckten Eindruck und weiß sich in englischer 
Sprache differenziert auszudrucken Auch die Geschlechtsentwicklung ist altersent-
sprechend Es besteht eine ausgeprägte Dysplasie der rechten Korperhalfte mit starker 
Verkürzung der Gliedmaßen, leichter Asymmetrie des Gesichtes und multiplen scharf 
umschriebenen, geröteten Hautarealen, die von gelblichen wachsartigen Schuppen bedeckt 
sind, teilweise aber auch nassen und Schuppenkrusten aufweisen (Abb I und 2) Auf der 
rechten Seite sind befallen Penoralregion, Nacken und Hinterhaupt, Beugeseiten der 
großen Gelenke, submamma re Region Vulva und Rima am sowie Hand und Fuß (Abb 3 
und 4) Es besteht eine ausgeprägte Dysplasie der Nagel Am rechten Fuß weisen die 
Interdigitalra urne papillomatose, nassende Proliferationen auf In geringerer Ausprägung 
bestehen entsprechende Hautveranderungen auch auf der linken Korperhalfte in der 
Ellenbeuge sowie an der Hand und am Vorfuß Auf der rechten Seite fehlt an 
umschriebenen Stellen die Behaarung nicht nur im Bereich des ichthyosiformen Nävus 
(z В Hinterhaupt), sondern auch dort, wo die Haut im übrigen normal aussieht (ζ В Mons 
pubis und Fußrucken) (Abb 1 und 4) Am linken Arm besteht eine systematisierte 
Haarlosigkeit in Streifenform, entsprechend dem Muster der Blaschko-Linien 
Histologische Untersuchung 
Über einer akanthotischen Epidermis sieht man eine ausgeprägte Hyperkeratose, 
überwiegend vom Typ der Parakeratose Die Breite des Stratum ganulosum wechselt 
zwischen 2 und 6 Zellagen Im oberen Konum besteht ein lumphozytares Infiltrat, 
durchmischt mit eosiophillen Granulozyten und Plasmazellen 
Therapie und Verlauf 
Zum Ausgleich der Beinlangendifferenz wurde in der Orthopädischen Universitätsklinik 
Nijmegen em Schuh mit verdickter Sohle angefertigt Von der Abteilung für Plastische 
Chirurgie wurde der Rat gegeben, die besonders hinderlichen Haulveranderungen an der 
rechten Fußsohle operativ entfernen zu lassen, wobei der Defekt mit Spalthaut gedeckt 
werden sollte Zunächst machten wir jedoch einen konservativen Behandlungsversuch mit 
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Acitretin 20 mg/Tag (0,5 mg/kg KG). Innerhalb von 4 Monaten bildeten sich die 
Hautveränderungen an den Fußsohlen so weit zurück, daß das Mädchen wesentlich leichter 
gehen konnte. An den übrigen Körperstellen blieb der ichthyosiforme Nävus jedoch 
unbeeinflußt und breitete sich eher noch aus. 
Abb. 1. CHILD-syndrom. Ichthyosiformer Nävus 
und fehlende Schambehaarung mit scharfer 
Begrenzung in der Medianlinie. 
Abb. 3. CHILD-syndrom. Dysplasie der rechten 
Hand mit Unregelmäßig verkürzten Fingern und 
Onychodystrophie. 
Abb. 2. CHILD-syndrom. Ichthyosiformer Nävus 
mit gelber wachsartiger Schuppung in der rechten 
Kniekehle. 
Abb. 4. CHILD-syndrom. Dysplasie des rechten 
Fußes mit Hypotrichose, Onychodystrophie und 
nässenden, papillomatösen Proliferationen in den 
Interdigitalräumen. 
Patientin 2 (Mutter) 
Die 44jährige Frau ist von guter Gesundheit. Es ist keine Asymmetrie des Körperbaus 
erkennbar. Ab dem 5. Lebensjahr haben sich streifenförmige ichthyosiforme 
Hautveränderungen am Kinn sowie am Mittel- und am Ringfinger der linken Hand 
entwickelt. Diese hyperkeratotischen Areale sind von einem von uns (D.K) über mehrere 
47 
Jahre hinweg beobachtet worden Eine dritte lineare ichthyosiforme Hautveranderung ist 
ab dem 13 Lebensjahr am Mons pubis aufgetreten Sie verlief, ebenso wie die Lasion am 
Kinn, rechts von der Medianlinie und parallel zu ihr Alle 3 navoiden Hautveranderungen 
haben sich um das 20 Lebensjahr herum spontan zuruckgebildet 
Befund 
Am Kinn und am Mons pubis bestehen streifenförmige haarlose Areale dort, wo früher die 
hyperkeratotischen Hautveranderungen vorhanden waren Der linke Mittelfinger weist 
einen streifenförmigen Nageldefekt vom Typ der Onychorrhexis auf, die radiare Haine der 
Lunula zeigt eine unregelmäßige Kontur 
Besprechung 
Bei der Tochter ist die klinische Symptomatik so typisch, daß kein Zweifel an der 
Diagnose bestehen kann Die Beobachtung macht deutlich, warum es besser ist, die 
charakteristischen Hautveranderungen als ichthyosiformen Nävus zu beschreiben und nicht 
als ichthyosiforme Erythrodermie wie ursprünglich von uns vorgeschlagen68 Eine 
Agenesie der ipsilateralen Niere war bisher zweimal beobachtet worden71! Ein bislang 
noch wenig beachteter Befund ist das Fehlen der Korperhaare in streifenförmiger 
Verteilung entsprechend dem System der Blaschko-Linien 
Mit dieser Beobachtung haben wir zum ersten Mal die Vererbung der charakteristischen 
Hautveranderungen von der Mutter auf die Tochter nachgewiesen, wie es aufgrund des 
ätiologischen Konzeptes zu erwarten ist Bedeutsam erscheint uns die Tatsache, daß bei 
der Mutter nur geringgradige Hautveranderungen bestanden Erst nachdem wir die Mutter, 
die selbst Naturwissenschaftlerin ist, über den X-chromosomal-dominanten Erbgang mit 
Letalwirkung für männliche Embryonen und über das Phänomen der X-Inaktivierung mit 
der Möglichkeit einer extremen Lyonisierung6 unterrichtet hatten, erzahlte sie uns, daß bei 
ihr in der Jugendzeit streifenförmige hvperkeratotische Hautveranderungen an 3 
verschiedenen Korperstellen bestanden hatten, und machte uns auf die Nagelveranderung 
als Restzustand nacht spontaner Ruckbildung dieser navoiden Lasionen aufmerksam Die 
Krankheit der Tochter hatte somit sehr leicht irrtümlich als sporadisch angesehen werden 
können 
Die Beobachtung ist insofern bedeutsam, als sie alle bisher mitgeteilten sporadischen Falle 
in einem neuen Licht erscheinen laßt Ohne eine sehr sorgfaltige Untersuchung der Mutter 
bestehen Zweifel am sporadischen Auftreten des Syndroms Dabei sollte man auch an die 
Möglichkeit extrakutaner Minimalsymptome denken So haben Schlcnzka et al 19 eine 
leichte Verkürzung des linken Armes und Beines bei der Mutter eines Kindes mit CHILD-
Syndrom beschrieben Bei den früheren unzweifelhaften Familienbeobachtungen 2 '°14 
wurden die Mutter als erscheinungsfrei geschildert Ohne eine gezielte Untersuchung der 
Haut und des Skelettes kann man jedoch nicht mit Sicherheit davon ausgehen, das sie 
phänotypisch gesund waren 
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Die Dinge liegen beim CHILD-Syndrom somit ähnlich wie bei der X-chromosomal-
dominanten Chondrodysplasia punctata. Nachdem es gelungen war, ausgehend von der 
Geschlechtsverteilung und dem Mosaikmuster der Hautanomalien den Erbgang 
aufzudecken7, haben andere Autoren ihre "sporadischen" Beobachtungen nachuntersucht 
und bei den Müttern charakteristische Hautanomalien in Mosaikartiger Verteilung 
gefunden, wie es beim X-chromosomal-dominanten Erbgang zu erwarten ist.'2 
Auch beim CHILD-Syndrom werden solche Familienbeobachtungen zunehmen. Das die 
Kenntnis dieser Krankheit noch ungenügend ist, kann nicht verwundem, denn das 
Syndrom wird bisher in den dermatologischen Standardwerken mit keinem Wort 
erwähnt.'·318 Wir nehmen an, das die Genodermatose bislang unter folgenden 
Fehldiagnosen archiviert wird, denn unter diesen Bezeichnungen finden wir das CHILD-
Syndrom bis auf den heutigen Tag auch in der Literatur beschrieben: ILVEN, 
Epidermalnävus-Syndrom, Solomon-Syndrom, halbseitige Psoriasis, atypische 
Erythrokeratodermie, Conradi-Syndrom."1·16·20·4 '7 
Das die Mutter meist sehr viel milder befallen sein wird als die Tochter, läßt sich damit 
erklären, das die Fähigkeit zur Fortpflanzung umso größer ist, je geringer der Phänotyp 
ausgeprägt ist, und das sich andererseits das CHILD-Syndrom umso leichter erkennen läßt, 
je schwerer die Patientin betroffen ist. 
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Chapter 6 
Co-occurrence of Linear Psoriasis and Porokeratotic 
Eccrine Ostial and Dermal Duct Naevus 
PCM van de Kerkhof 
PM Steijlen 
R Happle 
Acta Derm Venereol (Stockh) 1993; 73: 311-312 
In a previous communication a case report was presented on inflammatory linear 
verrucous epidermal naevus (ILVEN).' In this letter we report on some additional features 
which are of relevance for the understanding of ILVEN. 
At the age of 12 years the patient, a 47-year-old man, had experienced an jtching linear 
erythematosquamous lesion on his left shin, the left thigh, the dorsal aspect of the left 
lower leg, the genital region, the lumbar region and also on the trunk. The distribution 
pattern followed the lines of Blaschko as described in the previous publication.' The 
lesions on the left lower leg had a partly verrucous appearance. In addition to this linear 
pattern, erythematosquamous plaques with a typical psoriatic appearance were observed at 
the extensor aspects of both elbows and the scalp; the finger nails showed multiple pits. 
At careful examination we observed as an extension of the linear arrangement of 
erythematosquamous lesions at the left lower leg, discrete hyperkeratotic papules and pits 
at the plantar and lateral aspect of the left foot. More proximally at the lateral surface of 
the foot these lesions partly adopted a psoriatic appearance (Figure la-b). By contrast, the 
remaining erythematosquamous lesions within the mosaic pattern and the classical 
psoriatic plaques did not show any hyperkeratotic papules and pits but had the typical 
appearance of psoriasis. It is not known for how many years these hyperkeratotic papules 
and pits have been present. There was no family history of similar skin disorders. The 
response of the erythematosquamous lesions of this patient to an antipsoriatic treatment 
has been described before.' Topical corticosteroids, tar, UVB and PUVA did not improve 
the lesions, whereas short-contact dithranol treatment resulted in virtually total clearing of 
the erythematosquamous lesions after 8 weeks. The lesions, however, relapsed within 6 
months' treatment. Dithranol has been reinstituted on various occasions for the past 3 
years. 
Fig. 1. Porokeratose Eccrine Ostial and Dermal Duct Naevus, a. Discrete papules and pits on the left 
sole. b. Hyperkeratotic papules coalescing with a psoriasiform lesion. 
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Histopathological examination of biopsies taken from the erythematosquamous lesions on 
the left lower leg and thigh showed features typical of psoriasis: acanthotic epidermis with 
elongation of the rete ridges, hyperkeratosis of the ortho and para type, dermal 
accumulation of mononuclear cells and polymorphonuclear leukocytes, and intra-epidermal 
micro-abscesses filled with polymorphonuclear leukocytes. The eccrine glands did not 
show any abnormality. The histological appearance of a hyperkeratotic lesion on the left 
sole was quite different. The epidermis was acanthotic, with a pronounced granular layer 
and orthokeratosis. Dilated eccrine ducts were sleeved by a parakeratotic cornoid lamella 
(Figure 2). The glandular portions of the eccrine glands were not involved. 
Fig. 2. Histopathological appearance of a papule on the left sole: dilated eccrine duct sleeved by a 
porokeratotic cornoid lamella. 
Clinically and histologically the lesions on the left foot represent porokeratotic eccrine 
ostial and dermal duct (PEODD) naevus. PEODD naevus is a dermatosis that follows the 
lines of Blaschko. The naevus is characterized by porokeratotic plugs related to eccrine 
sweat ducts.2"5 This naevus can be best explained by a somatic mutation. In cases reported 
so far the lesions had been present since birth.2"5 In our patient the lesions were rather 
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discrete and may have gone unnoticed at birth Linear psoriasis superimposing linear 
verrucous epidermal naevus has been observed by several authors.6 '8 Bondi reported a case 
of linear psoriasis extending beyond the boundaries of linear verrucous epidermal naevus, 
associated with bilateral psoriatic lesions of the common type ' In the present case, at the 
lateral surface of the foot the topographical coexistence of linear psoriasis and PEODD 
naevus was evident. PEODD naevus may trigger psoriasis as a "Kobner" phenomenon. In 
the present case, however, linear psoriasis is extended beyond the areas clinically involved 
by PEODD naevus. This unusual observation can be best explained in the following way. 
PEODD naevus is caused by a specific somatic mutation. Within the systematized linear 
skin area representing a clonal outgrowth of cells carrying this mutation, the phenotype is 
only partially expressed. In other parts, the linear skin areas look normal but form a locus 
minora resislenliae, predisposing to the development of psoriasis. In other words, the 
mutation responsible for PEODD naevus would constitute a major psoriasis gene within a 
spectrum of polygenic predisposition for psoriasis. Other explanations, such as the 
assumption of a contiguous gene defect with deletion of a neighbouring psoriasis locus, 
appear to be less likely. Whatever explanation holds true, such clinical observations may 
help in the future to elucidate the enigmatic aetiology of psoriasis. 
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Part II 
Cell Biological Aspects 

Introduction 
Based on biochemical and cell biological studies attempts have been made to simplify 
classification of ichthyosis and other monogenic disorders of keratinization. Using 
histologic and cell kinetic studies, Frost and co-workers classified the ichthyoses into 
hyperproliferalion hyperkeratoses and retention hyperkeratoses. ' 
A drawback of this classification is that many entities are lumped together and that for 
many disorders of keratinization such an investigation has not yet been done. Besides the 
barrier function of epidermal lipids it is known that epidermal lipid metabolism plays an 
important role in the homeostasis of the stratum corneum. Alterations in epidermal lipids 
were detected in X-linked recessive ichthyosis, Refsum's disease and neutral lipid storage 
disease. Williams and Elias demonstrated that the clinical heterogeneity of lamellar 
ichthyosis was reflected in the alkane content of the stratum comeum.23 
Since these alkanes are probably exogenous their conclusions are now under debate. 
Epidermal lipid research gave only a marginal contribution to the classification of 
disorders of keratinization until now. 
In chapter I data are presented on the keratin expression patterns in a variety of 
monogenic disorders of keratinization. In particular the question is addressed to what 
extent these data can be of diagnostic relevance. Since it is known that the dermis also 
plays a role in epidermal proliferation and differentiation extracellular matrix components 
were studied in several disorders of keratinization (chapter 2 and 3). 
Molecular biology and the expanding knowledge of the human genome made tools 
available to study disorders of keratinization at the molecular level. Patients with bullous 
congenital ichthyosiform erythroderma suffer from fragility of the differentiating 
keratinocytes in the suprabasal layers of the epidermis (epidermolytic hyperkeratosis). This 
form of ichthyosis is caused by mutations in the genes coding for keratin 1 or keratin 10 
that are expressed in the suprabasal keratinocytes.'*"7 Palmoplanar hyperkeratosis of the 
Vomer type is histologically characterized by epidermolytic hyperkeratosis too This 
disease is caused by a mutation in the gene coding for keratin 98. Not until recently it was 
debated whether ichthyosis bullosa of Siemens was an entity distinct from bullous 
congenital ichthyosiform erythroderma (part 1, chapter 1). In chapter 4 and 5 molecular 
biological studies are presented which show that ichthyosis bullosa of Siemens is an entity 
distinct from bullous congenital ichthyosiform erythroderma but that ichthyosis bullosa of 
Siemens and autosomal dominant ichthyosis exfoliativa are identical. 
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Chapter 1 
Distribution of Keratins in Monogenetic Disorders of 
Keratinization: an Immunohistochemical Study 
PM Steijlen 
FCS Ramaekers 
GNP van Muijen 
M Link 
PCM van de Kerkhof 
To be submitted 
SUMMARY 
Fifty-five punch biopsies from 54 patients suffering from 13 different disorders of 
keratinization were examined lmmunohistochemically using a large panel of monoclonal 
and polyclonal antibodies of known and restricted spedifities For comparison we included 
biopsies from normal skin Disorders of keratinization without substantial inflammation 
ι e autosomal dominant ichthyosis vulgaris, x-hnked recessive ichthyosis and non-
erythrodermic lamellar ichthyosis yielded more or less the same staining pattern as 
observed in normal epidermis staining of the basal layer with the antibodies recognizing 
keratin 5 and keratin 14, suprabasal staining with the antibodies recognizing keratin 1 and 
10 Disorders of keratinization associated with substantial inflammation like erythrodermic 
lamellar ichthyosis, epidermolytic ichthyosis, erythrodermia variabilis, CHILD syndrome 
and Daner's disease showed an extension of staining with the antibodies recognizing 
keratin 5 and 14 into the suprabasal zone In these disorders staining with the antibodies 
recognizing keratin 6, 16, and 17 was observed frequently Although the present study 
demonstrates that the expression of keratins is distorted in various disorders of 
keratinization its diagnostic relevance seems limited 
INTRODUCTION 
Intermediate filaments of epithelial cells are composed of keratins and normally consist of 
two or more different keratin polypeptides In human epitheha the keratins are a family of 
at least 20 distinct polypeptides (numbered 1 to 20 by Moll et al)1 which can be divided 
into tow subfamilies, ι e the neutral to basic and the acidic keratins, forming 
heteropolymers 2i The composition of the intermediate filaments varies with epitheha 
lineage and with the stage of differentiation or development This variety is presumably 
needed to allow different epithelial cells to fulfil different needs, and functions e g cell 
differentiation, proliferation and migration In the normal human epidermis four major 
keratins are expressed sequentially during differentiation The basal keratinocytes contain 
the keratin pairs 5 and 14, while upon differentiation and migration out of the basal cell 
layer keratin 1 and 10 synthesis occurs 
The monogenetic disorders of keratinization form a large and heterogenous group of skin 
diseases In this group the ichthyoses represent a major part In patients with bullous 
congenital ichthyosiform erythroderma mutations have been found in the genes coding for 
keratin 1 or keratin IO4 7 
The aim of the present study was to evaluate the keratin expression patterns in a variety of 
monogenic disorders of keratinization In particular we want to know to what extent these 
disorders express keratins normally not present in normal adult skin, and to what extent 
these disorders display different topographical distribution patterns of normally occurring 
keratins that could be of diagnostic relevance 
Punch biopsies obtained from 54 patients suffering from 13 different disorders of 
keratinization were examined lmmunohistochemically using a large panel of monoclonal 
and polyclonal antibodies of known and restricted keratin specificity 
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MATERIALS AND METHODS 
Tissue samples 
Skin punch biopsies were obtained from patients with disorders of keratinization (Table I) 
including autosomal dominant ichthyosis vulgaris (ADIV, n=10), X-linked recessive 
ichthyosis (XRI; n=6), non-erythrodermic autosomal recessive lamellar ichthyosis (NELI; 
n=13), erythrodermic autosomal recessive lamellar ichthyosis bullosa (ELI; n=5), bullous 
congenital ichthyosiform erythroderma of Brocq (BCIE; n=5), ichthyosis bullosa of 
Siemens (IBS; n=4), epidermolytic epidermal naevus (EEN, n=2), harlequin fetus (n=l), 
CHILD syndrome (n=2), restrictive dermopathy (n=I), Darier's disease (n=2), collodion 
baby (n=2), and erythrokeratodermia variabilis (EKV; n=l). Biopsies were taken from the 
most affected regions, snap frozen directly after removal and stored in liquid nitrogen. 
Additionally, specimens of lesionai skin were taken for routine histological examination. 
Furthermore, in the patients affected with ichthyosis, harlequin fetus, CHILD syndrome, 
restrictive dermopathy, collodion baby and erythrokeratodermia variabilis, biopsies were 
taken for electron microscopical examination. Diagnoses were based on the clinical, 
histological and electron microscopical findings. The diagnosis XRI was based also on the 
assessment of steroid sulphatase deficiency in leucocytes.8 For comparison we included 
frozen biopsies from normal skin (n=9), from psoriasis involved skin (n=6) and 
uninvolved skin (n=2), dermatitis (n=2) and lichen ruber planus (n=l) (Table I) Patients 
on systemic and topical treatment with retinoids or glucocorticoids were excluded from 
this study. 
Table I. Clinical characteristics of patients studied 
Diagnosis No of cases Age (yrs) Sex 
Normal skin 
ADIV 
XRI 
NELI 
ELI 
BCIE 
IBS 
EEN 
Harlequin fetus 
CHILD syndrome 
Restrictive dermopathy 
Darier's disease 
Collodion baby 
Erythrokeratodermia variabilis 
Dermatitis 
Lichen ruber planus 
Psoriasis 
9 
10 
6 
13 
5 
5 
4 
2 
1 
2 
1 
2 
2 
1 
2 
1 
6 
30-70 
'/2-67 
19-58 
2-66 
'/4-8 
1/12-61 
22-53 
14, 45 
' /4 
12, 16 
1/12 
19, 36 
1/12 
17 
50-84 
59 
31-60 
F 
4 
6 
0 
4 
2 
1 
2 
1 
0 
2 
0 
2 
2 
1 
1 
0 
4 
M 
5 
4 
6 
9 
3 
4 
2 
1 
1 
0 
1 
0 
0 
0 
1 
1 
2 
Antibodies and immunohistochemistry 
Specifity, characteristics and references for these antibodies are summarized in Table II 
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A panel of 19 monoclonal and 2 polyclonal antikeratin antibodies were used in this study. 
The polyclonal antibodies AF87 and AFI24 were a kind of gift from Dr Stuart H. Yuspa 
(National Cancer Institute, Bethesda, Maryland, USA) These monospecific antibodies 
were raised in rabbits against C-terminal synthetic peptides of keratins 1 and 6 as 
described before.' The mouse monoclonal antibody KA12, reacting with keratin 6 in two 
dimensial immunoblots from oesophagus and placenta, was a kind of gift from Dr R. 
Nagle (Tucson, Arizona, USA). 
Four-six micron thick tissue sections were stained with the keratin antibodies using a two-
step indirect immunoperoxidase staining procedure as described previously.19 Exclusively 
the interfollicular epidermis was assessed for staining. 
Table II. 
Monoclonal/Pol>-
clonal Antibody 
Keratin Type of 
Specifity Differentiation 
Source and References 
AF87 
RKSE60 
RCK102 
RCK107 
LL002 
AF124 
KA12 
LL025 
6B10 
1C7 
2D7 
RCK105 
LE41 
CAM5 2 
M20 
RGE53 
RCK106 
CK182 
2C8 
E3 
RPN1165 
1 
10 
5 ( 
14 
14 
6 
6 ( 
16 
4 
13 
13 
7 
8 
8 
8 
18 
18 
18 
18 
17 
19 
:+8) 
:+5) 
suprabasal cells of 
stratifying, comifying 
epithelia 
basal cells 
hyperproliferative 
epithelia 
suprabasal cells of 
stratifying, non-
comifying epithelia 
simple epithelia 
simple epithelia, some 
stratifying epithelia 
D Roop, Bethesda, MD, 9 
Eurodiagnostics, Apeldoorn, NL, 10 
Eurodiagnostics, Apeldoorn, NL, 11 
F Ramaekers, Maastricht, NL, 12,13 
E Lane, Dundee, UK, 14,15 
D Roop, Bethesda, MD, 9 
R Nagle, Tuscon, AZ, 12 
E lane, Dundee, UK, 12,16 
Eurodiagnostics, Apeldoorn, NL, 17 
Eurodiagnostics, Apeldoorn, NL, 17 
Eurodiagnostics, Apeldoorn, NL, 17 
Eurodiagnostics, Apeldoorn, NL, 11 
E Lane, Dundee, UK, 18 
Becton&Dickinson, Etten-Leur, NL, 19 
G N P van Muijen, Nijmegen, NL, 20 
Eurodiagnostics, Apeldoorn, NL, 21,22 
Eurodiagnostics, Apeldoorn, NL, 11 
11 
GNP van Muijen, Nijmegen, NL,23 
Dakopatts, Glostrup, DK, 24 
Amersham, Little Chalfont/Bucks, UK, 25 
RESULTS 
The distribution pattern of the various keratins as detected in normal skin and in the 
various lesions are summarized in Figure 1 and depicted in Figure 2 
Normal skin (Figure la) 
In normal skin the basal cell compartment contains keratins 5 and 14, while the suprabasal 
cells express keratins 1 and 10 The keratin 14 antibody RCK107 in general showed 
staining of the basal, and to some extent the parabasal cell compartment. LL002 was an 
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exception to this rule, since it stained the whole epidermis. This holds true for all skin 
diseases described below (staining pattern not shown in the figures) 
X-linked Recessive Ichthyosis (XRI) (Figure lb) 
The keratin profile in all 6 patients with XRI is similar to that observed in normal skin. 
Autosomal Dominant Ichthyosis Vulgaris (ADIV) (Figure lc) 
The expression pattern of keratins in ADIV is largely similar to the pattern as seen in 
normal skin, except for keratin 6 and 16. Keratin 6 expression was observed sporadically 
in the suprabasal compartment in 4 out of 10 subjects. Only in one of these subjects 
keratin 16 was expressed sporadically in the suprabasal area. The antibody KA12 and 
AF124 showed practically identical reaction patterns. This holds true for all diseases 
described below. 
Non-erythrodcrmic autosomal recessive Lamellar Ichthyosis (NELI) (Figure Id) 
A distribution pattern largely similar to that of normal skin was observed. Keratins 5 and 
14 were seen in the parabasal cells in 5 out of 13 cases. Keratin 6 was expressed focally 
in 3 of these cases. 
Erythroderma autosomal recessive Lamellar Ichthyosis bullosa (ELI) (Figure le) 
Remarkably keratin 5 and 14 were seen in several cell-layers above the basal zone. In 4 
out of 5 patients basal and suprabasal expression of keratin 6 was observed focally using 
both antibodies. Moreover, 2 out of 5 patients showed expression of keratin 16. 
Epidemiol) tic hyperkeratosis (bullous congenital ichthyosiform erythroderma of 
Brocq (BCIE), ichthyosis bullosa of Siemens (IBS), and epidermolytic epidermal 
naevus (EEN) (Figure If) 
In 3 patients homogeneous staining of keratin 5 and 14 was observed. Five other cases 
showed an extended expression into the cell-layers just above the basal layer. 
In 4 out of 11 patients a homogeneously staining partem of keratin 6 with varying staining 
intensity was observed in the entire epidermis. The other patients showed a focal staining 
for keratin 6. In 3 out of 11 cases keratin 16 expression was homogeneously expressed in 
the suprabasal compartment. In the other 8 patients a focal staining pattern was observed. 
Two patients displayed expression of keratin 17 in the suprabasal zone 
Common inflammatory dermatoses (Figure lg) 
This group of lesions included dermatitis, psoriasis, and lichen planus. Keratin 1 and 10 
staining in these cases showed a pattern identical to normal skin Strikingly, 
immunoreactivity against keratin 5 and 14 was demonstrated in the entire epidermis in all 
cases Similarly, the antibodies keratin 6 and 16 stained the whole epidermis in 8 cases In 
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5 cases keratin 17 could be demonstrated in the middle and upper part of the epidermis. In 
one case the whole epidermis stained with the antibody against keratin 17. 
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Fig. 2. Immuno-perioxidase staining patterns: normal skin incubated with RKSE60 (a.); RCK107 (b.); 
non-erythrodermic lamellar ichthyosis incubated with AF124, note focal staining (arrows) (c); 
erythrodermic lamellar ichthyosis incubated with RCK107 (d.); KA12, note focal staining (arrows) (е.), 
and LL0025, note sporadic staining (arrows) (f.) 
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Fig. 2. Bullous congenital ichthyosiform erythroderma incubated with RCK107 (g.); KA 12 (h.); 
LL0025, note focal staining (arrows) (i.); ichthyosis bullosa of Siemens incubated with E3, note staining 
in the upper part of the epidermis (j.) 
Other inflammatory disorders of keratinization (Figure lh) 
This heterogeneous group of lesions included CHILD syndrome, morbus Darier, collodion 
baby, erythrokeratodermia variabilis, restrictive dermopathy, and harlequin fetus. Staining 
with antibodies against keratin 1 and 10 showed identical pattern as observed in normal 
skin in all cases. Staining with antikeratin 5 and 14 was essentially normal, except for 
collodion baby and erythrokeratodermia variabilis in which the suprabasal cell-layers were 
also stained. In morbus Darier, collodion baby and erythrokeratodermia variabilis a 
markedly extensive staining with antikeratin 6 and antikeratin 16 was observed. The 
remaining disorders in this group showed only focal staining with these antibodies. In one 
collodion baby keratin 17 expression was noted in the upper part of the epidermis. 
The staining pattern of RKSE60 (keratin 10) and AF87 (keratin 1) are superimposable as 
are the pattern of AF87 and AFI24 (keratin 6). The antibody LL002 recognizing keratin 
14 stains the whole epidermis in all biopsies. Probably the antibody recognized an epitope 
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which is preserved during differentiation In some cases the antibody RCKI07 shows a 
more extended expression as compared to the antibody RCK102 
DISCUSSION 
The present study using a large panel of antikeratins demonstrates that the expression and 
topographical distribution of keratins can vary considerably between the various disorders 
of keratinization The immunohistochemical approach does not permit a quantification of 
keratin expression, so we will restrict ourselves to the qualitative findings The 
topographical distribution of keratin 5 an 14 shows an extension of basal expression in 
normal skin to basal and suprabasal expression in erythroderma lamellar ichthyosis, 
epidermolytic hyperkeratosis, collodion baby, erythrokeratoderma variabilis and the group 
of common inflammation dermatoses Remarkably, these diseases are all characterized 
clinically and histologically by inflammation The expression of keratin 6, 16 and 17 is 
pronounced in the same group of diseases whereas these keratins are absent in normal 
skin Those biopsies which showed expression of keratin 6, showed always a 
topographical extension of expression of keratin 5 and 14 ADIV, XRI and NELI yielded 
the same keratin pattern as observed in normal skin However, in those patients suffering 
from ADIV who demonstrated focal keratin 6 and 16 expression atopic dermatitis may 
have complicated the situation 
Keratin 16 can only be demonstrated in those biopsies which express keratin 6 Keratin 17 
is present in those biopsies which express keratin 16 Other disorders of keratinization 
such as psoriasis, which show clinically and histologically a marked inflammation, 
demonstrate a marked extension of keratin 5 and keratin 14 expression and an induction of 
keratin 6, 16 and 17 expression 
The regulation of expression of keratin genes appears to be entirely at the level of 
transcription initiation26 Modulators at the level of transcription can be various 
environmental signals, such as hormones, vitamins, growth factors and possibly 
extracellular matrix components and cell adhesion molecules In how far inflammation 
factors such as cytokines may be involved is not known The present study is carried out 
at the protein level, therefore a defect of one of the genes coding for these keratins is not 
ruled out It is likely that the keratin may be recognized by the antibody although it is 
functional abnormal Recently, in patients with BCIE (epidermolytic hyperkeratosis) 
mutations have been found in the genes coding for keratin 1 or keratin 104 7 In our 
biopsies these keratins will still be recognized by the antibodies of patients with BCIE 
Therefore, further studies are indicated to discover keratin gene defects within the 
spectrum of disorders of keratinization 
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SUMMARY 
The extracellular matrix glycoprotein tenascin is sparsely distributed in normal human 
dermis The authors have shown that in a number of skin diseases (psoriasis, skin 
tumours), tenascin expression is strongly increased In this immunohistochemical study, 
using polyclonal and monoclonal antisera, we have tested the hypothesis that tenascin 
expression in vivo is linked to epidermal proliferation Using the sellotape stripping model 
in normal human skin, which causes a rapid recruitment of keratinocytes into the cell 
cycle, induction of tenascin expression was found in the upper dermis within 24 hours 
after stripping In contrast, in normoproliferative monogenic disorders of keratinization (X-
Iinked recessive ichthyosis, autosomal dominant ichthyosis vulgaris, non-erythrodermic 
lamellar ichthyosis), no increase in tenascin expression was found compared with normal 
skin These findings demonstrate a relationship between epidermal proliferation and 
metabolic alterations in the dermal compartment 
INTRODUCTION 
Tenascin is an extracellular matrix glycoprotein ' 4 that is identical to hexabrachion5, myo-
lendinous antigen6, cytotactin7 glioma mesenchymal extracellular matrix antigen8 and the 
high molecular weight Jl glycoproteins8 It is abundantly present in embryonic tissues but 
the expression is limited in adult tissues In addition, tenascin is reexpressed in connective 
tissue adjacent to epithelial malignancies ' l 0 " Tenascin is structurally distinct from other 
extracellular matrix glycoproteins such as fibronectin and laminin and its expression is 
subject to different control mechanisms *" cDNA clones mapping the cytotactin-tenascin-
hexabrachion gene16 " showed that there is homology to fibronectin, fibrinogen and 
epidermal growth factor 
Currently, little is known about the function of tenascin It has been shown to promote 
cartilage differentiation in vitro3 and it supports the growth of primary tumor cells in 
serumfree culture medium ' Tenascin can partially inhibit the attachment of cells to 
fibronectin", but appears to act as a surface adhesion molecule in the central nervous 
system ' 
The presence of tenascin in normal and injured rat skin4 and normal and diseased human 
skin" l5 has recently been reported In normal human skin, tenascin was detected in the 
papillary dermis and adjacent to the basement membranes of adnexal structures, using 
immunohistochemical techniques " ' 5 Electron microscopical examination of human skin" 
showed that tenascin is not a basement membrane component but is localized in patches 
beneath the basal lamina In rat skin, tenascin was detected in a discontinuous distribution 
near the basement membrane of the dermal-epidermal junction In addition, it was detected 
near basement membranes of subepidermal capillaries and around hair follicles We have 
recently studied the expression of tenascin in human skin diseases characterized by 
epidermal hyperprohferation ls It was shown that there is a strong increase in tenascin 
production both in benign and premahgnant skin diseases compared with normal skin The 
aforementioned observations suggest that activated epithelium, during embryonic 
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differentiation, wound healing, or disease (cancer, psoriasis), induces tenascin expression 
by the adjacent connective tissue. To obtain support for this hypothesis, we have studied 
tenascin expression in human dermis using a model for epidermal activation in vivo (the 
sellotape stripping model). We compared tenascin expression in this model with normal 
human skin and a number of skin diseases with an intrinsic defect in differentiation rather 
than in proliferation. In parallel, the expression of keratin 16, a known marker for 
hyperprol ¡feration in keratinocytes, has been studied. 
MATERIALS AND METHODS 
Antisera 
Antiserum against tenascin purified from rat embryo and chicken fibroblasts cultures was 
raised in rabbits and purified as described before.14" Both antisera yielded identical 
staining patterns in all tissues examined. A monoclonal antibody (T2H5) against human 
tenascin was obtained from a fusion between splenocytes from BALB/c mice, immunized 
with a human mammary tumor homogenate, and Sp2/0-Ag 14 nonsecreting mouse 
myeloma cells. The hybridoma supematants were screened by indirect peroxidase 
immuno-histochemistry on cryostat sections of human mammary tumors. Evidence that 
T2H5 detects an epitope of human tenascin was obtained by sequential immunoprecipitati-
on with polyclonal anti-tenascin and Western blotting Immunohistochemical staining with 
polyclonal anti-tenascin sera gave similar results as for the monoclonal antibody. 
Monoclonal antibodies against human plasma fibronectin (F7387) and keratin 13/16 
(Ks8.12) were obtained from Sigma Chemical Co, Mo, USA. Peroxidase-conjugated 
antisera to mouse and rabbit immunoglobulins were obtained from Dakopatts, Glostrup, 
Denmark. 
Biopsies 
Biopsies specimens were taken, after the subjects gave informed consent, either from 
healthy volunteers or patients from the Dermatology policlinic at the University of 
Nijmegen. The study included 10 healthy volunteers, 6 patients with autosomal dominant 
ichthyosis vulgaris (ADIV), 6 patients with X-linked recessive ichthyosis (XRI) and 7 
patients with non-erythrodermic lamellar ichthyosis (NELI). Permission from the local 
committee for experiments on humans was obtained. Punch biopsies (3 mm diameter, 5 
mm deep) or shave biopsies (5 mm diameter, 0.3 mm deep) were taken after local 
anaesthesia. Tissue specimens were snapfrozen in liquid nitrogen and stored at -80°C until 
further use. 
Stripping procedure 
The sellotape stripping model was used to induce epidermal proliferation in healthy human 
volunteers as described.20 Briefly, stratum corneum (from the back) is removed by 
consecutive applications of sellotape. Removal is complete when the area appears 
glistening, and the living cell layer is reached. At various time intervals after stripping, 
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shave or punch biopsies were taken and the tenascin expression was compared with 
untreated skin, using immunohistochemistry 
Histology 
Cryosections were prepared using standard procedures Immunoperoxidase staining was 
performed with antisera diluted in Phosphate-buffered saline (PBS), 1 100 for the 
polyclonal antitenascin sera and 1 500 for the monoclonal antibody, 1 50 for 
antifibronectin and 1 40 for Ks8 12 (60 minutes at room temperature for all antisera) 
After being washed in PBS, sections were incubated either with peroxidase-conjugated 
rabbit anti-mouse Ig or swine anti-rabbit Ig (I 100 dilutions in PBS with 5% normal 
human serum), 30 minutes at room temperature) The sections were developed using 
ammoethylcarbazole according to standard procedures 
All experiments included appropriate controls such as omission of the primary antibody or 
the use of non-immune serum 
RESULTS 
Tenascin expression following tape stripping 
Normal healthy volunteers were subjected to tape stripping (day 0) and biopsies were 
taken at 8 hours and on day 1, 2, 4, 7, 12 and 14 In addition, biopsy specimens were 
taken from untreated normal skin of all volunteers to determine the basal expression of 
tenascin In a previous study, we found that tenascin expression in normal skin varies 
from being almost absent to being present in a patchwise distribution in the papillary 
dermis 15 Cryosections were stained with monoclonal or polyclonal antisera All antisera (2 
polyclonal and 1 monoclonal) gave identical staining patterns Tape stripping of human 
skin is a model for superficial wounds Only the stratum comeum of the epidermis is 
removed, the dermis remains fully intact The data on tenascin staining are summarized in 
Table I Quantification of tenascin staining using the surface area of positive staining in 
the dermal layer was not attempted since this is strongly affected by the plane of 
sectioning Therefore we used the criterium whether tenascin staining of the papillary 
dermis was continuous or patchwise Since in normal skin tenascin expression is nearly 
always discontinuous (Figures la and 2a), the effect of tape stripping is easily noted as a 
layer of continuous tenascin staining of the papillary dermis along the basal membrane 
(Hgures lb and 2b, 48 hours after stripping) The expression of fibronectin, a structurally 
and functionally related glycoprotein which is present diffusely throughout normal dermis, 
was not found to be significantly increased at 48 hours after stripping (Figure 3a-c) This 
is in contrast with findings in models for healing of deep dermal wounds, where both 
tenascin and fibronectin expression are increased The distribution of fibronectin is 
markedly different from tenascin As already shown by others21, fibronectin is diffusely 
distributed in the entire upper dermis, whereas tenascin expression is more sharply 
demarcated and is usually restricted to the papillary dermis adjacent to the basal 
membrane In our model, the increased expression of tenascin at 48 hours, as shown in 
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Figures 1 and 2, was a consistent finding in all 10 healthy volunteers. In addition, a 
limited number of biopsy specimens were taken at other time points (up to 14 days after 
tape stripping). The presence of tenascin did not change very much over this period (not 
shown). Whether this represents continuous expression or slow turnover is not clear. 
Table I. Tenascin expression after tape stripping 
Time after 
stripping 
Tenascin expression 
in upper dermis 
0 h 
8 h 
24 h 
48 h 
7 days 
14 days 
Absent or patchy (10/10) 
Absent or patchy (4/4) 
Continuous (5/5) 
Continuous (10/10) 
Continuous (2/2) 
Continuous (4/4) 
Normal healthy volunteers were tape stripped as described. At various intervals punch or shave biopsies were taken 
and cryosections were stained for tenascin either with monoclonal or polyclonal antibodies, which gave similar 
results. The expression of tenascin was scored according to the distribution rather than the intensity. An increase in 
tenascin expression along the entire basal membrane was already seen 24 hours after tape stripping In parentheses. 
The number of biopsies performed at each time point and the number of biopsies showing the designated 
distribution pattern are given in parentheses. 
Fig. I. 
a. Tenascin expression in normal 
human skin before tape stripping, 
(punch biopsy, polyclonal anti­
serum). Note the sparse staining in 
the upper dermis (arrow heads). 
Blood vessels and connective 
tissue adjacent to adnexal 
structures are positive (arrows). 
Magnification χ 100, d=dermis, 
e=epidermis. b. Tenascin expres­
sion in normal human skin before 
tape stripping, (shave biopsy, 
monoclonal anti-body). Note the 
sparse staining in the upper dermis 
(arrows), magni-fication χ 100, 
d=dermis, e=epidermis. 
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Tenascin expression in disorders of keratinization 
To investigate the relationship of tenascin expression with keratinocyte proliferation, 
tenascin expression was studied in diseases with abnormal keratinocyte differentiation 
which are known to be normoproliferative (ADIV, XRI, NELI). Psoriatic skin, which was 
previously shown to give strong tenascin staining15 is shown as a positive control (Figure 
4). The results summarized in Table II, indicate that tenascin expression in XRI, ADIV 
and NELI is comparable to that in normal skin, i.e. staining for tenascin in these diseases 
was mostly absent or discontinuous. Continuous staining was rare (3 of 19 patients). 
Figure 5 shows an almost total absence of dermal tenascin staining in XRI. Occasional 
positive staining was found in the dermal papillae in NELI, as shown in Figure 6. 
Table II. Tenascin expression in disorders of keratinization 
Disease Tenascin expression 
in upper dermis 
Psoriasis Continuous (6/6) 
XLRI Absent to patchy (6/5) 
ADIV Absent to patchy (6/5) 
NELI Absent to patchy (7/6) 
Tenascin expression in disorders of keratinization was studied using polyclonal and monoclonal antibodies, which 
gave identical results. In lesionai psoriatic dermis intense staining was found in the entire upper dermis. In the 
monogenic disorders, tenascin expression was in general similar to that of normal skin. The number of patients 
studied and the number of patients showing the indicated distribution pattern are given in parentheses. 
Fig. 2. a · · 
a. Tenascin expression at 48 hours 
after tape stripping (same indivi­
dual as in figure la, shave biopsy, 
polyclonal antiserum). Note that 
the entire upper dermis shows 
positive staining, magnification 
xlOO, d=dermis, e=epidermis. 
b. Tenascin expression at 48 hours 
after tape stripping (same indivi­
dual as in Figure lb, punch biopsy, 
monoclonal antibody). Note that 
the entire upper dermis shows 
positive staining, magnification 
xlOO, d=dermis, e=epidermis. 
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Keratin 16 staining 
The suprabasal expression of keratin 16 in human epidermis is a known marker for 
keratinocyte hyperproliferation. Previous studies have shown that keratin 16 expression is 
induced in psoriasis and after tape stripping2 0, as shown by staining with the monoclonal 
antibody Ks8.12. In order to confirm the non-hyperproliferative nature of the XRI, ADIV 
and NELI, we investigated keratin 16 expression in these diseases since no published data 
are available. Keratin 16 expression was found to be similar to that of normal epidermis 
i.e. only the basal layer showed positive staining. Suprabasal staining was not seen in any 
of the XRI (Figure 7) or ADIV patients (not shown). In skin from only one of the NELI 
patients (not shown) focal suprabasal staining was seen. Thus, in nearly all cases a 
positive correlation between dermal tenascin staining and suprabasal keratin 16 expression 
was found. 
I 
Fig. 3. 
a. Fibronectin expression in normal 
skin before tape stripping, same 
individual as in figures lb and 2b, 
shave biopsy). Note the dimise, 
reticular staining of fibronectin in 
the upper part of the dermis, 
magnification χ 100, d=dermis, 
e=epidermis. 
b. Fibronectin expression at 48 
hours after tape stripping (same 
individual as in figure 3a, shave 
biopsy). The distribution and 
intensity of staining is similar to 
that of normal skin, magnification 
xlOO, d=dermis, e=epidermis. 
c. Control section of tape stripped 
skin at 48 hours (same individual 
as figure 3a and 3b, shave biopsy), 
showing complete absence of 
staining, magnification χ 100, 
d=dermis, e=epidermis. 
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Fig. 4. Tenascin staining in lesionai psoriatic skin 
(punch biopsy, monoclonal antibody). Note the 
intense continuous staining of the entire upper 
dermis, magnification χ 100, d=dermis, 
e=epidermis. 
Fig. 5. Tenascin staining in ADIV (punch biopsy, 
monoclonal antibody). Note positive staining 
around bloodvessels and adnexal structures 
(arrows). Staining of the upper dermis is weak to 
absent, similar to normal skin, magnification χ 
100, d=dermis, e=epidermis. 
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Fig. 6. Tenascin staining in NELI (punch biopsy, Fig. 7. Keratin 16 expression in XRI (punch 
monoclonal antibody) showing expression in the biopsy). Only the basal cells of the epidermis 
dermal papillae (arrows). Note that the expression show positive staining. Staining of the stratum 
is discontinuous, similar to normal skin, corneum is nonspecific, magnification χ 100, 
magnification χ 100, d=dermis, e=epidermis. d=dermis, e=epidermis. 
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DISCUSSION 
We have tested the hypothesis that expression of tenascin in human dermis is related to 
epidermal proliferation In a dynamic in vivo model for the induction of a proliferative 
response by human keratinocytes, tenascin expression was strongly increased in the dermal 
compartment In contrast, in a number of diseases characterized by a disturbance of 
differentiation but with normal epidermal proliferation rates, no increase of tenascin 
expression was found compared with normal human skin 
In normal adult human skin, tenascin is expressed in association with hair follicles, sweat 
glands, and blood vessels, and in the papillary dermis, although some discrepancies 
between different studies exist"15 Lightner et a l " were the first to report on the 
distribution in normal human skin Their findings suggest a higher level of expression in 
the papillary dermis compared to our previous study15 and the results of this study This 
discrepancy is probably caused by differences in location of the skin samples We have 
noted that the papillary dermis near adnexal structures shows an increased expression of 
tenascin compared with skin taken from sites with few hairs and sweat glands In our 
studies, skin was taken from the shoulders which have few adnexal structures, in the study 
of Lightner et al ", the skin samples appear to be taken from sites with many adnexal 
structures 
We have recently shown that in hyperprohferative skin disorders such as psoriasis, basal 
cell carcinoma, Bowen's disease, and solar keratoses, tenascin expression in the upper 
dermis is greatly increased 15 In the present study, we have used sellotape stripping of 
human epidermis as a means of inducing keratinocyte hyperprohferation to study the 
dermal response It has previously been shown that in this model a recruitment of G0-cells 
into the cell cycle is induced within 24 hours of removal of the stratum comeum 21 In 
addition, the expression of keratin 16, characteristic of a hyperproliferative phenotype, is 
induced This study shows that rapid changes in the dermal compartment can also be 
found As early as 24 hours after tape stripping, an increase in tenascin expression can be 
demonstrated The expression of fibronectin, a related extracellular matrix glycoprotein, 
was not increased However, an increase in fibronectin expression is more difficult to see 
since it is already strongly present in normal skin These observations, together with the 
observation that in normoprohferative disorders of keratinization (ADIV, XRI, NELI) 
tenascin expression is not altered, suggest that tenascin is an extracellular matrix 
component that is specifically increased in response to epidermal activation An additional 
argument for epidermal involvement in the expression of tenascin b> the dermis, is the 
observation that tenascin expression under non-hyperproliferative conditions (e g , normal 
skin) is often most pronounced in the dermal papillae (Figure lb) The function of 
tenascin expression in the dermis is currently unknown Speculatively, we propose that it 
functions as a substrate adhesion molecule in the development and regeneration of 
epidermal and adnexal structures Therefore, tenascin expression could be important in 
woundhealing processes as suggested by studies in rats A The sellotape stripping model is 
obviously not an ideal model for wound healing since it leaves the basal membrane and 
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the dermis intact. It is, however, a useful model to study the dermal response to epidermal 
injury A striking difference with healing of deeper wounds is that in the tape stripping 
model, no significant increase of dermal fibronectin expression is seen. This phenomenon 
indicates that tenascin and fibronectin expression are subjected to distinct control 
mechanisms 
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SUMMARY 
The distribution of three (recently discovered) extracellular matrix components (tenascin 
biglycan and deconn) was studied in normal adult human skin and in a number ol 
monogenic disorders of keratinization, using immunohislology The expression of tenascin 
which is sparsely distributed in normal human dermis, was found to be grossly increased 
in epidermolytic hyperkeratoses and in Daner's disease Tenascin expression in three types 
of ichthyosis (X-linked recessive ichthyosis, autosomal dominant ichthyosis vulgaris, non 
erythrodermic lamellar ichthyosis) was similar to that of normal skin The presence ol 
biglycan and deconn did not show a marked variation between the different disorders 
studied, suggesting that their expression is subject to regulatory mechanisms distinct frorr 
those of tenascin 
The increased expression of tenascin in two disorders of keratinization with a 
hyperproliferative phenotype, lends further support to the hypothesis that dermal tenascin 
expression is increased as a result of epidermal hyperprohferation 
INTRODUCTION 
Human skin contains a number of extracellular matrix components which contribute to the 
mechanical properties of the tissue (e g elastin, the major collagens, large aggregating 
proteoglycans), or exert regulatory functions with regard to cellular processes such as 
adhesion, migration, growth and differentiation (e g fibronectin and laminin) Recently, 
several new extracelullar matrix components have been identified in human skin It was 
shown that the glycoprotein tenascin (also known under various other names including 
cytotactin', hexabrachion2 and myotendinous antigen1), which is predominantly found in 
embryonic tissues and tumor stroma, is also expressed in normal human skin 4 6 It was 
found in low levels in the papillary dermis, and abundantly near hair follicles and sweat 
gland ducts The expression level in the papillary dermis was found to be strongly 
increased in hyperproliferative conditions such as psoriasis and epidermal tumors 457 
The small non-aggregating proteoglycans biglycan (also known as PG-I) and deconn (also 
known as PG-II), have been found in various connective tissues89, and have recently been 
demonstrated in fetal and adult human skin10" The expression patterns of tenascin, 
biglycan and deconn appear to be developmentally regulated in the tissues studied, 
suggesting that these molecules might be of interest in dermo-epidermal interactions 
leading to pattern formation and regulation of growth and differentiation Because the 
monogenic disorders of keratinization represent a heterogenous group of skin diseases with 
disturbances at the level of epidermal differentiation, we were interested to see whether 
there is a differential effect on the expression of extracellular matrix components 
METHODS 
Tissues 
Biopsies were taken after informed consent, either from healthy volunteers or patients 
from the department of dermatology at the University Hospital of Nijmegen The study 
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included healthy volunteers, and patients with autosomal dominant ichthyosis vulgaris 
(ADIV), X-linked recessive ichthyosis (XRI), non-erythrodermic lamellar ichthyosis 
(NELI), epidermolytic hyperkeratoses (including the Brocq type, the Siemens type, and the 
naevoid type), and Daner's disease Punch biopsies (4 mm diameter, 5 mm deep) or shave 
biopsies (5 mm diameter, 0 3 mm deep) were taken under local anaesthesic Tissue 
specimens for cryosectioning were snap frozen in liquid nitrogen and stored at -80°C until 
further use Tissue specimens for routine histology and for immunohistology on paraffin 
sections were fixed in 0 4% buffered formalin 
Anlisera 
A monoclonal antibody (T2H5) against human tenascm was prepared as described 
previously'. An antiserum against a synthetic peptide corresponding to residues 11-24 of 
the secreted form of biglycan was raised in a rabbit, after conjugating the peptide with 
bovine serum albumin '2 Repeated booster injections resulted in an antiserum which 
exhibited a similar titre as the deconn antiserum in an enzyme-linked immunosorbent 
assay The deconn antiserum was raised against a fully deglycosylated core protein 
purified from human fibroblast secretions n The applicability of the latter two antisera for 
staining the proteoglycans in human skeletal tissues has previously been ascertained >A As 
controls for the polyclonal sera we used preimmune sera from the same rabbits 
Peroxidase-conjugaled antisera to mouse and rabbit immunoglobulins were obtained from 
Dakopatts, Gloslrup, Denmark 
Immunohistology 
Cryosections and paraffin sections were prepared using standard procedures Sections used 
for staining of deconn and biglycan were pretreated with chondroitin ABC-lyase (ICN 
Biochemicals, Covina, CA, USA) at 0 625 u/ml for 20 mm at 37"C, in a 0 1 M Tris buffer 
with 0 05 M sodium acetate and 0 1% BSA, pH 8 0 This method was adapted from 
Bianco et al l0 
Immunoperoxidase staining, according to standard protocols, was performed with the 
T2H5 antibody diluted 1 500, 1 100 for the antideconn serum, and 1 50 for the 
antibiglycan serum Sections were incubated either with peroxidase-conjugated rabbit anti-
mouse Ig or porcine anti-rabbit Ig (1 100 dilutions in PBS with 5% normal human AB 
serum), for 30 min at room temperature The sections were developed using 
aminoethylcarbazole, according to standard procedures 
All experiments included appropriate controls, such as omission of the primary antibody 
or the use of pre-immune serum 
RESULTS 
Tenascm 
Table I summarizes the data found for tenascm In the epidermolytic ichlhyoses, the 
Siemens and Brocq type, and the naevoid type are grouped together The other diseases 
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comprise ADIV, XRI, NELI and Darier's disease. As described in previous studies, 
normal skin usually shows a patchy to negative staining for tenascin (Figure I). A 
continuous, and generally strong staining was seen in the papillary dermis of the 
epidermolytic disorders (Figures 2 and 3) and in Darier's disease (Figure 4). In XRJ, 
tenascin staining was mostly absent, whereas in NELI and ADIV, tenascin staining was 
stronger than in XRI but in general the pattern and intensity mostly resembled that of 
normal skin. 
Table I. Distribution and intensity of tenascin staining 
Disease N, Distribution Intensity (mean + SD) 
ADIV 
XRI 
NELI 
Epidermolytic 
ichthyoses 
Darier's disease 
Normal skin 
7 
5 
9 
8 
3 
7 
negative 
patchy 
continuous 
negative 
patchy 
continuous 
negative 
patchy 
continuous 
negative 
patchy 
continuous 
negative 
patchy 
continuous 
negative 
patchy 
continuous 
3 
2 
2 
4 
1 
0 
1 
6 
2 
0 
2 
6 
0 
I 
2 
2 
5 
0 
09 + 0 9 
02 ± 0 4 
10 + 05 
2 0 + 0 5 ' 
2 3 + 0.6' 
0 8 + 0 5 
Distribution and intensity of tenascin staining was scored scmi-quantitatively on frozen sections as indicated in Methods 
N,= total number of patients studied N= number of patients with the distribution pattern Significantly different from normal 
skin (P<0 001), " significantly different from norma) skin (P<0 05), Wilcoxon rank-sum test 
Biglycan 
Biglycan core protein was localized in the upper part of the epidermis (stratum spinosum 
and granulosum). The staining pattern, however, was extremely variable. It ranged from 
diffuse cytoplasmic staining to more sharply localized staining beneath the plasma 
membrane, sometimes the entire differentiated compartment of the epidermis was positive, 
in other cases only a focal expression was found (Figures 5 and 6). Whatever the pattern 
or intensity of staining was in the suprabasal layer, the basal layer was always negative 
The papillary dermis showed a continuous staining along the basal membrane (Figures 5 
and 6). The reticular dermis was virtually negative except for a variable staining of blood 
vessels and sweat glands The connective tissue sheath around hair follicles was found to 
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be positive. The indicated staining patterns were found both in normal adult and fetal skin, 
and in several types of keratinization disorders studied (ADIV, XRI, NELI, epidermolytic 
hyperkeratoses). Staining of the hair follicle connective tissue sheath appeared to be more 
intense in fetal skin than in adult skin. 
i 
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Fig. 1. Tenascin expression in normal skin. Note Fig. 2. Tenascin expression in epidermolytic 
the sparse staining in the upper papillary dermis. ichthyosis of the Brocq type. Note that the entire 
upper dermis shows positive staining. 
Fig. 3. Tenascin expression in epidermolytic 
ichthyosis of the Siemens type. Note that the 
entire upper dermis shows positive staining. 
Fig. 4. Tenascin expression in Darier's disease. 
Note that the entire upper dermis shows positive 
staining. 
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Fig. 5. Biglycan expression in normal skin. Note Fig. 6. Biglycan expression in autosomal 
that the suprabasal compartment shows focal dominant ichthyosis. Note that the suprabasal 
staining. The papillary dermis shows positive compartment of the epidermis shows cyto-
staining. plasmatic staining. The papillary dermis stains 
mildly. 
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Fig. 7. Decorin expression in normal skin. Note 
that the entire dermis shows positive staining. 
Decorin 
Decorin core protein was absent in all layers of the epidermis. It was found to be present 
throughout the dermal tissue, the papillary dermis showing the strongest expression 
(Figure 7). Staining patterns in normal skin and all diseases studied were similar. 
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DISCUSSION 
At the dermo-epidermal interface, reciprocal interactions between mesenchymal and 
epidermal cells lake place which can be mediated by soluble factors but also by the 
binding of cells to extracellular matrix components secreted by either cell type These 
processes are particularly important in embryonic development, and in adults during 
wound healing and tumour metastasis Under these conditions the epithelial tissues are 
actively involved in shaping, restoring or distorting a tissue The differentiation 
programme of the epidermis during fetal development, wound healing or tumour 
metastasis is distinct from the normal programme, which among others, involves 
expression of a defined set of cytokeratins in a homcostatic situation Also the 
composition of the mesenchymal extracellular matrix during development, wound healing 
and tumour growth differs from that of the normal adult tissue Spatially restricted 
expression patterns for many extracellular matrix components (including fibronectm, 
tenascin, deconn and biglycan) have been described 
In this study, we have investigated the expression of three recently discovered 
extracellular matrix components in a number of monogenic disorders of keratinization 
The results show that the expression of tenascin by the dermal fibroblasts differs markedly 
between the diseases studied In epidermolytic hyperkeratoses and in Daner's disease, 
tenascin expression is grossly increased compared with normal skin In ADIV, XR1 and 
NELI tenascin expression is similar to normal skin, as shown previously '5 An important 
difference between ADIV, XRI and NELI, and epidermolytic ichthyoses and Daner's 
disease, is the amount of epidermal destruction In the epidermolytic ichthyoses and 
Daner's disease, acantholysis and inflammation are prominent features of the pathological 
process The epidermal keratinocytes display a hyperproliferative phenotype with respect 
to keratin 16 expression, which is found to be elevated in the suprabasal compartment 
(P M Steijlen et al unpublished data) In ADIV, XRI and NELI none of these features are 
present This group of diseases displays a normoprohferative phenotype Thus, increased 
dermal tenascin expression appears to be a phenomenon primarily associated with 
epidermal hyperprohferation, as we have shown previously in psoriasis and epidermal 
tumours 5 
Because of the interpatient variation within a given disease, and the small number of 
patients in each group, the data do not allow definitive statements on the expression levels 
of deconn and biglycan in these diseases However, no gross variation in the expression 
patterns was evident in the material studied The distribution of both deconn and biglycan 
in frozen sections of normal human skin has been described peviously l 0 " Some 
descrepancies with our data were noticed, and some additional information was obtained 
The biglycan antiserum we used, only reacts weakly reacts with blood vessel endothelium 
in skin, whereas in the study by Fleischmajer et al " strong staining was found Both 
antisera were raised against synthetic peptides, albeit from different epitopes, which may 
explain the difference In contrast, the reactivity of our biglycan antiserum with the 
papillary dermis of human skin appears to be stronger than that of Fleischmajer et al " 
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The presence of biglycan in the connective tissue sheath of hair follicles, where it co-
localizes with tenascin6, is a new finding 
In conclusion, an increased expression of tenascin was observed in epidermolytic 
hyperkeratoses and Darier's disease Biglycan and deconn expression do not follow this 
pattern, indicating that these extracellular matrix components are differentially regulated 
Although the expression levels of extracellular matrix components are probably not 
causally linked to the disease process in these dermatoses, the data may provide an insight 
into dermo-epidermal interactions, and may contribute to the classification of these 
disorders 
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ABSTRACT 
Ichthyosis bullosa of Siemens is an autosomal dominant disease which is characterized by 
mild hyperkeratosis and blistering Autosomal dominant ichthyosis exfoliativa is a recently 
described disease with clinical features similar to ichthyosis bullosa of Siemens In 
contrast to ichthyosis bullosa of Siemens, no histological signs typical for epidermolytic 
hyperkeratosis are observed Linkage analysis was used to test whether keratin gene 
mutations might underlie both diseases This analysis showed linkage of both disorders 
with the region of chromosome 12 in which the keratin type II gene cluster is located The 
keratin type I gene cluster on chromosome 17 is excluded These data, combined with 
clinical observations, strongly suggest that the genes coding for keratin 1 or keratin 2e, 
both expressed in the suprabasal compartment of the epidermis and located in the type II 
gene cluster, are candidate genes for ichthyosis bullosa of Siemens and ichthyosis 
exfoliativa 
INTRODUCTION 
Epidermolytic hyperkeratosis is a histopathological characteristic of a variety of 
monogenic keratinization disorders comprising bullous congenital ichthyosiform 
erythroderma of Brocq (BCIE), epidermolytic palmoplantar keratoderma of Vomer 
(EPPK), ichthyosis hystnx of Curth-Macklin (IHCM) and ichthyosis bullosa of Siemens 
(IBS) The term epidermolytic hyperkeratosis is also used to refer to the diseases as such 
For two of these disorders there is convincing evidence that they are caused by mutations 
in keratin genes In patients with BCIE, mutations have been found in the genes coding 
for keratin 1 (Kl) or keratin 10 (K10)M and in case of EPPK in the gene coding for 
keratin 9 (K9) 5 6 On the other hand, IHCM seems not to be due to a defect in a keratin, 
since the loci of both the type I and type II keratin gene cluster (17ql2-q21 and 12qll-13, 
respectively) have been genetically excluded 7 So far, there are no clues about the defect 
causing IBS 
IBS has been described as a bullous form of ichthyosis distinct from BCIE 8 '° In the 
former disease blistering and hyperkeratosis are milder than m BCIE IBS can be further 
differentiated from BCIE by the absence of congenital erythroderma Light- and electron 
microscopical examination show the features of epidermolytic hyperkeratosis consisting of 
coarse keratohyaline granules, intracellular vacuolization and perinuclear clumping of 
tonofilamenls In IBS these features are confined to the stratum granulosum and the upper 
part of the stratum spinosum whereas in BCIE these findings are present in the whole 
suprabasal compartment It has been hypothesized that BCIE and IBS are allelic 
disorders " Autosomal dominant ichthyosis exfoliativa (IE) is a recently described type of 
bullous ichthyosis Only one family has been published sofar The clinical symptoms of IE 
are very similar to IBS However the histological features of epidermolytic hyperkeratosis 
were absent '2 Both IBS and IE show autosomal dominant inheritance 
We addressed the question whether IBS and 1С are due to keratin gene defects Linkage 
analysis was performed in the kindred with IBS that has been described previously8 and in 
90 
the kindred with IE, described by Vakilzadeh and Kolde12 employing polymorphic markers 
from (the close vicinity of) the type I and II keratin cluster In both families, 
cosegregation of the disease with the type II keratin gene cluster was observed 
MATERIALS AND METHODS 
Patients 
Family 1 has been reported as suffering from ichthyosis bullosa of Siemens 8 The affected 
individuals had brownish rimpled hyperkeratosis and superficial blistering since early 
childhood Blistering was more pronounced during hot and humid weather and could be 
provoked by mild trauma Erythroderma had never been present in any of the affected 
individuals Skin lesions were localized especially on the extensor surfaces of arms and 
legs and around the umbilicus, knees and ankles In the hyperkeratotic regions 
superficially denuded areas were observable Occasionally, fresh blisters ranging in size 
from 0 5 to 2 cm appeared Light microscopic examination of multiple biopsies of 
hyperkeratotic areas showed an acanthotic epidermis with orthohyperkeratosis In the 
stratum granulosum and the upper part of the stratum spinosum coarse keratohyaline 
granules, intracellular vacuolization and hyperchromatic pycnotic nuclei were observed 
(Hgure la) On ultrastructural examination keratinocytes in the upper spinous layer 
displayed aggregates of tonofilaments forming V shapes or shells around the nuclei 
Family 2 has been reported as suffering from ichthyosis exfoliativa ' 2 The patients showed 
dark grey hyperkeratotic lesions with denuded areas Superficial blistering occurred 
spontaneously especially during the summer but occurred also after trivial trauma There 
was no history of erythroderma in any of the patients Histological examination of 
multiple biopsies of hyperkeratotic areas showed an acanthosis and orthohyperkeratosis of 
the epidermis (Figure lb) The keratinocytes in the granular and upper spinous layer 
showed marked oedema with indistinct boundans The nuclei of the cells were small and 
hyperchromatic and the cells contained a few small keratohyaline granules The 
electronmicroscopical findings are described before "the cells of the granular and spinous 
layer were characterized by marked intracellular oedema, the number of tonofilaments and 
keratohyaline granules were markedly reduced with no grouping of the tonofilaments" 
Linkage analysis 
DNA of patients was isolated from peripheral blood according to the method of Miller et 
al , 3 For the type II keratin cluster we tested polymorphisms in the genes coding for Kl 
(KRT1)'\ K4 (KRT4)15, D12S96 and collagen type HAI (Col2Al)1 6 A map of the 
relevant region is given in Figure 2 [GDB, 17] For Kl the polymorphic glycine-nch 
carboxyl-lerminal domain was amplified with the forward (5'-l I IGTTGGGCTGG-
AAACGGA-GTT-3') and reverse (5'-ACCCCCAGAGCTGGATCCCC-3') primers 
200 ng of genomic DNA were amplified in a 15 μ ι PCR mix with 10 mM Tns-HCl pH 
8 3, 50 mM KCl, 15 mM MgCI2, 0 005 mM DTT, 0 001% (w/v) gelatin, 15 цСі 
a
32PdCTP, 250 μΜ of each dATP, dGTP, dTTP, 3 0 μMdCTP, 75 ng of each of the 
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primers, 10% (v/v) glycerol and 3% (v/v) formamide. After an initial denaturation of 5 
min at 94 °C, 35 cycles of 1 min 94 °C, 2 min 67 °C and 1.5 min 72 °C were performed. 
The K4 polymorphism was analysed as described by Wanner et al." and the VNTR in the 
Col2Al gene as described by Wu et al.16 and the marker D12S96 (GDB) according to.18 
To test linkage with the type I keratin gene cluster, a polymorphism in the gene coding for 
K10 (KRT10)" and the nearby loci D17S25020 and D17S57921 were analysed. The order 
of the markers of chromosoom 17q is cen-D17S250-KRT10-D17S579-tel (Figure 2). The 
genetic distance between D17S250 and D17S579 is about 6 cM.22 For amplification of 
the K.10 polymorphism the following primers were used: forward (5'-GTTTCGGCGGC-
GGCTACG-3') and reverse (5'-AGGAGGACTTGTGGCCTCCGC-3'). The same protocol 
as for Kl was followed with the exception of the use of radioactively labelled forward 
primer instead of incorporation of a32PdCTP. The amount of dCTP in the reaction mixture 
was adjusted to 250 μΜ. The loci D17S250 and D17S579 were analysed as described by 
Kremer et al.18 
Statistical analysis of the linkage data was performed with the program Linkage, version 
5.1.23 Penetrance was assumed to be 100%. The disease frequencies of 0.00001 for IBS 
and 0.00001 for IE were assumed. Allele frequencies given in the John Hopkins Genome 
Data Base, were used for the calculations. For multipoint analysis the distances between 
D17S250 and KRT10 and between KRT10 and D17S579 were assumed to be 3cM.22 
Fig. 1. a. Skin biopsy of a 
hyperkeratotic lesion in a patient 
from family 1. The epidermis is 
acanthotic and orthohyperkeratotic. 
In the stratum granulosum and the 
upper part of the vacuolization 
(arrows) spinosum perinuclear and 
coarse keratohyaline granules are 
observed (arrow heads). 
b. Skin biopsy of a hyperkeratotic 
lesion in a patient from family 2. 
The epidermis is acanthotic and 
orthohyperkeratotic. The keratino-
cytes of the granular and upper 
spinous layer show marked intra­
cellular oedema and indistinct 
cellular boundaries (arrows). Bar is 
100 цт. 
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Fig. 2. Map of the loci surrounding the keratin gene cluster on chromosome 12q (a) and on 
chromosome 17q (b) [GDB, 17,22] Distances are given in cM 
RESULTS AND DISCUSSION 
To sort out whether IBS and IE are due to mutations in keratin genes, with КI and К10 as 
particularly promising candidates, markers located within, or close to, the keratin gene 
clusters on chromosome 12q (type II keratins) and 17q (type I keratins) are tested 
(Figure 2). Haplotypes are depicted in the Figures 3 and 4 and in Table I the pairwise lod 
scores are given between the markers and IBS and IE. 
Table I. Pairwise lod scores between IBS, IE and loci within or close to the keratin gene clusters. 
The first three columns give the lod scores calculated for the family with IBS, the last three 
columns those for the family with IE. Statistical significant lod scores are obtained in both families 
with the marker Col2Al. The region surrounding the keratin type I cluster on 17q is excluded. 
θ 
Col2Al 
D12S96 
KRT1 
K.RT4 
DI7S250 
KRT10 
DI7S579 
00 
3 24 
0.63 
I 81 
1 52 
CO 
0 0 
0 0 
0 1 
2 56 
0 52 
1 31 
123 
-0.61 
-0 64 
-1 99 
02 
1 84 
041 
0.78 
0.98 
0 04 
-0 20 
-0 84 
00 
3 60 
148 
0 99 
001 
0 0 
1.19 
0 0 
0 1 
2 99 
1 21 
0 82 
0 00 
-1 19 
0 93 
0 98 
02 
2 28 
0 93 
0 65 
0 00 
-0.19 
0.68 
1.23 
In the family with IBS the lod score of 3.24 with Col2Al clearly shows linkage of this 
locus and IBS. Both KRTI and KRT4 are not completely informative in this family. 
— ColZAI 
8.3 
— D12S96
 6 
5.2 
— KHT1/4 
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However, construction of haplotypes (Figure 3) give no indication for recombination 
between IBS and the region of 12q analyzed with the four markers Col2Al, D12S96, 
KRT1 and KRT4 These results indicate that IBS is due to a defect in a gene in the 
analyzed region of chromosome 12q including the keratin genes 
K.RT 10 shows recombinations with the disease, in the persons IV 8 and V3 (Figure 3) 
thereby excluding the К10 gene and other keratin genes in the type I cluster as the cause 
of IBS in the present family Exclusion of the type I cluster is further substantiated by the 
lod score of -1 99 at 6=0 1 with D17S579, which is at a distance between 3 and 4 cM 
from the keratin cluster22 There also is recombination with D17S250 (Z=-l 95 at 6=0 03) 
which is located less than 3 cM proximal to KRTI0 22 In a second, small family with IBS 
comparable results as with the presented family have been obtained However, this family 
is by itself too small to show statistically significant linkage Combination of lod scores 
for both families with IBS resulted in the maximum lod score of 4 20 at 6=0 0 with the 
marker Col2Al 
In the family with IE, the lod score of 3 60 with Col2Al at 6=0 0 indicates linkage 
between IE and the Col2Al gene At 9=0 2 the lod score is 2 28 suggesting linkage also 
with the keratin genes which are at a distance of about 15 cM from the Col2AI gene 
[GDB, 17] The three markers closer to or in the keratin gene cluster on chromosome 12 
have a very limited informativity (Table I, Tigure 4) There is no recombination between 
IE and these markers The highest lod score of 1 48 was obtained with D12S96 which is 
located about 5 cM proximal to the keratin gene cluster As is shown for IBS, IE is 
indicated to be due to a defect in a gene in the region of the Col2Al gene Also for IE the 
defect may be in a keratin gene 
The markers D17S250 and D17S579, flanking KRT10, both recombine with IE in the 
persons III 5 and V I (Figure 4) Accordingly, haplotype analysis reveals that the interval 
of D17S250-KRT10-D17S579 is excluded from linkage with IE, which is reflected in a 
maximal lod score of -4 88 for this interval obtained by multipoint analysis The positive 
lodscore obtained with KRT10 is due to the fact that the recombinations in III 5 and V 1 
are not visible because the affected parent of those persons is homozygous for KRT10 
The results from linkage analysis show that among other genes in the region of the 
Col2Al gene, members of the type II keratin gene cluster are candidates for both IBS and 
IE So far, mutations found in keratin genes were in regions coding for the evolutionary 
conserved domains of the proteins ie (1) the helix initiation peptide at the end of helix 
domain 1A, (2) the helix termination peptide at the end of helix 2B, (3) the HI subdomain 
of type II keratins and (4) the L12 linker region 3 4 ani1 """""* ,herc,n Sequence analysis gave 
no indications for mutations in the HI region, the 1A rod domain, the LI2 linker region 
and the helix termination peptide of Kl in the present families However, a mutation 
outside the highly conserved parts of Kl may be even more likely regarding the mild 
phenotypes of IBS and I E 2 2 4 2 5 On the other hand, the genetic defect may be present in 
the K2e gene which is expressed suprabasally in the epidermis from the third or fourth 
cell layer onwards 2 6 This expression pattern exactly coincides with the occurrence of the 
9-1 
lesions in patients with IBS and IE i.e. in the upper part of the spinous layer and the 
granular layer. Mutation analysis in the K2e gene in patients of the present families are 
underway. 
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Fig. 3. Pedigree of the family with ichthyosis bullosa of Siemens. There ¡s co-segregation with the 
markers of chromosome 12 (left block) and recombiantion with the markers of chromosome 17 (right 
block). 
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Fig. 4. Pedigree of the family with autosomal dominant ichthyosis exfoliativa. Co-segregation can be 
seen with the marker of chromosome 12 (left block) and recombination with the markers of 
chromosome 17 (right block) 
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ABSTRACT 
Ichthyosis bullosa of Siemens is a blistering disorder with autosomal dominant inheritance. 
The disease resembles bullous congenital ichthyosiform erythroderma but is less severe. 
Keratins Kl and K10 have been implicated in bullous congenital ichthyosiform 
erythroderma. Linkage analysis pointed to the involvement of a keratin type II gene 
(12q 11-13) in ichthyosis bullosa of Siemens. Mutations in the highly conserved regions of 
Kl, a member of the type II gene cluster, were excluded. The gene coding for keratin 2e 
is also located in the type II gene cluster and the expression of the gene coincides with the 
occurrence of epidermolytic hyperkeratosis. Sequence analysis revealed the presence of 
mutations in the K2e gene in patients with ichthyosis bullosa of Siemens. Three different 
mutations were detected, one in the 1A domain and two in the 2B domain of the rod. 
Furthermore, histological and ultrastructural examination of skin biopsies indicated that 
ichthyosis exfoliativa is identical to ichthyosis bullosa of Siemens. This was confirmed by 
the results of the molecular analysis. In the family diagnosed as ichthyosis exfoliativa, a 
mutation was detected which was identical to the mutation found in one of the families 
with ichthyosis bullosa of Siemens. 
INTRODUCTION 
Patients with bullous congenital ichthyosiform erythroderma (BCIE), often referred to as 
epidermolytic hyperkeratosis, suffer from fragility of the differentiating keratinocytes in 
the suprabasal layers of the skin. BCIE is caused by mutations in the genes coding for 
keratin 1 or keratin 10 which are expressed in the suprabasal cells [1-4]. 
Ichthyosis bullosa of Siemens (IBS) has been described as an entity distinct from BCIE 
[5-7]. In the former disease hyperkeratosis and blistering are milder than in BCIE. 
Furthermore, IBS can be differentiated from BCIE by the absence of congenital 
erythroderma. Light- and electronmicroscopical examination show the features of 
epidermolytic hyperkeratosis, confined to the stratum granulosum and the upper part of the 
stratum spinosum, whereas in BCIE these findings are present in the whole suprabasal 
compartment. Although BCIE and IBS have been described as two diseases, it has also 
been hypothesized that they are allelic disorders [7,8]. 
Autosomal dominant ichthyosis exfoliativa (IE) is a recently described type of bullous 
ichthyosis [9]. Only one family has been published sofar (family 2 in the present study). 
The clinical symptoms of IE are very similar to IBS. However, according to the original 
paper, signs of epidermolytic hyperkeratosis were absent. 
Linkage analysis in two families with IBS and the family with IE already suggested that 
both disorders are due to a defect in a member of the type II keratin gene cluster (K1-K8) 
on chromosome 12qll-I3' . Kl is a good candidate because mutations in the gene can 
cause BCIE. However, sequence analysis gave no indications for mutations in the 
'Stcijlen PM, Kremer H. Vakilzadch F, Happle R, Lavrijsen SPM, Ropers H-H, Manman LCM Genetic 
linkage of Che keratin type II gene cluster with ichthyosis bullosa of Siemens and with autosomal dominant 
ichthyosis exfoliativa J \mest Dermatol 1994 103 286-289 
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conserved regions the HI region of the head domain of the type II keratins, the helix 
initiation peptide of the 1A rod domain, the helix termination peptide of the 2B rod 
domain, the LI2 linker between the IB and 2A rod domains, and an area close to the 
stutter in the 2B helix The mutations causing BCIE are exclusively detected in these 
regions of Kl and K.10 (1-3,10-12] 
The keratin 2e gene is expressed in the upper spinous layers, from the third or fourth cell 
layer onwards [13] Only these layers show epidermolytic hyperkeratosis in IBS patients 
[5-7] Sequence analysis of the K2e gene in IBS patients of three different families and in 
patients of the family with IE revealed three different mutations either in the helix 
initiation peptide or in the helix termination peptide As was suggested by the clinical 
picture, IE and IBS are identical disorders 
MATERIALS AND METHODS 
Patients 
Four families were included in the analysis 
Family 1 has been previously reported [7] as suffering from IBS 
The affected individuals had brownish wrinkled hyperkeratosis and superficial blistering 
since early childhood Blistering was more pronounced during hot and humid weather and 
could be provoked by mild trauma Erythroderma had never been present in any of the 
affected individuals Skin lesions were localized especially on the extensor surfaces of 
arms and legs and around the umbilicus, knees and ankles In the hyperkeratotic regions 
superficially denuded areas were observable Occasionally, fresh blisters ranging in size 
form 0 5 to 2 cm appeared In contrast to patients of the families 2-4, two affected family 
members also suffered from chronic relapsing pustular eruptions, surrounded by an 
erythematous flare Light microscopic examination revealed epidermolytic hyperkeratosis 
limited to the upper part of the epidermis On ultrastructural examination the cells of the 
granular and upper spinous layer showed marked oedema, while keratohyaline granules 
were coarse Keratinocytes in the upper spinous layer displayed aggregates of 
tonofilaments forming V shapes or shells around the nuclei 
Family 2 has been reported previously as ichthyosis exfoliativa [9] 
We re-examined the family including histological and ultrastructural analyses The patients 
showed dark grey hyperkeratotic lesions with denuded areas Superficial blistering 
occurred spontaneously especially during the summer, but occurred also after trivial 
trauma There was no history of erythroderma in any of the patients Light- and 
electronmicroscopical examination of a hyperkeratotic area showed the features of 
epidermolytic hyperkeratosis limited to the granular and upper spinous layers The features 
consist of keratohyaline clumps, perinuclear vacuolisation and aggregates of tonofilaments 
forming perinuclear shells (Figure la-b) Histopalhological examination of a developing 
blister showed marked extra- and intracellular oedema limited to the keratinocytes of the 
upper spinous layer PAS-positive deposits were seen within the subcorneal split The 
number of tonofilaments and keratohyaline granules were reduced The few tonofilament 
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bundles were localized at the periphery. Tonofilament clumping could be observed focally 
in the upper spinous layer (Figure lc). 
Fig. 1. Skin biopsy of a hyper-
keratotic lesions in a patient form 
family 2. a. The epidermis is 
acanthotic and orthohyperkeratotic. 
In the stratum granulosum and the 
upper part of the stratum spinosum 
perinuclear halos and keratohyaline 
clumps are observed. Scale bar is 
50 μ. b. Ultrastructurally keratino-
cytes of the upper spinous layer 
displaced pronounced aggregates of 
tonofilaments forming shells 
around the nuclei. Scale bar, 1 μ. 
с. Skin biopsy of a developing 
blister in a patient from family 2. 
The granular and upper spinous 
layer show a marked extra- and 
intracellular oedema. Serious 
deposits were seen within the 
subcorneal split reflecting early 
blistering. Clumping of tono­
filaments and coarse keratohyaline 
granules are less obvious. Scale 
bar, 50 μ. 
From family 3 four affected individuals were examined. They showed similar skin lesions 
as the patients of family 1 and 2. The light and electronmicroscopical findings in all 
patients were the same as in family 1 and 2. The diagnosis of the disease was IBS. 
From family 4 a 21-year-old man had blistering since the age of 3 years. Erythroderma 
was never present. He suffered from the same skin lesions as the patients of the families 
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1, 2 and 3. Histological examination showed the features of epidermolytic hyperkeratosis 
limited to the upper part of the spinous layer. The other family members could not be 
examined. 
Genomic DNA 
The genomic DNA, used for amplification of the fragments of the K2e gene, was isolated 
from peripheral blood according to the method described in [14]. 
Amplification of DNA fragments 
A fragment of 1.8 kb including the region coding for the HI and 1A domain of K2e, was 
amplified with primers 5'-CTGTGACTTTCCTCCCTGGA-3' (sense) and 5'-TCTGCA-
GTGAGCCCATCCAGA-3' (antisense). The PCR was performed in a volume of 50 μΐ 
containing 0.5-1 μg of genomic DNA, 250 ng of each of the primers, 200 μΜ of dATP, 
dGTP, dCTP and dTTP, 10 mM Tris/HCl pH 8.5, 50 mM KCl, 1 mM MgCl2, 0.01% 
gelatine, 10% dimethyl sulfoxide and 0.5U Taq Polymerase (Perkin Elmer). A PCR 
program with 35 cycles of 30 sec at 94°C, 1 min at 60°C and 2 min at 72°C was 
followed. The fragment including the region coding for the C-terminal part of the 2B 
domain was amplified with the primers 5'-GCAGTGTAAGAATGTGCAAGATG-3' 
(sense) and 5'-CAGTCACATTGCTGCTGAGGT-3' (antisense). The reaction conditions 
were as described above with the exception of an annealing temperature of 55°C instead 
of 60°C. Primer sequences were deduced from the cDNA sequence reported in [13]. 
Cycle sequencing 
Purification of the PCR fragments and cycle sequencing were performed as described by.15 
Sequencing of the 1A fragment was performed with the primer 5'-GGTGGCTTTGGGCC-
TGGA-3'and of the 2B fragment with the sense primer used for the amplification reaction. 
Allele-specific PCR 
The allele-specific PCR to detect for the transversion of A to С in the 1A domain (family 
1) was performed with the sense primer used for amplification of the 1A domain (see 
above) and the antisense primer 5'-TTGTTGTTGAGAGTTTTGATCG-3'. The last 
nucleotide at the 3' end of the primer corresponds to the mutation. The conditions for the 
amplification were as described above with an annealing temperature of 62°C instead of 
60°C and 2 mM MgCl2. 
Screening for the mutation present in families 2 and 3 
Screening for the G to A mutation in families 2 and 3 was performed through 
amplification of a 163 bp fragment with the primer 5'-GTTGAATGACCTGGAGGAGG-
3' (sense) and the primer 5'-TTCCCAGTGCCCACACCTG-3' (antisense, intron VII). The 
latter primer deviates in one nucleotide (underlined) from the sequence of the intron. This 
destroys an Mnll restriction site which simplifies the analysis. For amplification, the intron 
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primer was end-labelled with Ρ The PCR was performed in a reaction mixture of 25 μΐ 
with the components in the same concentration as described above Amplification involved 
30 cycles of 30 sec at 94°C, 1 mm at 55°C and 1 mm at 72°C For the digestion with 
Mnll lOx restriction buffer (supplied by the manufacturer) was added to the 
endconcentration of I χ and 100 mM spermidine was added to give a concentration of 
ImM After the addition of 1U Mnll (New England Biolabs) the reaction mixture was 
incubated at 37°C for 4 hours The fragments were separated on an 8% nondenatunng 
Polyacrylamide gel 
Screening for the mutation delected in family 4 
The transition of Τ to С detected in the patient of family 4 creates a Hpall restriction site 
The testing for the presence of the Hpall site was performed after amplification of the 
surrounding region with the primers 5'-GTTGAATGACCTGGAGG-3' (sense) and 5'-
TCCTCCCTTCCCAGTGCCC-3' (antisense, intron VII) For the amplification the protocol 
was identical to that described in 'amplification of DNA fragments' The digestion with 
2U Hpall was performed as described for the digestion with Mnll Fragments were 
analyzed on a 2 5% agarose gel 
Prediction of protein structure 
The Chou-Fasman algorithm [16] (Caos Camm Center, Nijmegen) was used for the 
prediction of protein structure 
Linkage analysis 
Two-point linkage analysis was performed with the Mlink program of the Linkage 
program package (version 5 03, [17]) The gene frequency of IBS was assumed to be 
0 000005 The mutations were treated as polymorphisms with a frequency of 0 001 
RESULTS 
To screen for the presence of mutations in the keratin 2e gene, we started with the direct 
sequencing of the regions coding for the helix boundary peptides and the HI domain from 
two patients of the families 1, 2, and 3, from the single patient of family 4 and from two 
unaffected persons 
family 1 A heterozygous transversion of adenosine (A593) to cytosine (C) was detected in 
patients of family 1 This transversion leads to the substitution of a proline for a glutamine 
at position 187 (numbering according to [13]) of the predicted protein sequence Through 
allele specific PCR we studied the inheritance of this mutation in the family to 
substantiate its disease causing nature The mutant allele could be detected in all affected 
family members and not in the unaffected persons (Figure 2) Linkage analysis between 
the mutation and the disease gave a maximum lodscore of 3 42 at a recombination fraction 
of zero The absence of this mutation in 50 control persons indicated that the mutation is 
not a common polymorphism 
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Fig. 2. Segregation of the mutation in the K2e gene in family 1. The mutation is detected by allele-
specific amplification. In each of the affected persons the mutated allele could be amplified but not in 
any of the unaffected family members. Persons in the pedigree marked with a bar are included in this 
analysis. 
family 2 and 3: In both families 2 and 3 the sequence coding for the helix termination 
region of the 2B rod domain contained an identical mutation. The GAG codon for 
Glutamic acid493 is changed into an AAG codon leading to the incorporation of a lysine 
in the predicted K2e protein. The mutation destroyed an Mnll restriction site making it 
possible to follow the inheritance of the mutation in the families. In family 2 the mutation 
completely co-segregated with IE (Figure 3a). From family 3 the father was the first 
affected member and thus a new mutation must have occurred. His three children all were 
affected and had the mutation (Figure 3b). His parents and 5 brothers and sisters all were 
unaffected and lacked the mutation. Together with the absence of the nucleotide change in 
50 control persons this indicates that the detected mutation causes the disorder. A lod 
score of 5.46 and 0.54 at no recombination was calculated in two-point linkage analysis 
between the mutation and IBS in family 2 and 3, respectively. 
The mutated G|510 is part of a CpG dinucleotide. These are known to have a 42-fold 
higher mutation rate than expected from random mutation [18]. The same mutation also 
was detected in a familial IBS patient by McLean et al.' 
family 4: A different mutation was detected in the sequence coding for the helix 
termination peptide in a familial IBS patient: the transition of T1502 to С leads to the 
substitution of proline for leucine490. Although the segregation of the mutation in the 
family could not be studied because of the lack of blood samples of the relatives, it is 
likely that this mutation causes the disease, because of the nature of the amino acid 
substitution (see below) and, because the mutation could not be detected in 50 unaffected 
persons. A Hpall site is created by the transition. 
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Fig. 3. Screening for the G1510 to A mutation in family 2 (a) and family 3 (b) by Mnll digestion of 
amplified DNA. The mutation destroys a Mnll site resulting in a 40 bp fragment. The normal allele 
gives a 34 bp fragment. All patients in both families are heterozygous. The unaffected persons are 
homozygous for the 34 bp fragment. The weak signal of the 40 bp fragment in unaffected relatives 
probably is the result of incomplete digestion due to the close proximity of the two Mnll sites. The 
persons included in this study are marked with a bar in the pedigree. 
Nature of the mutations 
In family 1 a nonpolar residue, proline, has been substituted for an uncharged but polar 
residue, glutamine, of the helix initiation peptide. This means the change of a relatively 
hydrophillic into a hydrophobic amino acid which can be expected to induce structural 
changes. Furthermore, proline is known to be interruptive in protein structure. The Chou-
Fasman algorithm [16] for prediction of protein structure predicted the mutation to cause a 
substantial decrease in the length of the α-helix in the corresponding region of the protein. 
In both families 2 and 3 the mutation results in the substitution of a basic lysine for the 
acidic glutamic acid493 in the helix termination peptide of the 2B rod domain. The change 
in charge of the conserved residue can be expected to have a strong effect on the 
secondary structure of the protein. This is also indicated by the decrease of the length of 
the helix structure which is predicted by the Chou Fasman algorithm. 
Although the substitution of proline for leucine490 in family 4 does not result in a change 
of charge or polarity, the incorporation of proline can be expected to have a disruptive 
influence (see above). Also this substitution leads to a marked shortening of the α-helix in 
the predicted protein structure. 
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DISCUSSION 
Ichthyosis exfoliativa was published as a disorder distinct from IBS on histopathological 
grounds [9] The identity of the clinical symptoms of both diseases and the linkage to the 
type II keratin gene cluster induced us to include IE in this study The results of the 
histological and ultrastructural re-examination of skin biopsies as well as the mutation 
analysis demonstrated the identity of IBS and IE In the remaining part of the discussion 
we will only use IBS to indicate the present disorder 
Linkage studies already suggested that IBS is caused by a defect in a type II keratin gene 
located in the gene cluster on chromosome 12qll-132 The detection of the mutations in 
IBS patients finally proved the hypothesis that a defect in keratin K2e causes IBS The 
mutations show a dominant phenotype as do all but one mutation in keratin genes 
identified so far [19] In one of the families (family 1) we found a mutation in the helix 
initiation peptide of the 1A domain In three other families (family 2-4) two different 
amino acid substitutions were detected in the helix termination peptide of the 2B domain 
The mutated glutamine
 t 8 7 in family 1 and the leucine490 substituted in family 4 both are 
conserved in all type II keratins The mutated glutamic acid493 in family 2 and 3 is not 
only conserved in the type II keratins but in the type I as well These mutations further 
underline the importance of the integrity of the helix boundary peptides for the appropriate 
KIF (keratin intermediate filament) formation (cf [10-12,20-23]) 
The helix boundary peptides are two out of six regions where a close juxtaposition occurs 
between neighbouring molecules in the KIF and thus specify the correct alignment of 
these molecules [11,24,25] According to the prediction of the structure of the mutated 
K2e molecules, the mutations cause a change in the corresponding part of the α-helical 
rod domain All of the three mutations result in the incorporation of a residue with a lower 
helix propensity parameter than the normal residues [16] The changes in structure can be 
expected to affect both the heterodimenzation through impairment of the coiled coil 
formation and the higher order filament assembly, reflected in the disturbed cytoskeleton 
in keratinocytcs of the upper spinous and granular layer of the epidermis (ct 
[20,22,23,26]) 
The clarification of the genetic defect causing IBS, finally demonstrates that IBS is 
distinct from BCIE The divergent expression patterns of K2e and Kl or K10 can explain 
the clinical and histological differences between both diseases Defects in filament 
formation are in the skin of IBS patients only visible in the granular layer and the upper 
spinous layer [5-7,9] This coincides with the expression of the K2e gene in normal skin " 
In BCIE, filament clumping is present in the whole suprabasal compartment which 
expresses Kl and KIO 
A substitution of lysine for the glutamic acid corresponding to the Glu4 9 3 in K2e has been 
introduced m K14 and subsequently expressed by transient transfection in SCC-13 cells 
The phenotype is milder than with transfection of a mutated K14 causing the severe EBS-
Dowling-Meara in patients [20] This suggests that the nature of the mutations can explain 
the milder epidermolytic hyperkeratosis of IBS compared to that of BCIE 
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Part III 
Therapy 

Introduction 
So far, in monogenic disorders of keratmization treatment is symptomatic Whereas one 
has to be a splitter to classify these disorders with respect to their origin, to advise 
families about inheritance and to predict the clinical course, the practical reality of 
therapeutic intervention is the world of lumpers The process of keratmization constitutes a 
joint therapeutic target in different disease entities, susceptible to a broad aspecific 
therapeutic intervention However, as will be shown in chapter 2 and 3 there are some 
differences in response to oral retinoids Topical treatment of disorders of keratmization 
include formulations containing urea, lactic acid, propylene glycol and salicylic acid Total 
body treatment with salicylic acid, however, should be avoided especially in children ' The 
introduction of oral synthetic retinoids was a major breakthrough in the treatment of the 
more severe disorders of keratmization Chapter 1, 2 and 3 describe our experience with 
these drugs 
Since 1962 it is known that topical treatment with vitamin A acid (0,05% all-trans-retinoic 
acid) is effective in disorders of keratmization2, however, its toxic side effects limit its 
use In chapter 4 and 5 the effect of 0,1% 13-cis-retinoic acid is shown in a variety of 
disorders of keratmization 
Calcipotnol is now an established drug in the treatment of psoriasis In a multicenter study 
the efficacy of calcipotnol ointment was investigated in a large group of disorders of 
keratmization The results are presented in chapter 6 
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Chapter 1 
Acitretin in the Treatment of 
Erythrokeratodermia Variabilis 
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ABSTRACT 
A patient with erylhrokeratodermia variabilis (Mendes da Costa's disease) is presented, 
and the clinical and histological response to acitretin is described An initial dose of 35 
mg of acitretin and a maintenance dose of 25-35 mg resulted in a pronounced and 
sustained improvement Further reduction of the dosage resulted in a relapse within a few 
days At the histological level the extensive hyperkeratosis and the moderate dermal 
inflammatory infiltrate decreased during treatment with acitretin In comparison with the 
other retinoids available so far, acitretin is the derivative of first choice in the treatment of 
erythrokeratodermia variabilis Mendes da Costa 
Erylhrokeratodermia variabilis (EKV) was described by Mendes da Costa in 1925 ' It is a 
rare genodermatosis with an autosomal dominant mode of inheritance 2 In 1984 a genetic 
linkage between EKV and Rh locus has been demonstrated 3 The skin manifestations are 
highly characteristic Sharply defined figurated patches of erythema that vary in size and 
localization are observed In addition, sharply demarcated yellow-brown hyperkeratotic 
plaques of geographic outline are seen, which show a more consistent appearance As a 
rule, the lesions are distributed symmetrically EKV usually becomes manifest during the 
first years of life and has a chronic course In general, the skin manifestations are rather 
extensive 
Histologically, the hyperkeratotic plaques are characterized by a laminated 
orthohyperkeratosis, acanthosis and papillomatosis with elongated capillaries, and a mild 
mononuclear infiltrate in the perivascular regions45 
Patients with EKV have been treated with several oral retinoids all-trans-retinoic acid6, 
I3-cis-retinoic acid5 and etretinate 7 '2 Etretinate is preferred in the treatment of disorders 
of keratinization for reason of a better ratio of clinical efficacy and side effects '3 " 
This communication reports the clinical and histological changes observed in a patient 
with EKV during treatment with acitretin 
CASE REPORT 
Clinical aspects 
A 17-year-old woman suffered from a widespread ichthyotic and erythematous skin 
disorder present since birth During the first year of life she had a generalized erythema, 
and after 9 months she developed erythematous patches and hyperkeratotic plaques with 
some itching The lesions varied as to size and localization, stress and heat elicited 
aggravation and extension of the erythematous lesions No other family member had these 
skin lesions The patient had been treated with emollients and keratolytics Between 1983 
and 1986 she has been treated with etretinate (average dose 25 nig per day) Between 
1986 and 1988, 13-cis-retinoic acid was prescribed Ftretinate resulted in a considerable 
improvement, in particular of the hyperkeratotic plaques, whereas 13-cis-retinoic acid at a 
dosage of 20 mg daily resulted in only a modest improvement She had been without 
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systemic treatment during 3 months when she presented for the first time at our 
department. Apart from oral contraception she had no systemic medication. 
On examination she had sharply demarcated figurated erythematous lesions symmetrically 
distributed predominantly on the trunk (Figure la). The erythematous patches varied in 
size and shape within hours. In addition, brownish hyperkeratotic plaques were seen, again 
sharply demarcated and distributed symmetrically, localized predominantly on the trunk, 
the knees, hands, elbows and lower legs. The palms showed a moderate keratoderma. 
Before treatment, blood parameters (clinical chemistry) were within the normal range, and 
X-ray examination of the vertebral column did not reveal abnormalities. 
Apart from bland emollients the patient did not use any topical therapy. Treatment with 
acitretin was started at a dosage of 35 mg per day, and the hyperkeratotic lesions 
improved markedly, whereas the erythematous component only showed a moderate 
improvement (Figure 1). 
The dose was adjusted according to the clinical response. During the first 6 months doses 
below 35 mg per day resulted in a relapse within a few days (Figure 2). After 9 months of 
treatment the dose could be decreased to 25 mg/35 mg on alternate days, and after 14 
months the dose was decreased to 25 mg per day without any aggravation of the condition 
of the skin. Side effects were limited to moderately dry lips. Blood investigations, 
urinalysis and X-ray examination during treatment did not reveal abnormalities. 
Fig. 1. Erythematous and hyperkeratotic lesions in a patient with EKV before treatment (a) and after 1 
month of treatment (b) with acitretin. 
Histopathological Examination 
Figure 3 illustrates the histological observations of a hyperkeratotic lesions at the right 
lower leg before and after 3 months of treatment with acitretin. 
Before treatment, the histological picture was compatible with the diagnosis of EKV. The 
stratum corneum showed a hyperkeratosis with a broadened stratum granulosum. The 
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epidermis was acanthotic; however, no pronounced papillomatosis was present. A 
moderate perivascular infiltrate of mononuclear cells was seen. 
After 3 months of treatment the hyperkeratosis and the epidermal acanthosis had 
diminished considerably. The inflammatory changes in the dermis had only slightly 
improved. 
0 4 8 
Treatment time, months 
Fig. 2. Severity scores in a patient with EKV during treatment with acitretin Erythema; 
scaling; = palmoplanar keratoderma. Severity score: l=mild; 2=moderate; 3=severe. 
· • * . 
Fig. 3. Histological picture of a hyperkeratotic plaque in a patient with EKV before treatment (a) and 
after 3 months of treatment (b) with acitretin. χ 150. 
DISCUSSION 
The present observation confirms the effectiveness of retinoids in EKV. The doses of 
various retinoids and their efficacy in the treatment of EKV are summarized in Table 1. 
The initial dose of acitretin in our case is relatively low, the maintenance dose, however, 
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is in the dose range of etretinate, as reported by several groups. In other monogenic 
disorders of keratinization (Darter's disease and X-linked recessive ichthyosis) the 
effective dose range of acitretin was found to be lower as compared to etretinate. '6 '8 In 
psoriasis, however, the average daily doses of acitretin and etretinate were similar" or 
only slightly lower.20 
A remarkable observation was the quick relapse following dose reduction after 8 weeks of 
treatment. Again, the direct dose-response relationship is in line with the experience in 
Darier's disease.16 In a group of 6 patients with palmoplanar pustulosis the relapse period 
following discontinuation of acitretin has been reported to be considerably shorter as 
compared to etretinate.2 ' 
Abnormal epidermal differentiation and inflammation are pathogenetic factors in EKV. 
Retinoids have been shown to interfere with the differentiation process and with various 
aspects of cutaneous inflammation.22 In the present case, the hyperkeratosis improved 
markedly, whereas the erythema diminished to a lesser extent. However, both phenomena 
improved and relapsed simultaneously following increase and decrease of the dose (Figure 
2) The keratinization process is characterized by a decreased number of keralinosomes 
and abnormal perinuclear aggregation of tonofilaments.4 5 
The spectrum of diseases responsive to acitretin is comparable with that of etretinate.21 
The relatively short elimination half-life of acitretin clearly has an important impact for 
the treatment of women of childbearing age, as the period of potential teratogenicity 
following discontinuation of acitretin is limited to 2 months only Moreover, evidence is 
accumulating that acitretin has a more direct dose-response relationship in comparison 
with etretinate. 
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Chapter 2 
Ichthyosis Bullosa of Siemens Responds 
Well to Low-Dosage Oral Retinoids 
PM Steijlen 
RJ van Dooren-Greebe 
R Happle 
PCM van de Kerkhof 
Br J Dermatol 1991; 125: 469-471 
SUMMARY 
Two patients with ichthyosis bullosa of Siemens (IBS) and one patient with bullous 
ichthyosiform erythroderma of Brocq (ΒΙΕ) were treated with etretinate Two additional 
patients with IBS received acitretin All patients had a marked improvement when on 
retinoids and the maintenance dose required was for IBS 10-25mg per day The patient 
with ΒΙΕ was on a maintenance dose of 40-60 mg per day 
Bullous ichthyosisform erythroderma is a relatively rare but severe and incapacitating type 
of congenital ichthyosis This type of epidermolytic hyperkeratosis has been described by 
Brocq' and further delineated by Lapiere2 However, in 1937 Siemens distinguished a 
particular type of congenital bullous ichthyosis without erythroderma3 Over the years this 
type of ichthyosis has been described as having a relatively mild involvement of the skin 
and the epidermolytic hyperkeratosis has been restricted to the upper part of the 
epidermis''' 
Aromatic retinoids have been effective in the treatment of various forms of congenital 
ichthyosis, 6 g but the treatment of bullous ichthyosis erythroderma of Brocq with oral 
retinoids has been difficult ' '2 Although a marked reduction of the hyperkeratosis can be 
achieved, exacerbation of the blistering is a serious complication and often limits the dose 
of the drug As yet there have been no reports of the use of retinoids in the treatment of 
ichthyosis bullosa of Siemens (IBS) This present study was to compare the responses of 
these two types of bullous ichthyosis to therapy with oral retinoids 
CASE REPORTS 
The clinical and histological aspects of Case 1 to 4 have been previously described5 All 
the patients were monitored at 4-weekly intervals while on treatment 
С a i e I 
A 27-year-old woman weighing 63 kg had superficial blistering of the skin on the 
extensor surfaces of the arms and legs in addition to ichthyosis (Figure la) Her father 
(Case 3), uncle (Case 4), sisters and son were also affected At no time she had an eryth­
roderma A skin biopsy showed mild acanthokeratolysis of the epidermis restricted to the 
region of the stratum granulosum and upper part of the stratum spinosum 
The patient was given acitretin m a dosage of 35 mg daily and after 4 weeks there was 
marked reduction of the scaling that was virtually absent after 8 weeks of therapy The 
dose was reduced after 12 weeks of treatment to 30 mg and further reduced after 16 
weeks to 25 mg (Figure lb) The dosage of acitretin was again reduced at 20 weeks 
because of some hair loss and slight elevation of the liver transaminases A further 
reduction of the dose was at 24 weeks when she was on 10 and 20 mg on alternate days 
During the follow-up period of 95 weeks no blistering of the skin had occurred 
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Fig. 1. Ichthyosis bullosa of Siemens: a. Before treatment; b. After 16 weeks of treatment with acitretin 
(25 mg/day). 
Case 2 
A 21-year-old woman weighing 77 kg presented with the same degree of involvement as 
seen in Case 1. The patient was given acitretin in a dosage of 35 mg daily and the 
hyperkeratosis diminished and was virtually absent after 8 weeks of therapy. The dosage 
was reduced to 30 mg and an excellent response was maintained from 13 weeks with a 
dosage of 25 mg. During the follow-up period of 22 months no blistering of the skin has 
occurred. 
Case 3 
The 51-year-old father of Cases 1 and 2 and weighing 77 kg had suffered from a scaly 
skin since birth. From the age of 15 he also had chronic relapsing pustular eruptions and a 
biopsy showed a subcorneal blister that was filled with numerous polymorphonuclear 
leukocytes. He was given etretinate in a dosage of 35 mg daily and after 4 weeks the skin 
had improved and there was no further pustulation. After 8 weeks of treatment the 
hyperkeratosis was hardly noticeable and the dosage was further reduced to 25 mg per 
day. In the 22nd week the dosage was further reduced to 25 mg on alternate days and by 
the 28th week to 10 mg daily. There was mild scaling of the arms but over the 
observation period of 14 months there was no blistering or pustulation of the skin. 
Case 4 
A 40-year-old uncle of Case 1 weighing 65 kg had the same disorder with relapsing 
pustular eruptions and was given etretinate in a dosage of 35 mg daily. After 4 weeks of 
treatment the hyperkeratosis and pustulation had resolved and the dosage of the retinoid 
was reduced to 25 mg daily. A further reduction to 10 mg daily resulted in an 
exacerbation with pustulation and scaling. Over a follow-up period of 12 months a good 
response was maintained with him having 10 and 20 mg of etretinate on alternate days. 
123 
Case 5 
A 15-year-old male weighing 67 had severe hyperkeratotic (Figure 2a) that covered the 
entire surface of the body apart from the face, palms and soles. The condition had been 
present since birth, but because the patient was an orphan it was uncertain about his first 
year of life and a family history was not available. A skin biopsy from the left forearm 
showed features of an epidermolytic hyperkeratosis that involved the entire epidermis. 
He was treated with etretinate in a dosage of 75 mg daily and within 4 weeks there was a 
marked improvement. However, a skin biopsy showed even more pronounced histological 
features despite the clinical improvement. During the subsequent 6 months he was treated 
with etretinate in a dosage of between 40-60 mg daily and apart from slight recurrence of 
mild hyperkeratosis with bulla formation he was otherwise satisfactory (Figure 2b). 
Fig. 2. Bullous ¡chtyosiform erythroderma of Brocq: a. Before treatment; b. After 10 weeks of treatment 
with etretinate (50 mg/day). Note the appearance of some blisters. 
DISCUSSION 
Ichthyosis Bullosa of Siemens is a relatively mild condition as compared to bullous 
ichthyosiform erythroderma. However, the extent of the lesions and the discomfort caused 
by scaling and pustulation in our cases justified the administration of oral retinoids. As 
yet there are no other reports on the response of this disorder to systemic retinoids. None 
of our patients showed any sign of blistering 
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of the skin during the follow-up period of 12-95 weeks The maintenance dose was much 
lower than that required for bullous ichthyosiform erythroderma 
The efficacy of etretinate in the treatment of ΒΙΕ is shown in our Case 5, though the 
maintenance dose of the drug was high at 40-60 mg daily, A maximum dose of retinoids 
is limited by introduction of blisters in this disorder' and it has also been reported that the 
blister formation was not inhibited by therapy with etretinate" as we found in our case 
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Acitretìn in the Treatment of Lamellar Ichthyosis 
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SUMMARY 
Etretinate and its metabolite acitretin have been shown to be highly effective in the 
treatment of various disorders of keratinization, including lamellar ichthyosis. The aim of 
the present study was to provide further information on acitretin dosage regimens in the 
management of acitretin in lamellar ichthyosis. 
Seven patients with classical manifestations of lamellar ichthyosis participated in the 
study. Five patients improved markedly, and the remaining patients showed mild to 
moderate improvement. Two patients improved following gradual incremental increase in 
dosage (>35 mg/day). Four patients, including a patient with the erythrodermic variant, 
required low-dose acitretin treatment (<25 mg/day), as higher doses resulted in a marked 
deterioration in their skin condition. The dichotomy with respect to the response to 
acitretin suggests that lamellar ichthyosis is a spectrum of at least two conditions. 
In severe disorders of keratinization retinoids constitute a well-established and highly 
effective treatment'2. In monogenic disorders of keratinization, however, information on 
dosage regimens is sparse. 
We report the results of acitretin treatment of lamellar ichthyosis. The principal aim of the 
study was to establish the dose-response relationship in this disorder. 
METHODS 
Patients 
A total of seven patients with lamellar ichthyosis participated in the study. Table I 
summarizes the patient details. All patients had a history of ichthyosis from birth. Patient 
3 had a life-long history of erythroderma. In one patient (patient 7) the family history 
revealed that two nephews suffered from the same condition. In the other cases family 
history was negative. 
Table 1. Patients details 
Patients 'i/o Bodyweigth Erythroderma Congenital 
ichthyosis 
1 9 40 
2 ? 39 
3 I 59 
4 | 51 
5 ¿ 57 
6 δ 59 
7 76 
In six patients the classical picture of non-erythrodermic autosomal recessive lamellar 
ichthyosis was seen, and in one case (patient 3) erythrodermic autosomal recessive 
ichthyosis was diagnosed. Flexural involvement, and palmoplantar keratoderma was 
present in all patients. In patient 1 the condition was associated with almost total alopecia. 
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Two patients (patients 1 and 3) suffered from pruritus In all patients the seventy of the 
skin condition required systemic treatment with retinoids 
In four out of seven patients, treatment was initiated with etretinate, resulting in a 
moderate to good clinical improvement Apart from mild to moderate cheilitis, no 
mucocutaneous side-effects occurred in these patients Table II summarizes the results 
with etretinate In these patients etretinate was discontinued for 1 month before the 
initiation of acitretin therapy This resulted in a deterioration of skin symptoms during the 
first 2-3 weeks 
Table II Response to etretinate 
Patient Duration 
(years) 
7 
6 
7 
5 
Optimal dose 
(mg/day) 
25 
20 
25 
50-75 
Improvement 
moderate 
good 
good 
moderate-good 
Mucocutaneous 
side effects 
mild 
mild 
moderate 
mild 
Treatment 
All patients were initially treated with acitetnn 35 mg daily for 4 weeks Thereafter, the 
dose was individualised on the basis of efficacy and tolerability in each patient Before 
treatment, and at monthly intervals, blood investigations were earned out ( full blood 
count, bilirubin, creatinine, urea, uric acid, blood sugar, alkaline phosphatase, 
transaminases, gamma-glutamyl transpeptidase, cholesterol, triglycerides) Before 
treatment, after 6 months treatment, and subsequently at yearly intervals, an X-ray of the 
spine was performed 
Table I I I . Response to acitretin 
Patient 
1. 
2. 
3. 
4. 
5 
6 
7. 
Duration 
(years) 
4 
4 
5 
5 
V* 
4 
Vi 
Opt imal dose 
(mg/day) 
35 
25 
10-25 
25 
35 
10-20 
55 
Improvement 
marked 
marked 
marked 
marked 
mild 
marked 
moderate 
Mucocutaneous 
side effects 
mild 
moderate 
moderate-severe 
moderate 
severe hairloss 
moderate 
moderate 
Results 
Acitetnn therapy produced a marked improvement in most patients Table 111 shows the 
results in individual patients Figure 1 illustrates the clinical improvement (patient 1) The 
optimal dose varied considerably between individual patients (Table III) The dynamics of 
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dosage adjustments, however, provided two distinct response patterns. Some patients 
improved following each dosage increment (patients 1 and 7: Figure 2). 
Fig. 1. Lamellar ichthyosis before treatment (a) and after 6 months treatment (b) with acitretin 
(35 mg/ day, patient 1) 
In these patients the maximum dose was limited by mucocutaneous side- effects (cheilitis, 
epistaxis or hair loss). The remaining patients worsened at a dosage of 35 mg/day, and 
required lower doses (10-25 mg/day, Figure 3). Reduction of the dosage below 35 mg/day 
resulted in an improvement of scaling, pruritus and tenderness of the skin. The patient 
with erythrodermic lamellar ichthyosis (patient 3) showed the most remarkable dose-
response relationship in this respect. Figure 2 illustrates dose response relationship of a 
"high-dose profile" and Figure 3 the dose-response relationship of a "low dose profile". 
After 4 years treatment there was cosmetically acceptable hair regrowth in patient 1, who 
had suffered from severe alopecia. 
Apart from some degree of cheilitis, epistaxis or hairloss, there were no other side-effects. 
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DISCUSSION 
The efficacy of acitretin in the treatment of lamellar ichthyosis has been reported 
previously2. The present study confirms this report, and suggests that two distinct response 
patterns may occur: (i) a high-dose response, in which maximum efficacy is limited by the 
tolerance of the individual patient to acitretin; (ii) a low-dose response, in which 
maximum efficacy is reached at a low dose. In the latter response type, increasing the 
dose results in more scaling and pruritus. Erythrodermic autosomal recessive lamellar 
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ichthyosis is characterized by a low-dose response-pattern However, 3 of the patients who 
responded optimally to the low-dose regimen had clinical and histological features which 
were similar to those observed in the patients requiring higher doses 
The clinical appearance of lamellar ichthyosis is highly variable ' Patients with lamellar 
ichthyosis may manifest erythroderma, or they may have the non-erythrodermic variant. In 
addition, patients may appear non-erythrodermic, but have a previous history of 
erythroderma At the cellular level, patients with erythrodermic manifestations tend to 
have increased labelling indices in the epidermis in combination with parakeratosis."1"6 
There is some overlap at the cellular level At the molecular level, patients with 
erythroderma have increased levels of n-alkanes in the epidermis, in contrast with the 
normal levels observed in the non-erythrodermic individuals.7 
It has been suggested that heterogeneity exist within the lamellar ichthyosis group, based 
on clinical, histological ultrastructural, cellular and biochemical studies The present study 
demonstrates that the patient with erythrodermic lamellar ichthyosis responded optimally 
to the low dose regimen The remaining patients who had clinical and histological features 
of the non-erythrodermic type showed a differential retinoid sensitivity 
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Chapter 4 
Topical Treatment with 13-CIS-Retinoic Acid 
Improves Darier's Disease and Induces the 
Expression of a Unique Keratin Pattern 
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SUMMARY 
A patient with Daner's disease was treated topically with either 13-cis-retinoic acid 0 1%, 
all-trans-retinoic acid 0 05%, or their cream base only Both 13-cis-retinoic acid and all-
trans-retinoic acid were effective However, all-trans-retinoic acid had to be discontinued 
because of irritation By contrast, 13-cis-retinoic acid was well tolerated and resulted in a 
complete remission Both retinoids caused a marked change in the expression of cytokera-
tms The most remarkable observation was the expression of cytokeratins 4, 13 and 19 at 
retinoid-treated areas So far known these cytokeratins are absent in adult normal or 
diseased epidermis and hence provide a cell-biological tool to substantiate a retinoid 
effect 
Daner's disease is an autosomal dominant disorder of keratinization Systemic retinoids 
have revolutionized the treatment of this chronic distressing dermatosis The results of 13-
cis-retinoic acid, etretinate and recently acitretin have been well documented ' 7 
In the older literature topical treatment with all-trans-retinoic acid has been shown to 
improve disorders of keratinization including Daner's disease " Irritation of the skin 
however is a serious drawback of this treatment Therefore the use of topical all-trans-
retinoic acid never became an established treatment in Daner's disease and was mainly 
limited to comedonic and papulopustular acne 
The aim of the present study was to investigate 13-cis-retinoic acid as a topical treatment 
of Daner's disease In particular the question was addressed whether the ratio of 
therapeutic response and skin irritation was favourable as compared to all-trans-retinoic 
acid In order to further elucidate the interference of 13-cis-retinoic acid with the process 
of keratinization and proliferation, an immunohistochemical assessment was earned out 
CASE REPORT 
A 62-year-old man suffered from Daner's disease from the age of 42 years At 
presentation he used no treatment at all Previously he had applied topical steroids and 
bland emollients during episodes of aggravation Secondary infections of the skin were 
controlled with antibiotics 
Clinical examination of the skin showed an eruption of brownish hyperkeratotic papules, 
disseminated over the trunk and the upper extremities Characteristic nail changes such as 
longitudinal bands with a V-shaped nick at the free margin and splitting of the nail plate 
were observed 
Prior to the investigation informed consent was obtained for topical treatment with 
retinoids Four representative test areas (20 χ 20 cm each) localized on the back were 
selected A shirt with four windows was manufactured permitting accurate and 
reproducible application of the ointments (Figure la) 
Using a bilaterally paired comparison, double-blind approach a cream containing 13-cis-
retinoic acid in 0 1% concentration the the cream base only (Hoffmann-La Roche, Basel, 
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Switzerland) were applied in the upper two quadrants. The lower two quadrants were 
treated with 13-cis-retinoic acid 0.1% and all-trans-retinoic acid (0.05%). 
The patient was examined at biweekly intervals. During the first 6 weeks the upper two 
quadrants were treated twice daily and during the subsequent 6 weeks the creams were 
applied once a day. The lower quadrants were treated once a day during a period of only 
6 weeks. 
Fig. 1. Clinical appearance of 
untreated and treated skin. 
a. Upper two test quadrants of 
untreated lesionai skin localized on 
the back, showing hyperkeratotic 
papules. 
b. Total clinical clearance of the 
13-cis-retinoic acid treated upper 
left quadrant after 12 weeks. Slight 
improvement at the upper right 
quadrant treated with cream base. 
ANALYTICAL PROCEDURES 
Tissue samples 
Four-millimetre punch biopsies were taken from the upper quadrants before as well as 
after 6 weeks and 12 weeks of treatment. From the lower quadrants biopsies were taken 
accordingly before and after 6 weeks of treatment. The biopsies from representative skin 
lesions were snap frozen in liquid nitrogen and stored at -80°C until processing. 
Antibodies 
Six monoclonal anticytokeratin antibodies and Ki-67, a marker for proliferation10"'2, were 
used in this study. The specificity and source of the anticytokeratin antibodies are 
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summarized in Table I. The monoclonal antibody Ki-67 was obtained from Dakopatts, 
Copenhagen, Denmark. 
Immunohistochemistry 
Four-micronmetre-thick sections were stained with cytokeratin antibodies using an indirect 
immunoperoxidase staining procedure as described previously." Ki-67 antigen was 
visualized as described by Gerdes et al .1 0" with minor modifications.'6 
The percentage of reacting cells in the different cell compartments was estimated using a 
five-point scale (Figure 2). 
Table I. Specificity of monoclonal cytokeratin antibodies used in this study 
Antibody Cytokeratin Differentiation Source Reference 
recognized cell type indicator 
6B10 CK4 stratifying, non-comifying 
(suprabasal) 
RKSE60 CK 10 stratifying, comifying 
(suprabasal) 
1C7 CK 13 stratifying, non-comifying 
(suprabasal) 
2D7 CK13 stratifying, non-comifying 
(suprabasal) 
RPN1165 CK 19 simple epithelia 
RESULTS 
Clinical response 
After 4 weeks a marked difference was observed between the upper quadrants in favour of 
the left one which proved to be treated twice daily with 13-cis-retinoic acid. Scaling was 
markedly diminished, papules were flattened, although a slight aggravation of erythema 
and mild tenderness was experienced. After 6 weeks the area treated with 13-cis-retinoic 
acid had a normal appearance apart from mild erythema (Figure lb). 
Subsequently the applications were reduced to once daily, and this was followed by 
further improvement and disappearance of the erythema and tenderness. After 12 weeks 
the experiment was stopped as total clearance was reached in the upper left quadrant 
treated with 13-cis-retinoic acid. 
The upper right quadrant treated with the cream base only showed only a slight 
improvement during the 12-week period of treatment. 
13-Cis-retinoic acid and all-trans-retinoic acid were applied once daily to the lower left 
and right quadrant, respectively. After 6 weeks both areas showed a similar reduction of 
scaling, and flattening of papules. When compared to the pronounced response of the 
application twice daily of 13-cis-retinoic acid the improvement was moderate. The site 
treated with all-trans-retinoic acid showed a severe erythema, and the patient experienced 
burning which necessitated discontinuation of treatment in this area. By contrast, the area 
treated with 13-cis-retinoic acid showed only a mild erythema. 
Sanbio 13 
Euro Diagnostics 14 
Sanbio 13 
Sanbio 13 
Amersham 15 
136 
Histological findings 
Biopsies taken before and during treatment with the cream base only showed a similar 
picture. The stratum corneum displayed a marked hyperkeratosis of the ortho- and 
parakeratotic type. The epidermis demonstrated acanthotic and acantholytic foci with 
typical dyskeratosis and suprabasal cleft formation. A pronounced band-like mononuclear 
infiltrate was noted in the papillary dermis. 
The sites treated with 13-cis-retinoic acid as well as all-trans-retinoic acid treated showed 
a marked reduction of the above mentioned abnormalities resulting in a mild acanthosis 
and a slight perivascular infiltrate. 
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Fig. 2. A schematic representation of the 
cytokeratin (CK) distribution patterns as 
detected by the different monoclonal antibodies 
in lesionai skin: Abbreviations: S.C. = Stratum 
Comeum; S.G. = Stratum Granulosum; S.S. = 
Stratum Spinosum; SB. = Stratum Basale; 
untr.= untreated; CR.B.= cream base; 13CRA6 
= 13-cis-retinoic acid treatment once daily 
during 6 weeks; 13CRA6" = 13-cis-retinoic acid 
treatment twice daily during 6 weeks; 
13CRA12 = 13-cis-retinoic acid treatment 
during 12 weeks; TRA6 = all-trans-retinoic acid 
treatment once daily during 6 weeks 
• = parakeratotic area; * = dyskeratotic area 
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Immunohistochemical findings 
The results obtained with the immunoperoxidase technique on frozen sections are 
summarized in Figure 2. 
Cytokeratins 4, 13 and 19 were not expressed in biopsies taken before treatment and taken 
from the sites treated with the cream base only. Cytokeratin 4 showed expression of 
varying intensity in the biopsies taken from the sites treated with 13-cis-retinoic acid and 
all-trans-retinoic acid. Staining was limited to the upper part of stratum spinosum, stratum 
granulosum and stratum corneum (Figure 3a). Remarkably, staining was more extensive in 
the biopsy taken from the site treated with all-trans-retinoic acid (Figure 3b). 
The monoclonal antibodies 1C7 and 2D7, recognizing cytokeratin 13, showed similar focal 
staining patterns with varying intensity in biopsies taken from the sites treated with 13-cis-
retinoic acid and all-trans-retinoic acid. Positive keratinocytes were found in the stratum 
spinosum (Figure 3c). In the biopsy from the site treated with all-trans-retinoic acid 
(Figure 3d) the expression of cytokeratin 13 appeared to be stronger. 
Fig. 3. Immunoperoxidase staining patterns of frozen sections from biopsies taken after 12 weeks of 
treatment, a. 13-Cis-retinoic acid treated site, showing cytokeratin 4 expression; b. All-trans-retinoic 
acid treated site, showing cytokeratin 4 expression; с 13-Cis-retinoic acid treated site, showing 
cytokeratin 13 expression; d. All-trans-retinoic acid treated site, showing cytokeratin 13 expression. 
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Cytokeratin 19 was expressed focally only in the stratum granulosum and stratum 
spinosum in the biopsies taken from the sites treated with 13-cis-retinoid acid twice daily 
or with all-trans-retinoic acid (Figure 2). 
Cytokeratin 10 was observed in the suprabasal compartment. In the biopsies taken before 
treatment and from the site treated with cream base only, the acantholytic and dyskeratotic 
regions showed no staining. The parakeratotic stratum corneum did not show staining 
either. In the sample taken after 12 weeks of treatment with 13-cis-retinoic acid expression 
of cytokeratin 10 was observed only focally in the stratum spinosum and stratum 
granulosum. 
Кі-67-positive nuclei were assessed in all biopsies In lesionai skin being untreated or 
treated with the cream base only, the numbers of positive nuclei were 36 and 37 per 
millimetre section length, respectively. At the sites treated with 13-cis-retinoic acid values 
were 24, 30 and 58 positive nuclei per millimetre, respectively. At the all-trans-retinoic-
acid-treated site the counts were 35 per millimetre. 
DISCUSSION 
The present case is the first demonstration of a therapeutic effect of topical 13-cis-retinoic 
acid in a monogenic disorder of keratinization. 
The clinical results of the present study show that topical treatment with 13-cis-retinoic 
acid and all-trans-retinoic acid in a 0.05% concentration are effective in Darier's disease. 
The clinical improvement was confirmed at the histopathological level by a marked 
reduction of acanthosis and hyperkeratosis. Topical treatment with 13-cis-retinoid acid 
during 12 weeks resulted in a total remission of the treated test area. 
Compared to the intolerable tenderness caused by treatment with all-trans-retinoic acid, 
irritation induced by treatment with 13-cis-retinoic acid once daily was negligible Topical 
application of 13-cis-retinoic acid with a concentration up to 0.3% showed an excellent 
tolerance in the hamster model". Therefore the concentration of 13-cis-retinoic acid used 
in the present study might be increased 2-3 times which might considerably enhance the 
therapeutic effectivity. 
Our results confirm that topical all-trans-retinoic acid is effective in Darier's disease.' In 
the hairless mouse model for ichthyosis a beneficial effect of 13-cis-retinoic acid had a 
comparable potency as to the reduction of scaling18. In view of the observations of 
Stuttgen8 with all-trans-retinoic acid, the excellent tolerability of 13-cis-retinoic acid in the 
animal model17, the beneficial effect in the hairless mouse model18 and the present study, 
13-cis-retinoic acid may have wider implications as a therapeutic tool in disorders of 
keratinization other than Darier's disease. 
Transformation of 13-cis-retinoic acid into all-trans-retinoic acid has been reported1920. In 
this respect the effect of ultraviolet radiaton is of significance. In our patient applications 
were carried out on sites not exposed to sunlight. Nevertheless it is remotely possible that 
relatively low doses of all-trans-retinoic acid may contribute to the therapeutic effect on 
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the sites treated with 13-cis-retinoic acid. The clinical effect of low doses of all-trans-
retinoic acid remains to be explored. 
The cytokeratin pattern of Darier's disease has been reported by Bürge et al. 2'. In the 
present report we can confirm their observations that cytokeratin 10 was not consistently 
expressed in acantholytic regions and their observation of the absence of cytokeratin 19 in 
untreated lesionai skin. We have extended their observations with respect to the absence 
of cytokeratin 4 and 13 in untreated skin (Figure 2). 
Topical application of 13-cis-retinoic acid and all-trans-retinoic acid induced the 
expression of cytokeratins 4, 13 and 19 which are not expressed in normal adult 
epidermis22. The expression of these cytokeratins is limited to the suprabasal compartment. 
To the best of our knowledge, the in vivo expression of these cytokeratins has never been 
described before, either in normal or diseased epidermis. Expression of cytokeratins 4, 13 
and 19 was reported in a differentiation model using cultured foreskin keratinocytes and in 
15- and 20-week-old fetal epidermis.22 In vitro it was shown by Kopan et al.2' that retinole 
acid induced synthesis of cytokeratins 13 and 19. Ponec24 reported the induction of 
cytokeratins 4, 13 and 19 in reconstructed epidermis in vitro by all-trans-retinoic acid and 
acitretin. The selective induction of these keratins, which are found in simple and non-
comifying stratified epithelium, is of practical significance as a marker for retinoid effect. 
After treatment with both 13-cis-retinoic acid and all-trans-retinoic acid acantholysis and 
dyskeratosis were no longer present. Twelve weeks of treatment with 13-cis-retinoic acid 
resulted in a down-modulation of cytokeratin 10, indicated by a rather weak staining 
pattern (Figure 2). 
In a recent study we demonstrated that normal epidermis had a total number of 24.7 ± 2.2 
Кі-67-positive nuclei per millimetre section length12. Five of the 6 biopsies examined in 
the present study showed an increased number of Кі-67-positive nuclei corresponding with 
an increased recruitment of actively cycling epidermal cells. This observation indicates 
that the increased labelling index as suggested by Lachappelle et al.25 can be explained at 
least in part by an escape of cells from the non-dividing basal cell population. The 
recruitment process of cycling cells has been shown to be a non-specific phenomenon in 
conditions characterized by a benign hyperproliferalion such as response to injury or 
psoriasis12. Therefore, it is attractive to speculate that the increased nuclear staining with 
K.i-67 in Darier's disease is an attempt to normalize the epidermal disintegration caused by 
dyskeratosis and acantholysis. In contrast to the marked changes of keratinization induced 
by topical 13-cis-retinoic acid and all-trans-retinoic acid, these retinoids did not affect cell 
proliferation. 
We conclude that topical treatment with 13-cis-retinoic acid is effective in Darier's 
disease. The assessment of cytokeratins 4, 13 and 19 may be useful to demonstrate 
interference with the disease process at the cellular level and may serve as a marker to 
indicate the bio-availability of the drug. 
HO 
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SUMMARY 
In a bilaterally paired double-blind comparison study, a cream containing 0 1% 13-cis-
retinoic acid (13-cis-RA) and cream base only were applied over 4 weeks in seven 
patients with non-erythrodermic lamellar ichthyosis (NELI), two patients with Daner's 
disease and one patient with autosomal dominant ichthyosis vulgaris (ADIV) In two 
patients with NELI and two patients with Daner's disease a half-side effect was observed 
in favour of the side treated with 13-cis-RA 
In three patients an induction of cytokeratin-4, and in one of these patients expression of 
cytokeratin-13, were observed after therapy Topical 13-cis-RA appears to be a promising 
approach in the treatment of disorders of keratinization The selective modulation of the 
cytokeratin pattern may provide an immunohistochemical tool to investigate the mode of 
action of retinoids 
The oral administration of retinoids has revolutionized the treatment of disorders of 
keratinization468"7 However, because of the risk of systemic side effects, topical 
application would be preferable Several reports indicate that topical treatment with all-
trans-retinoic acid has a therapeutic effect in disorders of keratinization " l 6 2 9 However, its 
irritative effect restricts its clinical application to the treatment of acne Recently, a new 
formulation containing 13-cis-retinoic acid (13-cis-RA) has become available for topical 
treatment 
The aim of the present study was to investigate the clinical effect of topical application of 
13-cis-RA in patients with ichthyoses and Daner's disease The question was also 
addressed as to whether in vivo topical treatment with retinoids modulates the expression 
of cytokeratins as has been described in vitro10" The expression of cytokeratins was 
assessed by immunohistochemical methods using a panel of well-characterized monoclonal 
and polyclonal anti-cytokeratin antibodies 
PATIENTS AND METHODS 
Patients 
Seven patients with non-erythrodermic lamellar ichthyosis (NELI), two patients with 
Daner's disease and one patient with autosomal dominant ichthyosis vulgaris (ADIV) 
were treated with topical 13-cis-RA after informed consent was obtained Before the trial, 
systemic treatment was stopped Further details regarding sex, age and previous treatment 
are summarized in Table I 
In every patient two comparable and representative test areas were selected In this 
bilaterally paired double-blind comparison study, a cream containing 0 1% 13-cis-RA and 
cream base only (Hoffmann-La Roche, Basel, Switzerland) were applied over 4 weeks 
Patients were instructed to apply the creams thinly and evenly twice daily If intolerable 
imtation occurred, they were advised to reduce the frequency 
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TABLE I Clinical data 
Patient 
1 
2* 
3 
4* 
5 
6 ' 
7* 
8 
9 
10 
Sex 
m 
m 
f 
f 
f 
m 
m 
f 
f 
m 
Age 
(years) 
40 
34 
53 
41 
24 
33 
38 
36 
18 
42 
Diagnosis 
NELI 
NELI 
NELI 
NELI 
NELI 
NELI 
NELI 
Darier's 
disease 
Darier's 
disease 
ADIV 
Time from stopping 
oral retinoid to 
starting trial 
not applicable 
19 days 
14 months 
not applicable 
22 months 
15 days 
10 years 
10 years 
12 days 
not applicable 
Previous topical 
treatment 
petrolatum 
propylaenglycol, 
petrolatum 
none 
urea 
propylaenglycol, 
urea 
acidum lacticum 
urea 
none 
none 
urea 
* patients from one family 
NELI = non-erythrodermic lamellar ichthyosis, ADIV = autosomal dominant ichthyosis vulgaris 
Analytical procedures 
Tissue samples Biopsies from representative skin lesions within the test areas were taken 
from every patient, one at the beginning of the trial and one from each area after 4 weeks 
of treatment The biopsies were snap-frozen in liquid nitrogen and stored at -80° С until 
processed 
Antibodies Used in the study were 16 monoclonal and 2 polyclonal anticytokeratin an­
tibodies (Table II) The polyclonal antibodies AF87 and AF124 were a kind gift from Dr 
Stuart H Yuspa (National Cancer Institute, Bethesda, Maryland, USA) The monospecific 
antibodies were raised against C-terminal synthetic peptides of cytokeratins 1 and 6 in 
rabbits as described previously " The mouse monoclonal antibody KA12, reacting with 
cytokeratin 6 on two-dimensional gels from oesophagus and placenta was a kind gift from 
Dr R Nagle (Tucson, Arizona) This antibody may also react partially with cytokeratin 5 
(Nagle, personal communication) 
The specificity and references for the other antibodies are summarized in Table II 
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TABLE II. 
Monoclonal/polyclonal 
antibody 
AF 87 
RKSE 60 
RCK 102 
RCK 107 
AF 124 
KA 12 
6BI0 
IC7 
2D7 
RCK 105 
LE 41 
Cam 5.2 
M20 
RGE 53 
RCK 106 
CK 18 2 
2C8 
RPN 1165 
Cytokeratin 
specificity 
1 
10 
5 (+8) 
14 
6 
6 (+5) 
4 
13 
13 
7 
8 
8 
8 
18 
18 
18 
18 
19 
Type of differentiation 
stratifying, comifying 
(suprabasal) 
basal cells 
hyperproliCeration 
stratifying, non-
comifying (suprabasal) 
simple epithelial cells 
simple epithelia, some 
stratifying epithelia 
Reference 
23 
21 
2 
30 
23 
14 
14 
14 
21 
11 
27 
25,26 
20 
21 
2 
25,26 
2,12 
Immunohistochemistry. Sections (4цт) were stained with the cytokeratin antibodies using 
a two-step indirect immunoperoxidase staining procedure as described previously.30 
RESULTS 
Clinical response 
The clinical results obtained after administration of 13-cis-RA are summarized in Table 
III. Two of the seven patients with NELI showed a half-side effect in favour of the 13-cis-
RA treated side. The clinical improvement in these patients consisted of a marked 
reduction in scaling and an improvement in the smoothness of the skin (Figure 1). Both 
patients with Darier's disease showed a moderate reduction of the hyperkeratotic lesions in 
the retinoid-treated areas. No clinical improvement was observed in the areas treated with 
cream base only. The patient with ADIV showed no (half-side) effect upon treatment. 
Both patients showed only a slight reduction of scaling. 
Three of the four patients responding to 13-cis-RA showed a marked erythema with 
itching, tenderness and a burning sensation. After 3 days patient 2 with NELI displayed a 
marked redness and swelling of the skin which led him to stop the treatment for 1 week. 
Nevertheless, a marked half-side effect was induced and could be maintained by 2-weekly 
applications (Figure 1). In contrast to the patients with a marked improvement, five 
patients without a clinical response showed a mild non-lender erythema. The other non-
responding patient (patient 7) complained of an itching redness of the scrotum, which 
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might have been due to spreading of the retinoid. After 2 weeks patient 6, having been 
free of systemic therapy for 4 weeks, restarted therapy with acitretin (35 mg /day) because 
of an unacceptable worsening of his ichthyosis. In this patient the topical applications 
were continued. 
Fig. 1. patient 2 with NELL a. clinical 
appearance of untreated skin; b. side treated 
with topical 13-cis retinole acid; с side treated 
with cream base only 
" 1 
: 
i 
с 
Cytokeratin expression patterns 
The immunohistochemical findings with the cytokeratin antibodies are summarized in 
Table IV. Before treatment both markers for cornifying epithelia, i.e. AF87 and RKSE60, 
recognizing keratins 1 and 10, respectively, reacted with the suprabasal compartment with 
a homogenous pattern. Treatment with topical 13-cis-RA did not change their reaction 
pattern. The basal cell markers RCK102 and RCK107 stained the basal layer in all 
biopsies taken before and after treatment. No consistent change in staining patterns could 
be observed after treatment with 13-cis-RA. 
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The two antibodies AF124 and KA12, reactive with hyperproliferation-related keratins, 
were found to be positive in biopsies taken before and after treatment. No consistent 
change in the expression pattern was induced by the 4-week topical application of 13-cis-
RA. The markers for non-cornifying stratified epithelia, i.e. antibodies 6B10 to cytokeratin 
4 and 1C7 and 2D7 to cytokeratin 13, showed no reaction in the biopsies taken before 
treatment. After treatment with 13-cis-RA sporadic suprabasal keratinocytes reacted with 
6B10 in two patients with NELI and one patient with Darier's disease. One patient with 
Darier's disease showed sporadic staining with 1C7 and 2D7 after topical applications 
with 13-cis-RA. The markers for simple epithelial cells, i.e. antibodies to cytokeratin 7, 8, 
18 and 19 (Table II), showed no epidermal staining in the biopsies taken either before and 
after treatment. 
Treatment with cream base showed no modulation of the cytokeratin reaction patterns. 
Fig. 2. patient 9. Sporadic immunohisto-
chemical staining pattern of frozen section of 
involved epidermis after treatment with topical 
13-cis-RA with the antibody to cytokeratin 4. 
Fig. 3. patient 9. Sporadic immunohisto-
chemical staining pattern of frozen section of 
involved epidermis after treatment with topical 
13-cis-RA with the antibody to cytokeratin 13. 
DISCUSSION 
After 4 weeks of treatment four out of the ten patients (two NELI and two Darier's 
disease) showed a marked reduction in scaling and an improvement in smoothness of the 
skin only at the 13-cis-RA treated side. All these responding patients demonstrated, in 
addition, an itching erythema, while the remaining six patients, not showing any 
significant half-side effect, displayed only a mild erythema. Both patients with Darier's 
disease responded well, which is in accordance with a previous observation.28 The great 
inter-individual variation as to responsiveness in patients with NELI is difficult to explain. 
It is known that 13-cis-RA is unstable to light exposure.513 However, the inter-individual 
variation in clinical response cannot be explained by differences in exposure to ultraviolet 
radiation. All patients protected the treated areas from light, so photoinactivation is 
unlikely as an explanation for the inter-individual variation. 
The efficacy of topical treatment with 13-cis-RA may be improved by changing the 
concentration, the form of application (such as occlusion) and the basis.18 The clinical 
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response and penetration are markedly influenced by the base ' 8 Other retinoids effective 
in topical application, such as the arotinoids, might be better candidates than 13-cis-RA 
for the treatment of disorders of keratinization because they cause less irritation ' 
The immunohistochemical examination revealed a selective modulation of the cytokeratin 
pattern after retinoid therapy The induction of cytokeratin 4 was demonstrated in three out 
of ten patients after topical application of 13-cis-RA Sporadic expression of cytokeratin 
13 was found in one patient after therapy The induction of cytokeratin 4 and/or 13 by 
retinoids in this study confirms previous in v ivo 2 2 1 4 2 8 studies and other in vitro 
observations 10 " 
The induction of these cytokeratins which are normally found in fetal, but not in adult, 
epidermis 1 5, in our view reflects a certain degree of dedifferentiation of the epidermis 
caused by the retinoid 
Further investigations with topical retinoids are needed to optimize the clinical response 
by adapting the concentration, the base and the mode of application to the individual 
patient Increasing the length of the treatment period might also improve the response 
The modulation of the cytokeratin expression pattern by topical application of 13-cis-RA 
may provide an immunohistochemical approach to elucidate and to monitor the mode and 
degree of action of retinoids 
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SYNOPSIS 
To study the effect of topical calcipotnol (calcipotnene) on disorders of keratinization 67 
patients were included in a randomized, double-blind, placebo-controlled, right-left 
comparative study After treatment for 12 weeks, calcipotnol had improved lesions of 
congenital ichthyosis, X-linked ichthyosis and ichthyosis vulgaris 
ABSTRACT 
Background and Design: Disorders of keratinization are a heterogenous group of 
diseases, which have in common a defect in comification The bioactive form of vitamin 
D3 has been shown to modulate epidermal proliferation and differentiation The purpose of 
the present study was to determine the effect of the synthetic vitamin D3 calcipotnol in a 
randomized, double-blind, placebo-controlled, right/left comparison comparative study 
The 67 patients included were at least 12 years of age Nine patients had ichthyosis 
vulgaris, 8 X-linked ichthyosis, 10 congenital ichthyosis, 20 hereditary palmo-plantar 
keraloderma, 9 keratosis pilaris and 11 Daner's disease All patients applied calcipotnol 
ointment 50 μg/g and placebo (vehicle of calcipotnol ointment) twice daily for up to 12 
weeks Patients were allowed to use up to 120 g calcipotnol ointment per week 
Results: At the end of treatment calcipotnol ointment had improved the ichthyoses, 
although to a variable degree No therapeutic effect was detected in palmo-plantar 
keratoderma or keratosis pilaris Eight of 11 patients with Daner's disease had to be 
withdrawn because of skin irritation or a worsening of the disease Skin irritation occurred 
in 18 cases (26%) only on the calcipotnol treated side, and in 1 case (1%) only on the 
placebo treated side Nine cases (13%) had irritation on both sides The amount of 
calcipotnol ointment used per week was lowest in palmo-plantar keratoderma (mean 11 8 
g/week, range 2 1-25 6 g/week) and highest in congenital ichthyosis (mean 59 3 g/week, 
range 11 4-94 7 g/week) There was no clinically significant change of serum calcium 
levels during the treatment period 
Conclusions: It is concluded that short-term treatment with calcipotnol ointment 50 μg/g, 
used in amounts up to about 100 g per week, is moderately efficaceous, well-tolerated and 
safe in adult patients with various ichthyoses 
Disorders of keratinization comprise a heterogeneous group of diseases characterised by 
dry and scaly skin (1) They include the ichthyoses, Daner's disease, pityriasis rubra 
pilaris, keratodermas and follicular keratoses The disorders of keratinization are chronic, 
often inherited, diseases with onset in childhood Treatment is often unsatisfactory, 
although lubrication with ointments or creams may soften the skin, and topical 
preparations containing salicylic acid may remove the scaling In some of the disorders, 
retinoids administered topically, but mainly systemically, are effective (2) Because of the 
associated risk of severe side-effect, the systemic retinoids are only used in severe and 
widespread cases 
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Although the disorders of keratmization are a heterogeneous group of diseases, they have 
in common a defect in comification The underlying pathogenic mechanisms involve 
disordered keratmocyte differentiation and/or proliferation (1) In addition to the epidermal 
changes, some of the disorders show dermal inflammation and immunological changes 
The biologically active form of vitamin D3, 1,25-dihydroxyvitamin D3, has been 
demonstrated to stimulate the terminal differentiation of epidermal keratinocytes and to 
inhibit the proliferation of epidermal keratinocytes (3) At least in vitro 1,25-
dihydroxyvitamin D3 modifies differentiation by stimulating the switch of suprabasal cells 
into comified cells (4) Apparently 1,25-dihydroxyvitamin Djinduces terminal 
differentiation of epidermal keratinocytes without changing their keratin gene expression 
in vitro (5) By modifying the epidermal growth pattern vitamin D3 may improve disorders 
of keratmization However, X-hnked ichthyosis and ichthyosis vulgaris have not responded 
to treatment with neither oral 1 alpha-OH-D3 (6) nor topical l,25(OH)2D3 (7) 
Calcipotnol is a synthetic vitamin D analogue, which is as effective as 1,25-
dihydroxyvitamin D3 in binding to the vitamin D receptor and in stimulating epidermal 
differentiation (8) Compared to 1,25-dihydroxyvitamin D3, calcipotnol, however, is about 
100-200 times less potent in its effect on calcium metabolism in rats (8) In clinical 
studies calcipotnol ointment 50 μg/g has been shown to be effective and safe for the 
treatment of psoriasis vulgaris (9) The purpose of the present study was to determine 
whether topical calcipotnol is effective, tolerated and safe in disorders of keratmization 
PATIENTS AND METHODS 
Study design and patients: The study was designed as a prospective, randomized, 
double-blind, right/left comparative study of calcipotnol 50 μg/g and placebo ointment 
(vehicle of calcipotnol ointment), both applied twice daily The ingredients of the vehicle 
were disodium hydrogen phosphate, polyoxyethylene-2-stearylether, prpylene glycol, 
tetracemine disodium, DL-alpha-tocopherol, petrolatum, liquid parafnn and water The 
study was conducted in 2 centers in Denmark and in 1 center in The Netherlands Patients 
were not treated during summertime It divided into two phases After a wash-out phase of 
2 weeks during which the patient used only an emollient, the patients were given double-
blind treatment with calcipotnol ointment on one side of the body and placebo ointment 
on the other side for 12 weeks or until clearance on one side The criterion for including 
patients was a clinical and histological diagnosis of one of the following dyskeratoses 
ichthyosis vulgaris, X-hnked ichthyosis, congenital ichthyosis, Daner's disease, pityriasis 
rubra pilaris, hereditary palmo-plantar keratoderma and keratosis pilaris The diagnose of 
X-hnked ichthyosis was based on an established human steroid sulphatase deficiency (10) 
Patients had symmetrically located lesions and were at least 12 years of age Excluded 
were patients with skin infection, atopic dermatitis, systemic treatment with retinoids, 
corticosteroids or PUVA within the 8 weeks period prior to the wash-out phase Also 
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excluded were patients with hypercalcaemie, high vitamin D or calcium intake and 
significant renal or hepatic disease Women of childbearmg potential were only included if 
using an adequate method of contraception All patients gave their informed consent All 
affected body areas, except for the face, scalp and genital region, were treated with the 
study medication A maximum of 120 gram was dispensed to each side of the body per 
week Patients with affected areas on the face and genital region used emollient for these 
areas All lubes were returned and weighed to determine amount of ointment used The 
use of other topical medication or systemic treatment for dyskeratosis was not allowed 
Patients outcomes: Clinical assessments were done at weeks 0, 2, 4, 8 and 12 separately 
for right and left side of the body The extent of the dyskeratotic involvement was 
recorded using the following scale 0, no involvement, I, less than 20%, 2, 20-39%, 3, 40-
59%, 4, 60-79%, and 5, 80-100% for each of the following regions (arms, legs and trunk) 
The investigator also assessed the seventy of the following signs in ichthyosis vulgaris 
and keratosis pilaris scales and roughness, in X-hnked ichthyosis scales, roughness and 
hyperpigmentation, in Daner's disease scales, erythema, papules, crust and excoriation, in 
pityriasis rubra pilaris scales, thickness and erythema, in hereditary palmo-plantar 
keratoderma scales, thickness, erythema and fissuring, and in congenital ichthyosis scales 
roughness and erythema These signs where assessed using the following scale 0, absent, 
1, slight, 2, moderate, and 3, severe Furthermore, the investigator assessed the overall 
response to the treatment compared to baseline using the following 6-point scale worse, 
no change, slight improvement, moderate improvement, marked improvement, and cleared 
The patients assessed the overall response to treatment using the same scale Blood 
samples for analysis of hematology and blood chemistry including serum total calcium, 
were taken before the start of treatment, after 2 weeks treatment and at the end of 
treatment 
Statistical analysis: Comparison of treatment effects at end of double-blind treatment 
were based on intrapatient variations of the calcipotnol treated side and the placebo 
treated side With respect to investigator's and patient's overall assessment the number of 
patients with the calcipotnol treated side superior to the placebo treated side were 
compared with the number of patients with the placebo treated side superior to the 
calcipotnol treated side by binomial tests Total sign score differences from baseline to 
end of double-blind treatment were calculated for both treatment sides separately and 
compared using one-sample t-test 
For adverse events the number of patients reporting adverse events on the calcipotnol 
treated side only was compared with the number of patients reporting adverse events on 
the placebo treated side only by binomial tests 
All statistical tests were two-sided and a 5% significance level was used 
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RESULTS 
Sixty-nine patients were randomized to receive treatment (Table I) However, 1 case 
included in the Daner's disease group had Hailey-Hailey disease Furtermore, I case of 
lamellar ichthyosis left the study before any collection of efficacy or safety data 
Therefore, efficacy and safety data were only available for 67 patients The subgroup 
hereditary palmo-plantar keratoderma had 20 patients randomized, while the other groups 
consisted of 8-12 patients each The subgroup congenital ichthyosis was heterogeneous 
consisting of 1 case of epidermolytic hyperkeratosis (bullous ichthyosiform erythroderma 
of Brocq, autosomally dominantly inherited), 2 cases of lamellar ichthyosis 
(nonerythrodermic autosomal recessive lamellar ichthyosis), 2 cases of Sjogren-Larsson 
syndrome, 1 case of ichthyosis linearis circumflexa, 2 cases of congenital ichthyosiform 
erythroderma (erythrodermic autosomal recessive lamellar ichthyosis), and 2 cases of 
ichthyosis bullosa Siemens No case of pityriasis rubra polaris was randomized At 
baseline there was no clinically significant difference in the total sign score on the right 
and left side (data not shown) Fifteen of the 69 randomized patients withdrew from the 
double-blind treatment (Table II) Adverse events were the reason for withdrawal in 9 of 
the 15 cases (see below) It was remarkable that 8 of the 12 patients with Daner's disease 
withdrew because of lesional/penlesional irritation, worsening of the disease In 
accordance with the high number of withdrawals, the mean duration of double-blind 
treatment was only 6 I weeks in Daner's disease compared with 9 6 to 12 3 weeks in the 
other subgroups 
Table I Number and demographic data of patients randomized 
Disease 
Ichthyosis vulgaris 
X linked ichthyosis 
Congenital ichthyosis 
Darier s disease 
Keratoderma 
Keratosis pilaris 
All patients 
η 
9 
8 
11 
12 
20 
9 
69 
No of 
males (%) 
5(56) 
8 (100) 
5(45) 
7(58) 
12 (60) 
1 (11) 
38 (55) 
Age (yrs) 
(mean, range) 
34 1 (16-52) 
34 4 (16-50) 
32 4 (16-55) 
38 6 (18-79) 
29 7 (11-57) 
23 4 (16-45) 
32 0 (11-79) 
Table III shows the investigator's overall assessment of the treatment response to 
calcipotnol and placebo at the end of treatment Marked improvement or clearance was 
observed on the calcipotnol treated side in 5 of 9 cases with ichthyosis vulgaris, in 4 of 8 
cases with X-linked ichthyosis and in 8 of 10 cases with congenital ichthyosis (Figure 1), 
but the difference between calcipotnol and placebo was only statistically significant for X-
linked ichthyosis (p=0 03) and congenital ichthyosis (p=0 02) The patient's overall 
assessment at the end of treatment is tabulated in the same way (Table IV) According to 
the patients, marked improvement or clearance was observed on the calcipotnol treated 
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side in 4 of 9 cases of ichthyosis vulgaris, 4 of 8 cases of X-Iinked ichthyosis and 7 of 10 
cases of congenital ichthyosis. Only in X-linked ichthyosis did the difference between 
calcipotriol and placebo reach statistical significance (p=0.03). 
Fig. 1. a. NEARLI patient with the typical phenotype consisting of large brown scales covering the 
trunk, b. After treatment, the calcipotriol-treated right side has improved markedly, whereas only slight 
improvement has occured on the ointment base-treated left side с After treatment, a significant 
unilateral improvement was observed in favour of the calcipotriol-treated right leg. d. Some 
improvement was also noted in the ointment base-treated left leg. 
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Table II. Reason for withdrawal from double-blind treatment 
Disease Adverse Unaccept Voluntary/ Total 
events (n) response (n) default (n) (n) 
Ichthyosis vulgaris (n=9) 
X-linked ichthyosis (n=8) 
Congenital ichthyosis (n=ll) 
Darier's disease (n=12) 
Keratoderma (n=20) 
Keratosis pilaris (n=9) 
0 
1 
0 
6 
1 
1 
0 
0 
0 
1 
0 
1 
0 
1 
1 
1' 
1 
0 
Total (n=69) 15 
' This patienl had Hailey-Hailey disease 
Table III. Investigator's overall assessment of treatment response at end of treatment 
Calcipotnol/Placebo 
No ptt. 
worse no slight moderate marked cleared 
change improvement improvement improvement 
Ichthyosis vulgaris (n=9) 0/0 
X-linked ichthyosis (n=8) 0/0 
Congenital ichthyosis (n=ll) 0/0 
Keratoderma (n=20) 0/0 
Keratosis pilaris (n=9) 2/1 
Darier's disease (n=12) 8/5 
0/0 
1/2 
1/4 
9/11 
1/2 
0/4 
2/4 
0/4 
0/4 
6/5 
2/3 
2/0 
2/4 
3/2 
1/1 
3/1 
2/3 
1/2 
5/0 
4/0 
8/1 
2/2 
2/0 
0/0 
0/1 
0/0 
0/0 
0/1 
0/0 
0/0 
Table IV. Patient's overall assessment of treatment response a t end of treatment 
Calcipotriol/Placebo 
No ptt 
worse no 
change 
slight 
improvement 
moderate 
improvement 
marked ι 
improvement 
:leared 
Ichthyosis vulgaris (n=9) 0/0 
X-linked ichthyosis (n=8)* 0/1 
Congenital ichthyosis (n=10) 0/1 
Keratoderma (n=20) 0/0 
Keratosis pilaris (n=9) 2/1 
Darier's disease (n=12) 8/5 
0/0 
0/3 
1/4 
8/10 
2/4 
0/3 
3/5 
0/2 
0/3 
8/5 
0/0 
1/1 
2/3 
3/1 
2/1 
3/2 
3/3 
2/1 
4/0 
4/1 
0/0 
1/2 
2/1 
0/1 
0/1 
0/0 
0/1 
0/0 
0/0 
' For one of the patients the calcipotriol treated side was not assessed 
The total sign score, defined as the sum of the severity scores for each side of the body, 
could as a minimum range from 0 to 6 for ichthyosis vulgaris and keratosis pilaris and as 
a maximum from 0-15 for Darier's disease. The decrease in the total sign score at the end 
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of treatment was greater on the calcipotriol treated side than on the placebo treated side in 
ichthyosis vulgaris, X-Iinked ichthyosis and congenital ichthyosis (Figure 2). 
7 
6 
5 : 
4 
3 
2 
1 
0 
Total sign score I C M i n y o S I S \ /uigans 
Placebo 
U 
" — J~l η 
Calcipotriol 
6 8 
Weeks 
10 12 
X-linked ichthyosis 
Total sign score 
6 
Weeks 
Congenital ichthyosis 
Placebo 
Fig. 2. Change in the mean total sign score during treatment with calcipotriol ointment 50 μg and 
placebo ointment in ichthyosis vulgaris (n=9), X-linked ichthyosis (n=8), and congenital ichthyosis 
(n=IO) 
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In congenital ichthyosis this reduction in the total sign score on the calcipotriol treated 
side was statistically highly significant compared to the placebo treated side (p=0.0015) 
There was no statistically significant difference between calcipotriol and placebo in mean 
total sign score of overall assessment in other subgroups of dyskeratosis (data not shown). 
The adverse events reported or observed during the treatment were almost exclusively 
localized to the skin and consisted almost exclusively of various forms of lesionai and 
perilesional irritation (Table V). No irritation was detected in congenital ichthyosis. 
Lesional/perilesional irritation was more often seen on the calcipotriol treated side 
(p<0.001). Skin irritation was most common in X-linked ichthyosis and Darier's disease. 
While only a single case of X-linked ichthyosis was withdrawn because of skin irritation, 
6 cases of Darier's disease withdrew because of lesional/perilesional irritation. The amount 
of calcipotriol ointment used per week was lowest in palmo-plantar keratoderma (mean 
11.8 g/week; range 2.1-25.6 g/week) and highest in congenital ichthyosis (mean 
59.3 g/week; range 11.4-94.7 g/week). With respect to the change in serum total calcium 
from baseline to the end of treatment, the subgroup X-linked ichthyosis showed a minor, 
but statistically significant reduction (p=0.045). No subgroup showed any statistically 
significant increase in serum total calcium (data not shown). 
Table V. Lesional/perilesional irritation reported/observed in disorders οΓ keratinization 
Disease Calcipotriol Pacebo Both sides 
side η (%) side η (%) η (%) 
Ichthyosis vulgaris (9) 
X-linked ichthyosis (8) 
Congenital ichthyosis (10) 
Palmo-plantar keratoderma (20) 
Keratosis pilaris (9) 
Darier's disease (12) 
2 (22) 
6(75) 
0 
5(25) 
2(22) 
3(25) 
1(11) 
0 
0 
0 
0 
0 
0 
0 
0 
2(10) 
2 (22) 
5(42) 
Total number of irritations 18 (26) 1(1) 9 (13) 
COMMENT 
The results of the present study indicate that topical treatment with calcipotriol for 12 
weeks is moderately efficaceous in various forms of ichthyosis. Palmo-plantar keratoderma 
and keratosis pilaris seem to be unresponsive to calcipotriol, whereas Darier's disease may 
worsen during treatment with calcipotriol, probably due to the irritating capacity of 
calcipotriol ointment. The presence of eroded and fissured lesions in Darier's disease may 
be the reason for the increased suspectability to become irritated by calcipotriol ointment. 
Expect for Darier's disease, the cutaneous side-effects in the dyskeratotic disorders were 
similar to those observed in psoriasis with respect to their nature, severity and frequency 
(9). Among the ichthyoses, X-linked ichthyosis and congenital ichthyosis were particularly 
responsive to calcipotriol. The group congenital ichthyosis is very heterogeneous, and the 
low number of patients in each subtype does not allow any conclusions as to any variation 
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in the responsiveness to calcipotnol In contrast to calcipotnol, neither oral 1 alpha-OH-D3 
(6) nor topical 1,25 (OH)2D3 (7) are reported to improve X-hnked ichthyosis or ichthyosis 
vulgaris The reason for this apparent discrepancy is most likely that I alpha-OH-D3 and 
l,25-(OH)2D3 were used in too low doses Thus the applied concentration of 1,25 (OH)2D3 
(1 μg/g) has no significant effect on psoriasis (12,13) 
A major concern during treatment with vitamin D analogues is whether percutaneously 
absorbed vitamin D may change calcium metabolism In large scale studies of psoriasis, it 
has been found that a weekly dose of up to 100 gram calcipotnol ointment 50 μg/g does 
not change serum calcium levels (9) Furthermore, the biochemical markers of calcium 
and bone metabolism do not change in psoriatics receiving a calcipotnol dose ranging 
from 40 g/week (11) or 100 g/week (14) In the present study, during which patients were 
allowed to use up to 120 gram per week, no significant changes of serum calcium levels 
were found This indicates that patients with disorders of keratinization are not more likely 
than psoriatics to develop hypercalcaemia after topical application of calcipotnol, 
However, it should be bom in mind that only one half of the affected skin lesions were 
treated with calcipotnol In some of the patients with more widespread disease, it might 
have been possible to treat all lesions with the allowed amount of calcipotnol 
(120 g/week) As it is recommended for psoriasis, calcipotnol ointment 50 μg/g was 
applied twice daily in the dyskeratoses It is, however, possible that application of 
calcipotnol ointment once daily is efficaceous for the treatment of ochthyosis If so, 120 g 
of calcipotnol ointment per week might be sufficient in most patients 
Vitamin D analogues have multiple actions on the cellular and molecular level, and it has 
still not been sorted out whether vitamin D analogues work m psoriasis by modifying 
keratinocyle differentiation/proliferation or whether their immunosuppressive effects are 
important for their anti-psonatic effect The fact that treatment with calcipotnol can 
improve the ichthyoses supports the idea that calcipotnol in vivo has an effect on 
epidermal differentiation and/or proliferation independent of immunomodulation 
It can be concluded that topical treatment with calcipotnol 50 μg/g for 12 weeks can 
induces a moderate improvement of various forms of ichthyoses While calcipotnol is 
well-tolerated in ichthyosis, it may worsen Daner's disease, probably due to its irritating 
capacity Although ichthyosis may be reponsive to calcipotnol treatment, large-scale 
studies, but especially long-term studies, are needed to confirm the present results If 
calcipotnol ointment is used for the treatment of ichthyosis, it is important that the weekly 
dose is kept below 120 gram If calcipotnol is applied twice daily, about 15-20% of the 
body surface can be treated, but application once daily makes it possible to increase the 
treated skin area The safety and efficacy of this alternative approach warrants further 
investigation If topical calcipotnol is found to be efficaceous and safe in long-term large-
scale studies, this treatment may be of great benefit to patients severely affected by 
ichthyosis Also, it should be investigated whether it is beneficial to combine calcipotnol 
with a retinoid In addition to a simple additive effect of these two classes ol compounds, 
an interaction might occur on the molecular level leading to a synergistic effect (15) 
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Summary, Discussion and Conclusion 
At the end of the general introduction three questions were addressed with respect to the 
nosology and treatment of monogenic disorders of keratmization Chapters 2, 3 and 4 
provide the original contributions regarding these questions Here, these contributions will 
be discussed In the appendix guidelines for classification of monogenic disorders of 
keratmization will be presented 
Question 1: 
To what extent do our clinical descriptions of phenotypes, regarding disorders of 
keratinization, refine and or simplify the existing nosology of monogenic disorders of 
keratinization? 
The case reports presented in Part I of this study demonstrate that the list of disorders of 
keratinization is prone to further extension On the other hand, unifying concepts have 
been developed based on clinical descriptions The cases described in Part I call for a 
critical reappraisal of some of the existing concepts In the case description of ichthyosis 
bullosa of Siemens (Part I, chapter I) a precise clinical, histopathological, and 
ultrastructural analysis clearly demonstrates that in morphological terms this condition is 
distinct from bullous ichthyosiform erythroderma of Brocq Ironically, this paper was 
rejected by the British Journal of Dermatology, as the referee was of the opinion that 
splitting within the bullous ichthyoses group was not relevant However, subsequent 
molecular genetic analyses (Part II, chapters 4 and 5) revealed that ichthyosis bullosa of 
Siemens is an entity distinct from bullous congenital ichthyosiform erythroderma of 
Brocq From a therapeutic point of view this distinction is relevant as the two conditions 
show a different response to retinoids (Part II, chapter 2) 
On the other hand the molecular genetic analysis in Part II, chapters 4 and 5 demonstrated 
that the so-called autosomal dominant ichthyosis exfoliativa is not an entity but is identical 
to ichthyosis bullosa of Siemens 
The cases described in chapters 4, 5 and 6 of Part I further substantiate the concept of 
cutaneous mosaicism It is already known that an individual with the epidermolytic type of 
epidermal naevus', is at risk for having a germ-line mosaicism and may transmit the 
underlying gene to the next generation in the form of a bullous congenital ichthyosiform 
erythroderma of Brocq In this disease an autosomal dominant mutation is involved The 
naevus comiculatus (Part I, chapter 4) and the porokeratotic eccnne ostial and dermal duct 
naevus (Part I, chapter 6) are probably also caused by somatic mutations Recently a child 
with an erythrodermic type of ichthyosis was demonstrated whose mother had an 
extensive eccnne ostial and dermal duct naevus 2 The transmission of CHlLD-syndrome 
from mother to daughter in chapter 5 of Part I provides further support to the concept of 
X-linked dominant inheritance with lethality for male embryos Chapter 6 of Part I 
demonstrates that coexistence of two genetic diseases does not necessarily imply a genetic 
link, but may be due to isomorphic elicitation 
Question 2: 
To what extent do our immunohistochemical and molecular findings refine and or 
simplify the existing nosology of monogenic disorders of keratinization? 
Part II provides new immunohistochemical and molecular data on aspects of epidermal 
growth, keratinization, and inflammation in various disorders of keratinization. Disorders 
of keratinization characterized clinically and histopathologically by inflammation (Table I) 
showed an extended expression of keratin 5 and 14, an induction of keratin 6 and 16, and 
in some cases of keratin 17 (Part II, chapter 1) These disorders demonstrated an increased 
expression of the extracellular matrix component tenascin as well (Part II, chapters 2 and 
3). It is tempting to hypothesize that both keratin and tenascin expresssion in disorders of 
keratinization are modulated by concommittant inflammation. The interrelation between 
inflammation and abnormal keratinization has been discussed in chapter 1 of Part II 
Keratin 6, 16, and 17 have been shown to be proliferation associated keratins. As the 
inflammatory disorders of keratinization as a rule are hyperproliferative, the changes of 
the keratin pattern can be interpreted as a reflection of a hyperproliferative epidermis. As 
such, it is most likely that these findings do not form the primary genetic defect, but are 
probably epiphenomens. 
Table I. Disorders of keratinization with a normal and abnormal profile of keratins 5, 14, 6, 16, 
17 and tenascin. 
Disorders with abnormal expression of keratins and 
tenascin 
• Erythrodermic lamellar ichthyosis 
• Bullous congenital lchthyosiform erythroderma 
• Ichthyosis bullosa of Siemens 
• Restrictive dermopathy 
• CHILD-syndrome 
• Collodion baby 
• Harlequin ichthyosis 
Disorders with normal expression of keratins 
and tenascin 
• Autosomal dominant ichthyosis vulgaris 
• X-linked recessive ichthyosis 
• Nonerythrodermic lamellar ichthyosis 
Molecular biological techniques are capable of elucidating the primary defect. Recently, in 
patients with bullous congenital ichthyosiform erythroderma of Brocq mutations were 
found in either the gene coding for keratin 1 or keratin 10. The epidermolytic type of 
palmoplanar keratoderma, type Vomer, appeared to be caused by a mutation in keratin 9, 
a keratin present in the epidermis of palms and soles. Despite of its clinical and 
histological characteristics ichthyosis bullosa of Siemens was not commonly accepted as 
an entity. Mutation analysis however, demonstrated that the disease is due to mutations in 
a unique keratin, namely keratin 2e (Part I, chapter 5). Further studies on the genetics of 
monogenic disorders of keratinization, including gene mapping and mutation analysis, are 
the approaches which will provide the rationale for the nosology of genetically determined 
disorders of keratinization. 
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A precise clinical diagnosis of a disorder of keratinization is not art for art's sake, but is 
necessary for genetic counseling,for estimating the prognosis, and for selecting therapy 
Question 3: 
To what extent are systemic acitretin, topical 13-cis retinoic acid, and topical vitamin 
D3 (all Iigands for members of the steroid receptor superfamily) effective in the 
treatment of disorders of keratinization? 
In Part III (chapters 1-6) the therapeutic potential of two Iigands for the steroid receptor 
superfamily, retinoids and vitamin D3, is described with respect to the treatment of 
monogenic disorders of keratinization Table II summarizes the therapeutic response of the 
various disorders of keratinization to systemic treatment with acitretin and the dosage 
which proved to be advisable Our findings demonstrated that several disorders of 
keratinization are a good indication for systemic retinoid therapy Dose management 
however, depends on the diagnosis The studies in Part HI showed that ichthyosis bullosa 
of Siemens requires a lower dose of systemic retinoids than bullous congenital 
ichthyosiform erythroderma The same is true for erythrodermic lamellar ichthyosis 
compared to non-erythrodermic lamellar ichthyosis It has been reported that a large 
intenndividual variation exists in the treatment of M Darier Therefore, it is advisable to 
initiate treatment in this condition with a low dose schedule 
Table II Response of various disorders οΓ keratinization to treatment with acitretin 
Diagnosis 
Ichthyosis bullosa of Siemens* 
Bullous congenital ichthyosiform erythroderma* 
Nonerythrodermic lamellar ichthyosis* 
Erythrodermic lamellar ichthyosis* 
Erythrokeratodermia variabilis* 
Mal de Maleda® 
M Greifher5 
M Darier" 
' etretinate (the ethyl-ester of acitretin) * present thesis Part III, chapters 1-3 
Dr J Dermatol 1992,127 191-192 'Eur J Dermatol 1992,2 503-505 
" Br J Dermatol 1989,121 375 379 
The profile of systemic side-effects was not disease associated However, "irritation" and 
aggrevation of the inflammatory component occur in Darier's disease and erythrodermic 
lamellar ichthyosis if the dosage of acitretin is too high 
Since cytostatics that have an effect on proliferation do not have a clinical response in 
disorders of keratinization, the beneficial effect of retinoids is probably due to a direct 
effect on the differentiation process and not on epidermal proliferation Topical retinoids 
Response 
excellent 
excellent 
mild excellent 
excellent 
excellent 
moderate 
excellent 
moderate-excellent 
Optimal Dosage 
Range (mg/day) 
10-25 mg 
40-60 mg' 
10-55 mg 
10-25 mg 
25-35 mg 
10-30 mg 
25-35 mg 
10-60 mg 
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like 13-cis-retinoic may be useful in some cases (Part III, chapters 4 and 5). In particular 
the efficacy in Darier's disease and in some patients with lamellar ichthyosis is 
impressive. The limitation of topical all-trans-retinoic acid is its irritative potential. As has 
been shown in chapters 4 and 5 of Part III, 13-cis-retinoic acid has a more favourable 
efficacy/irritancy ratio. New compounds such as the arotinoids have an even lower 
irritative potential and therefore might be promising candidates as topical treatment of 
disorders of keratinization for the future. 
The vitamin D3 analogue calcipotriol is a well established antipsoriatic drug. In chapter 6 
of Part III calcipotriol proved to be effective in various disorders of keratinization (Table 
III). The study with topical vitamin D3 showed that this treatment can be used with 
success in the treatment of congenital ichthyoses and to a lesser extent in X-linked 
recessive ichthyosis. 
Table III. Response of various disorders of keratinization to calcipotriol ointment 
Beneficial No effect Deterioration 
Ichthyosis vulgaris + 
X-linked ichthyosis + 
Darier White disease ++ 
Keratoderma + 
Keratosis pilaris + 
Congenital ichthyosis ++ 
It is striking that all the investigated drugs that appear to have a beneficial effect in 
monogenic disorders of keratinization belong to the ligands of the steroid receptor super 
family. In this respect it would be interesting to study the therapeutical effect of other 
ligands of the members of the steroid receptor super family like topical oestrogens, 
androgens, and thyroxin. An important breakthrough in the treatment of disorders of 
keratinization has been provided by the cytochrome P450 inhibitor Liarozole® (Janssen 
Pharmaceutica, Beerse, Belgium). This inhibitor increases the endogenous levels of 
vitamin A in the tissues. A recent study, carried out by the genodermatology research 
group of Nijmegen, revealed that clearing occurred in all 12 patients with various forms of 
ichthyosis during treatment with this compound.3 
CONCLUSION 
The future nosology of monogenic disorders of keratinization has to be defined based on 
the gene defects involved. Descriptive studies using markers for epidermal differentiation 
and proliferation so far have not revealed a valuable adjunct to clinical description and 
genetic definition. Future studies however, might indicate new candidate genes. New 
treatments interfering with the steroid-receptor-superfamily are likely to broaden the 
spectrum of treatments for disorders of keratinization. 
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Samenvatting, Discussie en Conclusie 
In de algemene inleiding van dit proefschrift zijn drie vragen gesteld, die betrekking 
hebben op de nosologie en de behandeling van keratinisatiestoomissen. In deel I, II en III 
zijn de publicaties ondergebracht welke betrekking hebben op deze vraagstellingen In dit 
hoofdstuk worden deze studies bediscussieerd in het kader van de geformuleerde 
vraagstelling In de appendix wordt een handleiding gepresenteerd, die kan helpen bij de 
classificatie van de monogene keratinisatiestoomissen 
Vraagstelling 1: 
In welke mate verfijnen of simplificeren onze klinische beschrijvingen van 
keratinisatiestoomissen de bestaande nosologie van de monogene keratinisatie-
stoomissen? 
De beschrijvingen van de patiënten in deel I laten zien dat de lijst van 
verhoomingsstoomissen zich steeds verder uitbreidt Op grond van klinische 
beschrijvingen zijn algemene concepten ontwikkeld De patiënten, beschreven in deel I, 
helpen bij een kritische herwaardering van enkele bestaande concepten In de beschrijving 
van patiënten met ichthyosis bullosa Siemens (deel I, hoofdstuk 2) laat een precíese 
klinische, histologische en ultrastructurele analyse zien, dat deze aandoening op 
morphologische gronden moet worden onderscheiden van de bulleuze congenitale 
ichthyosiforme erythrodermie van Brocq Dit artikel werd door de British Journal of 
Dermatology geweigerd, omdat de referee van mening was dat een onderscheid binnen de 
groep van bulleuze ïchthyoses niet relevant was Ook in de Amerikaanse literatuur wordt 
het onderscheid niet gemaakt en worden beide aandoeningen geschaard onder hel begrip 
epidermolytische hyperkeratose, dit is echter een histologische bevinding Moleculair 
biologisch onderzoek heeft echter aangetoond dat ichthyosis bullosa Siemens een entiteit 
is die verschilt van de bulleuze congenitale ichthyosiforme erythrodermie van Brocq (deel 
11, hoofdstuk 4 en 5) Wat betreft de behandeling is dit verschil ook relevant, omdat de 
twee aandoeningen een verschillende respons laten zien op retinoiden (deel III hoofdstuk 
2) 
Aan de andere kant toonde hel moleculair biologisch onderzoek in hoofdstuk 4 en 5 van 
deel II aan dat de zogenaamde autosomaal dominante ichthyosis exfoliativa geen entiteit 
is, maar identiek is aan ichthyosis bullosa Siemens 
De beschrijvingen van patiënten in hoofdstuk 4, 5 en 6 van deel I geven een verdere 
onderbouwing van het concept van het cutané mozaïek Het is bekend dat een ouder met 
het epidermolytische type van epidermale naevus, het risico heeft op een gonadaal 
mozaïek' Dit betekent dat de ouder het risico heeft op het krijgen van een kind met 
bulleuze congenitale ïchthyosiforme erythrodermie van Brocq De naevus berust op een 
somatische mutatie, vroeg in de embryogenese De naevus comiculatus (deel I, hoofdstuk 
4) is waarschijnlijk ook het gevolg van een somalische mutatie vroeg in de embryogenese 
De "porokeratotic eccnne ostial and dermal duct" naevus (de . I, hoofdstuk 6) wordt 
waarschijnlijk ook veroorzaakt door een somatische mutatie. Recent werd een kind 
gedemonstreerd met een erythrodermische vorm van ichthyosis, waarvan de moeder een 
"porokeratotic eccnne ostial and dermal duct" naevus had2. Het kind overleed aan de 
aandoening op zeer jonge leertijd. De overerving van het CHILD syndroom van moeder 
op dochter levert verder ondersteuning aan het concept dat het bij dit syndroom gaat om 
een X-gebonden dominante overerving, die letaal is voor mannelijke embryos (deel 1, 
hoofdstuk 5). Hoofdstuk 6 van deel I laat zien dat het naast elkaar bestaan van twee 
genetische aandoeningen niet noodzakelijkerwijs een genetische "link" inhoudt, maar dat 
in dit geval de psoriasis ook het gevolg kan zijn van het isomorph prikkelphenomeen. 
Vraagstelling 2: 
In welke mate verfijnen of simplificeren onze immunologische en moleculaire 
bevindingen de bestaande nosologie van de monogene keratinisatiestoornissen? 
Deel II levert nieuwe immunohistochemische en moleculaire gegevens over epidermale 
groei, keratinisatie en ontsteking bij de verschillende keratinisatiestoornissen. 
Keratinisatiestoornissen die klinisch en histopathologisch gekenmerkt worden door 
ontsteking (Tabel I) laten een uitgebreidere expressie zien van kératine 5 en 14, een 
inductie van kératine 6 en 16 en in sommige gevallen van kératine 17 (deel II, hoofdstuk 
1). Deze aandoeningen laten ook een verhoogde expressie zien van tenascinc (deel II, 
hoofdstuk 2 en 3) Het is verleidelijk om te hypothetiseren dat zowel de kératine expressie 
als de tenascine expressie gemoduleerd wordt door de aanwezigheid van ontsteking. Het 
verband tussen ontsteking en de abnormale kératine expressie is bediscussieerd in 
hoofdstuk 1 van deel II. Keratine 6, 16 en 17 zijn proliferatie-geassocieerde kératines. 
Aangezien keratinisatiestoornissen met een ontstekingscomponent in de regel 
hyperproliferatief zijn, kan de verandering in het keratinepatroon worden beschouwd als 
een weerspiegeling van een hyperproliferatieve epidermis. Het is dan ook zeer 
waarschijnlijk dat deze bevindingen niet het primaire defect vormen, maar epiphenomenen 
zijn. 
Tabel I. Keratinisatiestoornissen met een normaal en abnormaal expressiepatroon van kératine 5, 
1-4, 6, 16, 17 en tenascine. 
Aandoeningen met abnormale expressie van 
kératines en tenascine 
• Erythrodermische lamellaire ichthyosis 
• Bulleuze congenitale ichthyosiforme erythrodermie 
• Ichthyosis bullosa van Siemens 
• "Restrictive dermopathy" 
• CHILD-syndroom 
• "Collodion baby" 
• Harlekein ichthyosis 
Aandoeningen met normale expressie van 
kératines and tenascine 
• Autosomaal dominante ichthyosis vulgaris 
• X-gebonden recessieve ichthyosis 
• niet-erythrodermische lamellaire ichthyosis 
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Moleculair-biologische technieken zijn in staat het primaire defect op te helderen. Recent 
werden bij patiënten met een bulleuze congenitale ¡chthyosiforme erythrodermie van 
Brocq, mutaties gevonden in hetzij het gen coderend voor kératine 1 , hetzij het gen 
coderend voor kératine 10. De epidermolytische vorm van palmoplantaire hyperkeratose, 
type Vömer, blijkt te worden veroorzaakt door een mutatie in het kératine 9, een kératine 
aanwezig in de epidermis van handpalmen en voetzolen. Ondanks de kenmerkende 
klinische en histologische eigenschappen, werd ichthyosis bullosa van Siemens niet 
beschouwd als een entiteit. Mutatieanalyse toonde echter aan dat de ziekte het gevolg is 
van mutaties in een uniek kératine, namelijk kératine 2e (deel II, hoofdstuk 5). Verder 
onderzoek naar de genetica van keratinisatiestoomissen waaronder genkartering en 
mutatieanalyse zal de basis verschaffen voor de nosologie van genetisch bepaalde 
keratinisatiestoomissen. 
Een juiste klinische diagnose van een keratinisatiestoomis in niet een kwestie van 'T art 
pour Γ art", maar is nodig om de prognose te bepalen, voor het geven van genetisch 
advies, en voor het selecteren van de behandeling. 
Vraagstelling 3: 
In welke mate is toepassing van systemisch acitretin, topisch 13-cis-retinoic acid, en 
topisch vitamine D3 (allen liganden van de "steroid receptor superfamily") effectief 
bij de behandeling van keratinisatiestoomissen? 
In deel III (hoofdstuk 1-6) wordt het therapeutisch potentieel beschreven van twee 
liganden van de "steroid receptor superfamily" bij de behandeling van monogene 
keratinisatiestoomissen: retinoiden en vitamine D\ Tabel II vat de therapeutische respons 
samen van de verschillende keratinisatiestoomissen op systemische behandeling met 
acitretin en de te adviseren dosis. Onze bevindingen tonen aan dat meerdere 
keratinisatiestoomissen een goede indicatie vormen voor behandeling met systemische 
retinoiden. De dosis is echter afhankelijk van de diagnose. De studies van deel III laten 
zien dat voor de behandeling van ichthyosis bullosa Siemens een lagere dosis noodzakelijk 
is dan voor de bulleuze congenitale ichthyosiforme erythrodermie van Brocq. Hetzelfde 
geldt voor de erythrodermische lamellaire ichthyosis vergeleken met de niet-
erythrodermische lamellaire ichthyosis. Er is gepubliceerd dat er een grote interindividuele 
variatie bestaat bij de behandeling van de ziekte van Darier. Daarom wordt er bij deze 
aandoening geadviseerd met een lage dosis te starten. 
Het profiel van met name de mucocutane bijwerkingen is niet afhankelijk van de ziekte, 
maar van de dosering. Bij de erythrodermische vorm van lamellaire ichthyosis en de ziekte 
van Darier, die een lagere dosis vragen, worden naast mucocutane bijwerkingen, irritatie 
en een verergering van de ontstekingscomponent waargenomen, wanneer een te hoge dosis 
wordt gegeven. 
Het gunstige effect van retinoiden is waarschijnlijk het gevolg van een direct effect op het 
differentiatieproces en niet van een werking op de epidermale proliferatie, omdat 
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zeer goed 
zeer goed 
matig-zeer 
zeer goed 
zeer goed 
redelijk 
zeer goed 
goed 
redelijk-zeer goed 
10-25 mg 
40-60 mg' 
10-55 mg 
10-25 mg 
25-35 mg 
10-30 mg 
25-35 mg 
10-60 mg 
cytostatica, die een effect hebben op proliferatie, bij keratinisatiestoornissen geen 
verbetering geven. 
Tabel II. De respons van de verschillende keratinisatiestoornissen op acitretine 
Diagnose Respons Optimale Dosis 
"range" (mg/dag) 
Ichthyosis bullosa van Siemens* 
Bulleuze congenitale ïchthyosiforme erythrodermie * 
Niet-erythrodermische lamellaire ichthyosis' 
Erythrodermische lamellaire ichthyosis* 
Erythrokeratodermia variabilis* 
Mal de Maleda® 
M Greither5 
M Darier" 
' etretinate (de ethyl-ester van acitretine) ' dit proefschrift deel III, hoofdstuk 1-3 
@ Br J Dermatol 1992,127:191-192 sEur J Dermatol 1992;2:503-505 
" Br J Dermatol 1989,121.375-379 
Locale retinoiden zoals "13-cis-retinoic acid" kunnen in sommige gevallen van nut zijn 
(deel III, hoofdstuk 4 en 5). Met name de effectiviteit bij de ziekte van Darier en bij 
sommige patiënten met lamellaire ichthyosis was indrukwekkend. Een beperking van 
locaal all-trans-retinoic acid was tot dusver de irritatieve bijwerking. Zoals werd 
aangetoond in de hoofstuk 4 en 5 van deel III heeft "13-cis-retinoic acid" een gunstiger 
therapeutische (effect/irritatie) breedte. Nieuwe stoffen zoals de arotinoiden hebben een 
nog minder irritatieve werking en zijn mogelijk veelbelovende kandidaten voor de topische 
behandeling van keratinisatiestoornissen in de toekomst. 
Locale applicatie van het vitamine D3 analoog calcipotriol is een gevestigde behandeling 
voor psoriasis. In hoofdstuk 6 van deel III bleek calcipotriol effectief bij de behandeling 
van verscheidene keratinisatiestoornissen (Tabel III). De studie met topisch vitamine D3 
liet zien dat deze behandeling met succes kan worden toegepast bij de behandeling van 
congenitale ichthyosis, en in mindere mate bij de X-gebonden recessieve ichthyosis. 
Tabel III. De respons van de verschillende keratinisatiestoornissen op calcipotriol zalf 
Gunstig Geen effect Verergering 
Ichthyosis vulgaris 
X-gebonden ichthyosis 
de ziekte van Darier 
Keratoderma 
Keratosis pilaris 
Congenitale ichthyosis 
Het is interessant dat alle bestudeerde geneesmiddelen, die een gunstig effect hebben bij 
de behandeling van keratinisatiestoornissen behoren tot de liganden voor de leden van de 
"steroid receptor superfamily". In dit verband is het aangewezen om het therapeutisch 
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effect van andere liganden voor de leden van de "steroid receptor superfamily", zoals 
topische oestrogenen, androgenen en thyroxine te bestuderen. Een belangrijke doorbraak 
bij de behandeling van keratinisatiestoomissen is geleverd door de cytochroom P450 
9 
inhibitor Liarozole (Janssen Pharmaceutica, Beerse, België). Deze inhibitor verhoogt de 
endogene vitamine A spiegel in de weefsels. Een door ons recent uitgevoerde studie 
toonde aan dat dit middel bij alle 12 deelnemende patiënten met een ernstige vorm van 
ichthyosis, een zeer goede verbetering gaf3. 
CONCLUSIE 
De nosologie van de monogene keratinisatiestoomissen zal in de toekomst vooral 
gebaseerd zijn op de oorzakelijke gendefecten. Het toepassen van merkstoffen voor 
epidermale differentiatie en proliferatie heeft tot dusver slechts een geringe bijdrage 
geleverd tot een betere definitie van de verschillende keratinisatiestoomissen Dergelijk 
descriptief onderzoek kan echter behulpzaam zijn bij het vaststellen van kandidaatgenen. 
Nieuwe behandelingen, die interfereren met de leden van de "steroid receptor 
superfamily", zullen mogelijk het therapeutisch arsenaal voor de behandeling van 
keratinisatiestoomissen uitbreiden. 
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Appendix 
The monogenic disorders of keratinization display an enormous genetic heterogeneity and 
a phenotypic variation even in the same genetic type. A correct clinical diagnosis is not a 
mere academic excercise but is necessary for adequate genetic counseling, for estimating 
the prognosis and selecting the right therapy. Missing a diagnosis for instance in Refsum's 
disease may have dramatic consequences for the patient, since a special diet can prevent 
neurological damage. 
An integrated approach is necessary for giving a correct diagnosis. Therefore, the 
appendix contains tables with clinical presentations, and histopathological (lightmicro-
scopical and electronmicroscopical), biochemical, and genetic findings. They have been 
simplified in order to be didactic. Further details can be found in the references. The 
tables are based on those published by Traupe on ichthyosis. Here other disorders of 
keratinization are included. 
Obviously this classification is provisional and must be modified continually as new 
information becomes available. Over the years to come, new types of disorders of 
keratinization will emerge or disappear. 
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Table I Clinical presentations of monogenic disorders of keratinization 
ichthyosis, 
vulgar 
ichthyosis, 
congenital 
palmoplantar 
h>pcrkeratosis, 
diffuse 
palmoplantar 
hyperkeratosis, 
nummular/hnear 
palmoplantar 
hyperkeratosis 
papular 
inheritance 
AD 
AR 
X-hnked 
AD 
AR 
AR/AD'' 
X-hnked 
AD 
AR 
AD 
AR 
0 
AD 
AR 
no associated features 
• autosomal dominant 
ichthyosis vulgaris 
• X-Iinked recessive ichthyosis 
• autosomal dominant lamellar 
ichthyosis 
• bullous ichthyosiform 
erytroderma of Brocq 
• ichthyosis bullosa of Siemens 
• ichthyosis hyslnx of Curth Macklm 
• erythroderma lamellar 
ichthyosis 
• non-erythrodermic lamellar 
ichthyosis 
• harlequin fetus 
• Unna-Thost 
• Greither 
• Vomer 
• Sybert 
• Mal de Mcleda 
• Gamborg Nielsen 
• Nagashima 
• aerai kcratodLrma 
• Wachters 
• PPK nummularis 
• Davies-Collcy 
• acrokaratoelastoidosis 
• focal aerai hyperkeratosis 
associated features 
• Refsum's disease 
• multiple sulfatase deficiency 
• associated steroid sulfatase 
deficiency 
• KID syndrome 
• neutral lipid storage disease 
• Sjogren-l arsson syndrome 
• Tay syndrome 
• X-linked dominant ichthyosis 
• Vohwinkel 
• Но чеІ-Evans syndrome 
• Hunez syndrome 
• Clouston syndrome 
• PPK and sensorineural deafness 
• Olmsted syndrome 
• Papillon-Lefevre syndrome 
• Bureau-Bam ere-Thomas 
• congenital atrichia, 
palmoplantar hyperkeratosis 
mental retardation, and early 
loss of teeth 
• Richner-IIanhart 
• pachyonychia congenita 
• focal plamoplantar and oral 
mucosa hyperkeratosis 
syndrome 
• pachyonychia congenita 
• Jakac-Wolf 
• acantholytic ectodermal 
dysplasia 
• Hanhart 
• Schopf-Schulz-Passarge 
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Table I (cent.). Clinical presentations of monogenic disorders of keratinization 
inheritance no associated features 
A D ' erythrokeratodermia variabilis 
• erythrokeratodermia symmetrica el progressiva 
1
 porokeratosis of Mibelli 
' porokeratosis palmans, plantaris et disseminata 
' disseminated superficial actinic porokeratosis 
1
 Darter's disease 
1
 keratitis, ichlhyosis-like hyperkeratosis, 
and deafness syndrome 
1
 keratosis pilaris* 
AR ' familial continual skin peeling syndrome 
XR • keratosis pilaris decalvans = keratosis follicularis 
spinulosa decalvans (Siemens)** 
* can occur isolated and in some syndromes and conditions 
** can occur isolated or associated with photophobia 
Table I I . Mozaic patterns in the monogenic disorders of keratinization 
inheritance 
AD 
disorder of keratinization 
• epidermolytic epidermal naevus 
• acantholytic epidermal naevus 
• linear porokeratosis 
X-linked dominant 
lethal for affected 
male embryos 
• CHILD-syndrome 
• X-linked dominant ichthyosis 
unknown* porokeratotic eccrine ostial epidermal 
and dermal duct naevus 
1
 naevus comiculatus 
monogenic basis unknown 
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Table III. Prominent lightmicroscopical features 
feature diagnosis 
reduced or absent granular 
layer 
' autosomal dominant ichthyosis vulgaris 
• Comel-Netherton syndrome 
1
 Tay syndrome 
1
 X-hnked dominant ichthyosis 
epidermolytic hyperkeratosis ' bullous congenital ichthyosiform 
erythroderma of Brocq 
1
 ichthyosis bullosa of Siemens 
1
 ichthyosis hystnx of Curth-Macklin 
• palmoplantar hyperkeratosis of Vomer 
• keratosis palmoplantaris nummulans 
lipid droplets in basal and 
suprabasal keraiinocytes 
(Sudan red) 
vacuolated granulocytes 
Refsum's disease 
1
 multiple sulfatase deficiency syndrome 
' neutral lipid storage disease 
acantholysis Daner's disease 
' naevus comiculatus 
acanlholytic ectodermal dysplasia 
comoid lamella 
splitting between granular 
layer and stratum comeum 
porokeratosis 
continuous skin peeling syndrome 
banding pattern of hair m 
polarizing light 
1
 Tay syndrome 
trichorrhexis invaginata • Comel-Ncthcrton syndrome 
Table IV. Electronmicroscopical features 
features 
absent or abortive keratohyalin 
granules 
clumping of tonofilaments 
lipid vacuoles in the stratum 
comeum 
cholesterol crystals in 
comeocytes 
laminated membrane structures, 
vesicular lamellar bodies 
laminated structures different 
from the type NELI-A 
increased transition layer 
Table V. Biochemical features 
features 
arylsulfatase С deficiency 
steroid sulfatase deficiency 
increased creatine kinase 
reduced fatty alcohol NAD* 
oxidoreductase activity 
reduction or absence of 
filaggnn and profilaggrin 
phytanic acid oxidase deficiency 
tyrosine aminotransferase 
deficiency 
diagnosis 
• autosomal dominant ichthyosis vulgaris 
• bullous congenital ichthyosiform 
erythroderma of Brocq 
• ichthyosis bullosa of Siemens 
• ichthyosis hystnx of Curth-Mackhn 
• keratosis palmoplantaris type Vomer 
• keratosis palmoplantaris nummularis 
• erythrodermic lamellar ichthyosis 
(type A) 
• erythrodermic lamellar ichthyosis 
(type B) 
• non erythrodermic lamellar ichthyosis 
(type A) 
• non erythrodermic lamellar ichthyosis 
(type B) 
a
 autosomal dominant lamellar ichthyosis 
diagnosis 
• X-hnked recessive ichthyosis 
• neutral lipid storage disease 
• Sjogren-Larsson syndrome 
• autosomal dominant ichthyosis 
vulgaris 
• Refsum's disease 
• Richner-Hanhart syndrome 
Table VI. Location of gene defects in disorders of keratinization 
chromosome 12, 12q 11-13, · bullous congenital ichthyosiform 
mutation in keratin 1 erythroderma of Brocq 
chromosome 17, 17q 12-21 
mutation in keratin 10 
chromosome 12, I2qll-I3 * ichthyosis bullosa of Siemens 
mutation in keratin 2e 
chromosome 17, 17q 12-21 · keratosis palmoplantaris Vomer 
mutation in keratin 9 
X-chromosome, Xp22 3 · X-linked recessive ichthyosis 
X-chromosome · X-linked dominant ichthyosis 
X-chromosome · CHILD-syndrome 
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STELLINGEN 
behorende bij het proefschrift 
"The Monogenie Disorders of Keratinization" 
I Epidermolytische hyperkeratose is een histologische bevinding en niet een 
diagnose. 
2. Ichthyosis bullosa van Siemens is een vorm van ichthyosis die moet worden 
onderscheiden van de bulleuze congenitale ichthyosiforme erythrodermie 
van Brocq 
3. Het beschrijvend dermatologisch onderzoek van de cutané mozaïeken leidt 
tot nieuwe genetische concepten. 
4. Beschrijvend onderzoek met behulp van immunohistochemische merkstoffen 
leidt slechts zelden tot het aanwijzen van kandidaatgenen. 
5. De monogene keratinisatiestoornissen kunnen het best worden 
geclassificeerd op basis van hun primaire gendefecten. 
6 Liganden voor de "steroid receptor superfamily" zijn effectief bij de 
behandeling van monogene keratinisatiestoornissen. 
7. BIJ dysplastische (atypische) naevi zijn meerdere genen betrokken. 
8. Het minst dysplastische van de promovendus zijn zijn naevi. 
9. Topische immuuntherapie is de enige behandeling die bij alopecia areata tot 
een cosmetisch bevredigend resultaat kan leiden 
10 De rol van stress bij het ontstaan van veel huidziekten wordt sterk 
overdreven, de stress is meestal een gevolg van deze huidaandoeningen. 
I I De kwalificaties "echte clmicus" of "echte wetenschapper" worden vaak als 
alibi gebruikt voor het hebben van weinig affiniteit met wetenschap 
respectievelijk kliniek. 
12. Het w o o r d "zalf" in "kwakzalver i j" suggereert dat kwakzalvers zich 
voornameli jk bezighouden met huidziekten. 
13 Een za l fkwakker is nog geen kwakzalver. 
14. Voor een lage drempel in de gezondheidzorg zijn veel artsen nodig 
15. Een v o l k s w a g e n is ook voor Leidenaren. 
16. Paranimfen zijn een levende decoratie ( J . M . B . J . van Luyken) 
17. Flexibiliteit dient niet te worden v e r w a r d met chaos. 
Ni jmegen, 7 december 1 9 9 4 Ρ M. Steijlen 
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